

DEPARTMENT OF HEALTH & HUMAN SERVICES
Centers for Medicare & Medicaid Services
7500 Security Boulevard, Mail Stop S2-25-26
Baltimore, Maryland 21244-1850



State Demonstrations Group

January 2, 2026

Bill Hanna
State Medicaid Director
Wisconsin Department of Health Services
1 W. Wilson St.
Madison, WI 53701

Dear Director Hanna,

The Centers for Medicare & Medicaid Services (CMS) completed its review of the Evaluation Design, which is required by the Special Terms and Conditions (STCs), specifically, STC #9.3 of the Wisconsin's BadgerCare Reform section 1115 demonstration, (Project No: 11-W-00293/5). CMS determined that the Evaluation Design, which was submitted on April 25, 2025 and revised on December 15, 2025, meets the requirements set forth in the STCs, and therefore approves the Evaluation Design.

CMS has added the approved Evaluation Design to the demonstration's STCs as Attachment E. A copy of the STCs, which includes the new attachment, is enclosed with this letter. In accordance with 42 CFR 431.424, the approved Evaluation Design may now be posted to the state's Medicaid website within 30 days. CMS will also post the approved Evaluation Design on Medicaid.gov.

Please note that an Interim Evaluation Report, consistent with the approved Evaluation Design, is due to CMS one year prior to the expiration of the demonstration, or at the time of the extension application, if the state chooses to extend the demonstration. Likewise, a Summative Evaluation Report, consistent with this approved design, is due to CMS within 18 months of the end of the demonstration period. In accordance with 42 CFR 431.428 and the STCs, we look forward to receiving updates on evaluation activities in the demonstration monitoring reports.

We appreciate our continued partnership with Wisconsin on the BadgerCare Reform section 1115 demonstration. If you have any questions, please contact your CMS demonstration team.

Sincerely,

Danielle Daly
Director
Division of Demonstration Monitoring and Evaluation

cc: Mai Le-Yuen, State Monitoring Lead, CMS Medicaid and CHIP Operations Group

**Wisconsin's Medicaid & BadgerCare Plus Health Coverage
CMS § 1115 Waiver Provisions for 2024-2029**

Evaluation Design Report

**Submitted to the
Wisconsin Department of Health Services**

April 25, 2025

**Revised November 19, 2025
Based on CMS Comments**



**Institute for
Research on
Poverty**

UNIVERSITY OF WISCONSIN-MADISON

PROJECT TEAM

Faculty Investigators:

Daniel Sacks, Ph.D., Co-Principal Investigator
Associate Professor
Wisconsin School of Business
Department of Risk and Insurance, University of Wisconsin-Madison

Laura Dague, Ph.D., Co-Principal Investigator
James M. Griffin Professor of Health Policy
Bush School of Government & Public Service, Texas A&M University

Marguerite Burns, Ph.D.
Professor
Department of Population Health Sciences, University of Wisconsin-Madison

Alyssa Tilhou, MD, Ph.D.
Assistant Professor
Department of Family Medicine, Boston University School of Medicine/Boston Medical Center

Project Manager:

Tim Connor, M.A., M.S.
Institute for Research on Poverty, University of Wisconsin-Madison

The preparation of this design report benefited from consultation with staff of the Wisconsin
Department of Health Services

TABLE OF CONTENTS

List of Tables and Figures	3
List of Acronyms	4
General Background Information.....	5
I. DEMONSTRATION WAIVER AND EVALUATION BACKGROUND	7
IA. Waiver Overview and Target Populations	7
IB. Evaluation Team Background and Qualifications	8
IC. Evaluation Design Approach and Methods.....	8
ID. Data Sources	8
IE. Primary Data Collection: Medicaid Member Survey.....	12
II. EVALUATION PROVISIONS, HYPOTHESES, AND QUESTIONS	20
IIA. Provision 1: Coverage up to 100% FPL for Childless Adults.....	20
A1. General Background Information	20
A2. Evaluation Questions and Hypotheses	21
A3. Methodology	22
A4. Methodological Limitations	28
IIB. Provision 2: Emergency Department Co-Payments.....	28
B1. General Background Information	28
B2. Evaluation Questions and Hypotheses	29
B3. Methodology.....	30
B4. Methodological Limitations	33
IIC. Provision 3: Substance Use Disorder – Expansion of Covered Services	33
C1. General Background Information	33
C2. Evaluation Questions and Hypotheses	35
C3. Methodology.....	36
C4. Methodological Limitations	49
III. ATTACHMENTS	50
Attachment A: Waiver Approval Letter, Waiver Provisions, and Special Terms and Conditions (STCs)	
Attachment B: Independent Evaluator Assurance of No Conflict	
Attachment C: Timelines of Major Evaluation Milestones	
Attachment D: Budget and Budget Narrative	

List of Tables and Figures

TABLES

TABLE 1. SURVEY DOMAINS RELEVANT TO STUDY HYPOTHESES.....	14
TABLE 2. SURVEY SAMPLE GROUPS	17
TABLE 3. SURVEY STUDY DESIGN COMPARISONS	19
TABLE 4. PROVISION 1: SUMMARY OF HYPOTHESES, QUESTIONS, DATA SOURCES, AND ANALYTIC APPROACHES FOR EVALUATION OF THE EXPANSION OF MEDICAID BENEFITS TO CHILDLESS ADULTS (CLAs)	23
TABLE 5. PROVISION 2: SUMMARY OF HYPOTHESES, QUESTIONS, DATA SOURCES, AND ANALYTIC APPROACHES FOR EVALUATION OF EMERGENCY DEPARTMENT COPAYMENT REQUIREMENTS FOR CLAs.....	31
TABLE 6. PROVISION 3: SUMMARY OF QUESTIONS, HYPOTHESES, DATA SOURCES, AND ANALYTIC APPROACHES FOR EVALUATION OF THE SUD DEMONSTRATION WAIVER.....	37

FIGURES

FIGURE 1. DRIVER DIAGRAM FOR CHILDLESS ADULTS COVERAGE EXPANSION	21
FIGURE 2. DRIVER DIAGRAM: EMERGENCY DEPARTMENT CO-PAYMENT REQUIREMENTS.....	29
FIGURE 3. DRIVER DIAGRAM: SUBSTANCE USE DISORDER WAIVER PROVISION	34

List of Acronyms

ACS	American Community Survey
BRFSS	Behavioral Risk Factor Surveillance Survey
CARES	Wisconsin Medicaid's Eligibility and Enrollment System
CLA	Childless Adults: Adults without dependent children who are eligible for Wisconsin's BadgerCare program
CMS	U.S. Centers for Medicare and Medicaid Services
DHS	Wisconsin Department of Health Services
DiD	Difference-in-Differences method
FPL	Federal Poverty Level
IRP	University of Wisconsin-Madison Institute for Research on Poverty: independent evaluators for Wisconsin's Medicaid waiver
ITS	Interrupted Time Series method
MAT	Medication-Assisted Treatment
SAHIE	Small Area Health Insurance Estimates
SUD	Substance Use Disorder
WHIO	Wisconsin Health Information Organization: Wisconsin's private sector, voluntary all-payer claims database

General Background Information

The University of Wisconsin-Madison Institute for Research on Poverty has prepared this design to conduct an evaluation of the Wisconsin BadgerCare Reform Demonstration Project, as proposed by the Wisconsin Department of Health Services (DHS) and approved by the federal Centers for Medicare and Medicaid Services (CMS). The evaluation uses quasi-experimental study designs to assess how the provisions of Wisconsin's Medicaid § 1115 Waiver Demonstration, for the period CY2024-CY2029, affect two Medicaid populations: (1) childless adults (CLAs) with an effective income at or below 100% of the federal poverty level (FPL), and (2) all Medicaid members eligible for an expanded coverage of treatment services for substance use disorders (SUD).

The evaluation addresses the waiver demonstration provisions defined by DHS and approved by CMS for a temporary one-year extension in 2024 and a full five-year demonstration period ending December 31, 2029. **Attachment A** includes the CMS demonstration approval letter and Special Terms and Conditions (STCs). Hypotheses and associated research questions focus on the following provisions and programmatic changes:

- Extension of a full Medicaid benefit for adults without dependent children ("childless adults") with incomes up to and including 100% FPL.
- An \$8 co-payment for non-emergency use of the emergency department.
- Expanded coverage for substance use disorders including a residential treatment benefit and coverage for existing services when they are provided in an institution of mental disease (IMD) specifically including medically supervised withdrawal management, inpatient services, and medication-assisted treatment (MAT).

The evaluation requires administrative data from the Wisconsin DHS pertaining to application and enrollment, claims and encounters, and vital statistics (for example, death records). The evaluation also requires several other sources of administrative data, including Wisconsin's all-payer claims database and unemployment insurance data, which will permit construction of appropriate stratifications and controls, along with state and national population survey data. Two separate member surveys occurring in CY2026 and CY2029 will provide important sources of primary data from Medicaid members for evaluation of multiple hypotheses and research questions.

This multi-disciplinary evaluation team, with collaborating scholars from several universities, has conducted Medicaid section 1115 waiver evaluations for over a decade, and has published a wide range of Medicaid-related research and evaluation studies. The investigators bring expertise and skills with the full range of clinical expertise, health services research, and econometric methods needed to assure a rigorous independent evaluation. The Wisconsin Medicaid agency lays out ambitious goals with this demonstration waiver, and the evaluation will contribute important findings for state and federal Medicaid policy.

WAIVER PROVISIONS AND HYPOTHESES

Provision 1: Medicaid benefits to non-elderly childless adults (CLAs) up to 100% FPL.

- H1.1. The expansion of benefits to non-elderly CLAs will reduce the state's uninsured rate.
- H1.2. The expansion of benefits to CLAs will lead to their increased access to medical care.
- H1.3. The expansion of benefits to CLAs will lead to their improved health.
- H1.4. The expansion of benefits to CLAs will lead to lower provision of uncompensated care by hospitals.

Provision 2: \$8 co-payment for non-emergent use of the emergency department for CLAs

- H2.1. The imposition of a co-payment for non-emergent use of the emergency department will lead to more appropriate uses of medical care among CLAs enrolled in Medicaid.

Provision 3: Substance Use Disorder (SUD) Demonstration Waiver: Expansion of coverage of substance abuse disorder treatment services*

- Q3.1. Does the waiver increase the supply of SUD providers for Medicaid members?
- Q3.2. Does the waiver increase access to, and use of, newly covered SUD services for Medicaid members?
- Q3.3. Does the waiver change Medicaid members' use of existing covered SUD services?
- Q3.4. Does the waiver reduce the rate of drug overdose deaths among Medicaid members including opioid-related deaths?
- Q3.5. What are the patterns and trends in Medicaid costs associated with the SUD demonstration waiver?

* Consistent with the CMS guidance for evaluation of SUD waivers, the evaluation for the SUD portion is organized around evaluation questions, with specific hypotheses following each question.

I. DEMONSTRATION WAIVER AND EVALUATION BACKGROUND

The University of Wisconsin-Madison Institute for Research on Poverty (IRP) has proposed this design to conduct an evaluation of the Wisconsin BadgerCare Reform Demonstration Project, as proposed by the Wisconsin Department of Health Services (DHS) and approved by the federal Centers for Medicare and Medicaid Services (CMS). BadgerCare is Wisconsin's combined Medicaid and Children's Health Insurance Program (CHIP) for low-income families and for adults without dependent children.

IA. Waiver Overview and Target Populations

The waiver primarily concerns adults without dependent children, referred to as childless adults (CLAs), and also includes a substance use disorder (SUD) provision that applies to the entire Medicaid population. CMS approved a temporary extension and amendment on November 17, 2023, expiring December 31, 2024, and a five year extension on October 29, 2024, with an approval period through December 31, 2029. An additional provision covers former foster care youth from other states; this provision is not included in the evaluation design due to the small population limiting feasibility and its planned phasing-out. There are no new provisions to the demonstration waiver and limited changes outside of those reflecting authority removals during the extension period.

Childless Adults Waiver Provisions

The BadgerCare Reform demonstration waiver authorizes Wisconsin to provide a full Medicaid benefit package to non-pregnant, non-disabled, non-elderly CLAs with incomes of up to and including 100% FPL. This coverage began under a prior waiver, initiated in April 2014, and the current demonstration approval continues coverage for this population through 2029. The waiver also includes an \$8 co-payment for non-emergent use of the emergency department for CLAs.

SUD Waiver Provision

This demonstration waiver also includes a substance use disorder (SUD) program available to all Wisconsin Medicaid members. The SUD program expands coverage for substance use disorder treatment in facilities that qualify as institutions for mental diseases (IMDs) for all Medicaid members. The provision authorizes a new residential treatment benefit and coverage for existing services when provided in an institution of mental disease (IMD) specifically including medically supervised withdrawal management, inpatient services, and medication-assisted treatment (MAT). The purpose of the program is to ensure that a broad continuum of care is available to Wisconsin Medicaid members with a substance use disorder, helping improve the quality of substance use treatment and health outcomes for those Medicaid members. The State of Wisconsin identifies this waiver provision as part of a comprehensive statewide strategy to combat substance use disorders and drug overdose.

IB. Evaluation Team Background and Qualifications

Our team has conducted and published studies on a broad range of Medicaid-related evaluation and research topics, addressing coverage and care utilization, labor market impacts, crowd-out of private insurance, premiums, restrictive non-enrollment periods, health needs assessments, application and enrollment systems, and churning.¹ Sponsors of this team’s work include the state and federal governments, foundations, and private sector concerns. We have conducted the CMS-required evaluations of all Wisconsin’s BadgerCare demonstration § 1115 waivers that were approved since 2008, Wisconsin’s SeniorCare prescription drug program, and the Medicaid medical homes for high risk pregnant women.

The multi-disciplinary team of faculty and staff researchers is based at the University of Wisconsin-Madison, in the Institute for Research on Poverty, with the following collaborating faculty investigators: Dr. Daniel Sacks, an economist in the UW Department of Risk and Insurance, Dr. Marguerite Burns, a health services researcher in the UW School of Medicine and Public Health; Dr. Laura Dague, an economist at Texas A&M University’s Bush School of Government & Public Service; and Dr. Alyssa Tilhou, a physician and health services researcher at Boston University in the Department of Family Medicine.

IC. Evaluation Design Approach and Methods

The evaluation of the demonstration waiver will involve a variety of analytic approaches. Our team is both experienced in and familiar with the statistical and econometric tools needed for analysis of observational data, including causal inference methods. Because no new policies are planned to be introduced in the current waiver period, approaches are focused on identifying changes over time in outcomes and designs that do not require differences. Where possible, we include appropriate causal inference methods. Further detail regarding the application of these methods to specific evaluation questions is included in Section II of this evaluation design report alongside the methods for each individual evaluation question. In general, we will adopt a standard significance level (alpha) of 0.05 for all statistical analyses. In addition to p-values, we will report 95% confidence intervals and effect sizes to provide a comprehensive understanding of the magnitude, precision, and practical importance of our findings. Additional development of methods and details may occur as the evaluation progresses, as sometimes changes in data availability, methods technology, or new empirical insights inform improved approaches. A complete timeline of major evaluation milestones is detailed in **Attachment 3**.

ID. Data Sources

The evaluation of the demonstration waiver will rely on multiple data sources, including state administrative data, population survey data, and a member survey. These data elements are described

¹ Information about the team’s work is available here: <https://www.irp.wisc.edu/health-policy/>

below. The specific sources that will be used to evaluate each provision, and the outcomes derived from each source, are noted in the relevant sections of this evaluation design report. At least one investigator on the team has experience with every data source in the list below.

1. All Payer Claims Database, WHIO.² The Wisconsin Health Information Organization, known as WHIO, is private-sector-operated, voluntary, multi-payer claims database. WHIO includes Medicaid along with commercial insurance covering most of Wisconsin's population. It is missing Medicare fee-for-service, self-funded employers whose third-party administrators do not submit claims, and individuals insured by national or border state companies (examples include HealthPartners, Aetna, and Cigna). The WHIO data have both a claims file and a member enrollment file, which permits us to track unique individuals' enrollment in health insurance regardless of whether members actually incur claims. WHIO does not release identifiable data, so it is not possible to link these data directly to Medicaid administrative data in order to identify the Medicaid sample. Rather, we will use the member file to identify both the Medicaid and privately insured samples.
2. American Community Survey. The American Community Survey (ACS), a nationally representative survey conducted by the U.S. Census Bureau, contains state-level geographic identifiers. The survey asks about sources of health insurance coverage in the previous year, including Medicaid coverage, private group and non-group insurance, Medicare, and military coverage. The survey is administered annually and is publicly available with only a short lag.
3. Behavioral Risk Factor Surveillance System (BRFSS). Run by the Centers for Disease Control and Prevention, the BRFSS is a set of state-level surveys that collect data from all 50 states and the District of Columbia on the health and health behaviors of U.S. residents. The survey also collects information on health insurance coverage, though not the source of that coverage, and on employment. The data are available at the state level and with roughly a two-year lag.
4. CARES. Wisconsin CARES is the state's online eligibility and enrollment portal for public benefits, including Medicaid, Temporary Assistance for Needy Families (TANF), and FoodShare (SNAP). We use data from CARES to attain longitudinal administrative data pertaining to enrollment. Demographic information includes age, sex, educational attainment, county of residence, income, and income sources. CARES data also include reason codes associated with disenrollment.
5. Disproportionate Share Hospital (DSH) Audits. For states to receive FFP for DSH payments, federal law requires states to submit an independent certified audit and an annual report to describing DSH payments made to each DSH hospital. The reports include uncompensated

² Wisconsin Health Information Organization. Datamart Guide Version 2.1. 2014. Optum, Inc: Waltham, MA.

care amounts for each hospital that got a DSH payment adjustment. Data are available on a delayed timeline only (for example, in early 2025, were published through 2019).

6. Hospital Cost Reports. These reports are submitted annually to CMS by all acute-care and critical access hospitals. Data on uncompensated care (UCC) are reported in Worksheet S-10 of Form CMS-2552-10, which was first used beginning in May 2010. UCC is the sum of two reported items: the cost of charity care provided to uninsured patients (line 23 column 1) and the cost of non-Medicare bad-debt expense (line 29). As needed, we will supplement Hospital Cost Report data with Wisconsin data on hospital uncompensated care available from the Wisconsin Hospital Association.³
7. Medicaid Member Survey. Described in detail in Section IE. Primary Data Collection: Medicaid Member Survey, below.
8. Marketplace Open Enrollment Period Public Use Files (OEPUF). The OEPUF includes total health plan selections by state and county, as well as average monthly premium, financial assistance, age, gender, metal level, self-reported race and ethnicity, household income as a percent of the FPL, and plan switching behavior.
9. Medicaid Outcomes Distributed Research Network (MODRN). MODRN is a collaboration between 15 state and university partnerships including the Wisconsin partnership of the Wisconsin Department of Health Services and the University of Wisconsin-Madison.⁴ The MODRN was formed to support cross-state learning among Medicaid agencies and researchers while ensuring the security of each Medicaid program's data. The MODRN designed and uses a common data model to support centralized development, but local execution, of analytic programs. Each state-university partnership adopts the common data model, contributes to a common analytic plan, and conducts analyses locally on their own Medicaid data using standardized code developed by the data coordinating center at the University of Pittsburgh. The state-university partners provide aggregate results, not data, to the data coordinating center which synthesizes the aggregate findings from multiple states for reporting. Use of MODRN comparison data is conditional on continuing contribution of aggregate results to the partnership and the agreement of participating states.

³ Uncompensated care for Wisconsin hospitals is reported by the Wisconsin Hospital Association annually as well as other hospital financial information: <https://www.whainfocenter.com/Publications>.

⁴ Zivin K, Barnes AJ, Kim JK, Tang L, Kennedy S, Ahrens KA, Burns M, Clark S, Cole E, Crane D, Idala D, Lanier P, Mohamoud S, Jarlenski M, McDuffie MJ, Talbert T, Gordon AJ, Donohue JM. Design, Implementation, and Evolution of the Medicaid Distributed Research Network (MODRN). *Medical Care*. 2022;60(9): 680-690.

10. National Substance Use and Mental Health Services Survey (N-SUMHSS).⁵ Previously called the National Survey of Substance Abuse Treatment Services (N-SSATS), The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts this annual survey to provide a census of facilities nationwide that provide substance abuse treatment and collect data on their location in each state and characteristics including populations served, available services, and whether the facility accepts Medicaid as a payer. The unit of observation is the facility-year.
11. Small Area Health Insurance Estimates (SAHIE). The SAHIE program was created to develop model-based estimates of health insurance coverage for counties and states. SAHIE data can be used to analyze geographic variation in health insurance coverage, as well as disparities in coverage by race/ethnicity, sex, age, and income levels that reflect thresholds for state and federal assistance programs.
12. Wisconsin Family Health Survey. The Wisconsin Family Health Survey is an annual statewide random-sample telephone survey of all household residents. This survey includes topics such as health insurance coverage, health status, health problems, and use of health care services.
13. Wisconsin Medicaid claims and encounter data. We will obtain claims and encounter data from the State's MMIS claims database. These data files include detailed ICD-10 diagnostic codes. The claims and encounter data contain detailed information on diagnoses, procedure, and billing codes from which we will construct outcomes measures of health care use.
14. Unemployment Insurance Wage and Benefits Records (UI). UI wage and benefits records are longitudinal administrative data from the UI earnings reporting system, with individual-level measures of reported quarterly employment, wages, and firm industry code. These data may be matched to Medicaid administrative enrollment data from CARES, to identify an individual's employment status regardless of whether they are currently enrolled in Medicaid.
15. Wisconsin Death Records. The State Registrar in the Wisconsin DHS collects vital statistics death data. The source of these data are death certificates filed with the Wisconsin DHS. Cause of death is coded according to ICD-10. We will examine resident deaths, specifically all deaths that occurred in Wisconsin within the Wisconsin resident population. Conditional on approval by the Wisconsin DHS, we will link death records to Medicaid enrollment date to identify deaths among Medicaid members.

⁵ Substance Abuse and Mental Health Services Administration. National Substance Use and Mental Health Services Survey (N-SUMHSS). Information available at: <https://www.samhsa.gov/data/data-we-collect/n-sumhss-national-substance-use-and-mental-health-services-survey>

16. Wisconsin Third Party Liability (TPL) Database. TPL is an individual-level database that contains all members in state health insurance programs who are covered by a private health insurance plan. We can match individuals in TPL using social security numbers. This database may not contain information on whether individuals were covered by health insurance provided by a self-funded employer (whose policies are not subject to state regulation).

IE. Primary Data Collection: Medicaid Member Survey

A survey of current and former Medicaid members provides the opportunity to examine the respondents' experiences specifically in relation to the waiver provisions, including several domains not well-suited to measurement with administrative data or other state and national data. These domains include perceptions and understanding of various waiver provisions, reported reasons for changes in enrollment status or health care use, reported health status over different enrollment entry and exit spells, self-reported health status, and knowledge of and interest in various services (such as SUD treatment).

The evaluation design includes use of a survey at two separate points in the five-year evaluation period including CY2026 and 2029. The evaluation plan relies on an agile project management approach for design of the member surveys. We expect to re-define the more specific parameters of the survey cohorts, instrument domains, and data collection in consultation with DHS as the dates for the surveys draw near. General plans based on past practices are included below.

i. Survey Domains

The evaluation design includes plans to field cross-sectional surveys of members at two separate points in the five-year evaluation period. Overall plans are as follows:

- Mixed mode (self-administered questionnaire (SAQ), web, and telephone)
- Surveys in the first round are sent to 8,450 people; offered in Spanish and English
- Sample groups include CLAs and parents/caretakers, and people with a history of SUD treatment

The planned domains within the survey instruments include the following:

- Health insurance coverage status – past year and current
- Medicaid eligibility and enrollment changes
- Health care needs, access, and use
- Health status and health behaviors
- Substance use treatment need and use of services
- Awareness of waiver provisions
- Demographics

In prior surveys, questions were developed using items from previous surveys of Wisconsin Medicaid members, from national surveys and from other state surveys of Medicaid members. These include: the Behavioral Risk Factor and Surveillance System, the Urban Institute Health Reforming Monitoring Survey, Kaiser Family Foundation Health Tracking Polls, the National Health Interview Survey, the

Michigan waiver’s survey of Medicaid members⁶ and the Oregon Health Insurance Experiment⁷. Because there are few opportunities for strong causal inference methodologies during the waiver period, we plan to develop randomized information treatments related to the waiver hypotheses where feasible, administered within the surveys.

Table 1 below displays how the waiver provision and hypotheses relate to each of the survey domains. We may adjust survey questions to account for changes in the waiver and in the Medicaid context and policy environment over the demonstration time period.

⁶ Healthy Michigan Voices Survey. <https://ihpi.umich.edu/featured-work/healthy-michigan-plan-evaluation/healthy-michigan-voices-survey>

⁷ Oregon Health Insurance Experiment – Documents. <https://www.nber.org/programs-projects/projects-and-centers/oregon-health-insurance-experiment/oregon-health-insurance-experiment-documents>

Table 1. Survey Domains Relevant to Study Hypotheses

Hypothesis	Target population	Survey domain(s)	Survey question(s)
Provision 1: Provide state plan benefits, other than family planning and tuberculosis-related services, to non-elderly childless adults with family income of up to 100% FPL			
Hypothesis 1.2. The expansion of benefits to CLAs will lead to increased access to medical care.	CLA	<ul style="list-style-type: none">• Health insurance status and recent history of uninsurance• Access and use of general medical care• Demographics and socioeconomic status	Self-reported access/barriers to care; utilization of care; self-reported quality of care; annual household income; recently uninsured status
Hypothesis 1.4. The expansion of benefits to CLAs will lead to lower provision of uncompensated care by hospitals.		<ul style="list-style-type: none">• Health insurance status and recent history of uninsurance• Access and use of general medical care	Self-reported use of uncompensated care; recently uninsured status
Provision 2: Implement an \$8 copayment for non-emergent use of the emergency department for childless adults			
Hypothesis 2.1. The imposition of a co-payment for non-emergent use of the emergency department will lead to more appropriate uses of medical care among CLAs enrolled in Medicaid.	CLA	<ul style="list-style-type: none">• Knowledge and perceptions of current provisions of the waiver• Attitudes about consumerism and personal responsibility• Demographics and socioeconomic status	Health insurance literacy; self-reported eligibility for the copayments; ability to pay copayments

Hypothesis	Target population	Survey domain(s)	Survey question(s)
Provision 3: Provide residential benefit for SUD treatment and coverage for existing SUD services when they are provided in an institution of mental disease (IMD).			
Hypothesis 3.2a. After implementation of the SUD demonstration waiver, members' awareness of available SUD treatment services will increase over time	All Medicaid-Enrolled Adults	<ul style="list-style-type: none"> • Substance use and use disorders • Access and utilization of drug treatment • Knowledge and perceptions of current provisions of the waiver 	Substance use/use disorders; access and utilization of SUD treatment; interest and motivation to receive SUD treatment; information treatment on service availability
Hypothesis 3.3a. The SUD demonstration waiver will increase or have no effect on SUD outpatient services and pharmacotherapy treatment provided outside of IMD settings.		<ul style="list-style-type: none"> • Substance use and use disorders • Access and utilization of drug treatment • Knowledge and perceptions of current provisions of the waiver 	Substance use/use disorders; access and utilization of SUD treatment; interest and motivation to receive SUD treatment
Hypothesis 3.3b. The SUD demonstration waiver will reduce use of hospital-based services, conditional on increased supply of SUD providers or increased use of new and existing covered SUD services.	All Medicaid-Enrolled Adults	<ul style="list-style-type: none"> • Access and utilization of general medical care • Substance use and use disorders • Access and utilization of drug treatment • Knowledge and perceptions of current provisions of the waiver 	Self-reported access/barriers to care, utilization of care; substance use/use disorders; access and utilization of SUD treatment; interest and motivation to receive SUD treatment
Hypothesis 3.3c. The SUD demonstration waiver will increase use of health care for co-morbid physical and mental health conditions among members with an SUD, conditional on increased supply of SUD providers or increased use of new and existing covered SUD services.		<ul style="list-style-type: none"> • Health status and chronic conditions • Access and utilization of general medical care • Substance use and use disorders • Access and utilization of drug treatment • Knowledge and perceptions of current provisions of the waiver 	Self-reported access/barriers to care; utilization of care; quality of care; substance use/use disorders; access and utilization of SUD treatment; interest and motivation to receive SUD treatment

Hypothesis	Target population	Survey domain(s)	Survey question(s)
Hypothesis 3.3d. The SUD demonstration waiver will increase adherence to SUD treatment, conditional on increased supply of SUD providers or increased use of new and existing covered SUD services.		<ul style="list-style-type: none"> • Substance use and use disorders • Access and utilization of drug treatment • Knowledge and perceptions of current provisions of the waiver 	Self-reported access/barriers to care; utilization of care; substance use/use disorders; access and utilization of SUD treatment; interest and motivation to receive SUD treatment

ii. Sample Construction and Data Collection

Table 2 displays the tentative sample groups for the first CY2026 survey. The main sample groups are based on eligibility and enrollment status.

The survey includes individuals in Group A who will be currently enrolled CLAs at the time the sample is drawn. Group C will be current Medicaid members classified as parents and caregivers who will serve as a comparison group to CLAs. Group B will include members from the full Medicaid population to assess the SUD waiver and will include individuals with a diagnosed SUD or a hospital/emergency department visit related to SUD in the past 12 months.

Hispanic/Latino members, given the unique challenges in health insurance that face this population, will be included in an oversample based on Medicaid administrative data identifying Spanish as their primary language.

Table 2. Survey Sample Groups

Group	Composition	Sample	Spanish Language Over-Sample	Total Sample
A	Childless adults randomly sampled from the list of current members at the time of the sample construction	3,000	150	3,150
B	Adults who have a diagnosis of a substance use disorder or a hospital/ED visit related to a substance use disorder in the prior 12 months based on recent claims	2,000	150	2,150
C	Parents and caregivers who will serve as a contemporaneous comparison group	3,000	150	3, 150
Total Sample		8,000	450	8,450

iii. Weighting, Coding, and Analysis

After baseline data are collected, we will construct survey weights. Following best practices in statistical survey, we will likely use “raking weights” (i.e., iterative proportional fitting)⁸, as we did in our prior survey analysis. This method will allow us to adjust for non-response to the survey by adjusting on observed factors from the sample to make it match the sampling frame (e.g., in terms of age, sex, race/ethnicity, and rurality). Survey weights will be designed to address two issues: purposeful over-sampling of subgroups and differential non-response (i.e., differences in the likelihood of different contacted individuals completing the survey). As with prior surveys, we will recode variables from their “raw” response categories to groupings that enhance their interpretability. We will also examine outlier

⁸ Battaglia, M. P., Izrael, D., Hoaglin, D. C., & Frankel, M. R. (2009). Practical considerations in raking survey data. *Survey Practice*, 2(5), 1-10.

values and ensure logical consistency, making data cleaning decisions that we will document for consumers of the survey.

Planned analytic tasks include the following:

- Conduct descriptive analysis with weighted and unweighted samples.
- Examine means and frequencies for all key study variables and compare differences across different study populations of interest (e.g., between CLAs and parents/caretakers).
- Focus some analyses on specific groups (e.g., use of substance use treatment among people with recent experiences of treatment).
- Run regression models to predict the likelihood of key study outcomes. For example, since age and sex may independently influence health care demand, we will include the variables in regression models examining group-level differences in health care use.
- Leverage data from historical surveys in prior evaluation periods to compare trends in outcomes that may be influenced by changes in program design over time.

After the survey is implemented, our design will allow us to link survey responses back to administrative data.

iv. Relationship of the Survey to Econometric Study Designs

The survey is designed to test for differences-in-differences (DiD) comparing the CLA population to parents over time and to support descriptive analyses. **Table 3** identifies how each of these study design groups will be used for comparisons.

Table 3. Survey Study Design Comparisons

Provision	Primary treated group(s)	Primary comparison group(s)
Provision 1: Provide state plan benefits, other than family planning and tuberculosis-related services, to non-elderly childless adults with family income of up to 100% FPL		
Hypothesis 1.2. Expansion of benefits to CLAs will lead to their increased access to medical care.	Group A	Group C
Hypothesis 1.3. Expansion of benefits to CLAs will lead to their improved health.	Group A	Group C
Hypothesis 1.4. Expansion of benefits to CLAs will lead to lower provision of uncompensated care by hospitals.	Group A	Group C
Provision 2: Implement an \$8 copayment for non-emergent use of the emergency department for childless adults		
Hypothesis 2.1. The imposition of a co-payment for non-emergent use of the emergency department will lead to more appropriate uses of medical care among CLAs enrolled in Medicaid.	Group A	Group C
Provision 3: Provide residential treatment benefit for SUD and coverage for existing SUD services when they are provided in an institution of mental disease (IMD).		
Hypothesis 3.2a. After implementation of the SUD demonstration waiver, members' awareness of available SUD treatment services will increase over time	Groups A, B, and C	None
Hypothesis 3.3a. The SUD demonstration waiver will increase or have no effect on SUD outpatient services and pharmacotherapy treatment provided outside of IMD settings.	Groups A, B, and C	None
Hypothesis 3.3b. The SUD demonstration waiver will reduce use of hospital-based services.	Groups A, B, and C	None
Hypothesis 3.3c. The SUD demonstration waiver will increase use of health care for co-morbid physical and mental health conditions among members with an SUD.	Groups A, B, and C	None
Hypothesis 3.3d. The SUD demonstration waiver will increase adherence to SUD treatment.	Groups A, B, and C	None

II. EVALUATION PROVISIONS, HYPOTHESES, AND QUESTIONS

IIA. Provision I: Coverage up to 100% FPL for Childless Adults

A1. General Background Information

Provision: Provide state plan benefits, other than family planning and tuberculosis-related services, to non-elderly CLAs with family income of up to 100% FPL.


In April 2014, Wisconsin initiated a CMS-approved 1115 Demonstration Waiver that allowed federal Medicaid matching funds for providing health care coverage for CLAs between the ages of 19 and 64 years old who have income at or below 100% FPL. The childless adult population receives the standard benefit plan, which is the same benefit plan that covers parents, caregivers, and children. That waiver expired on December 31, 2018, a new waiver extended it through 2023, and the current demonstration extends it through 2029.

Medicaid program goal: To improve health outcomes and reduce unnecessary services. By establishing an eligibility income limit at 100% FPL, rather than implementing a full ACA-authorized Medicaid expansion, the State of Wisconsin focused on “creating a program that is sustainable” and “available to those who need it most.” **Figure 1** below displays the driver diagram for the CLA coverage expansion. In the logic of the driver diagram, the immediate outcomes are necessary mechanisms or conditions to achieve the secondary outcomes which in turn contribute directly to realizing the overall goal of the CLA coverage expansion: *to improve health outcomes and reduce unnecessary services for the Medicaid population.*

The immediate outcome from the CLA coverage expansion is to increase health insurance coverage for the Medicaid population and thereby decrease the overall uninsured rate across the state. The net size of this change depends on whether there are declines in coverage from other sources. Secondly, the covered CLA population should increase their health care utilization and hospitals should hypothetically experience a decrease in the uncompensated care they provide due to a decreased uninsured population. Finally, increased health care utilization that is appropriate can lead to improved health in the longer run.

A1.1. Driver Diagram

Figure 1. Driver Diagram for Childless Adults Coverage Expansion



A2. Evaluation Questions and Hypotheses

A2.1. Hypotheses & Research Questions

Hypothesis 1.1. The expansion of benefits to non-elderly CLAs will reduce the state's uninsured rate.

Primary Research Question 1.1: Did the expansion of benefits to CLAs reduce the state's uninsured rate?

Q 1.1a. What are the trends in Wisconsin's adult uninsured rate and uninsured rate among CLAs?

Q 1.1b. How much did the change in the number of CLAs due to the benefit expansion contribute to the overall change in the adult uninsured rate in Wisconsin?

Hypothesis 1.2. The expansion of benefits to CLAs will lead to their increased access to medical care.

Primary Research Question 1.2: How did the CLA expansion affect the use of health care services?

Q 1.2a. Is the expansion of benefits to CLAs associated with increased or stable use of medical care among CLAs in Wisconsin since the initial implementation of the coverage provision?

Q 1.2b. What are the short- and long-term effects of CLA eligibility and coverage policies on Medicaid health service expenditures?

Hypothesis 1.3. The expansion of benefits to CLAs will lead to their improved health.

Primary Research Question 1.3: How did the CLA expansion affect the health of CLAs?

Q 1.3a. Is the expansion of benefits to CLAs associated with increased or stable use of medications for common chronic conditions?

Q 1.3b. How did trends in mortality change after expansion of benefits to CLAs?

Hypothesis 1.4. The expansion of benefits to CLAs will lead to lower provision of uncompensated care by hospitals.

Primary Research Question 1.4. Did the expansion of benefits to CLAs reduce the provision of uncompensated care (charity care plus bad debt) among Wisconsin hospitals?

Q 1.4a. What are the trends in the provision of uncompensated care among Wisconsin hospitals and did it change along with the expansion of benefits to CLAs?

Q 1.4b. Did hospitals in areas with greater reductions in the number of uninsured CLAs experience differential changes in uncompensated care?

A3. Methodology

A3.1. Evaluation design summary

We will use three analytic approaches to address the primary research question for the evaluation of coverage for CLAs up to 100% FPL. These are interrupted time series, difference-in-differences, and panel data models based on geographically contiguous and matched counties. All analyses will include a comparison of changes in the current waiver period compared to past waiver periods and to baseline. The evaluation team recognizes that parents and caregivers have a different health profile than CLAs and will address this using matching analyses and out of state control groups where feasible. We will also identify factors associated with outcomes, for example, what factors are predictive of utilization. The details of the statistical specifications and controls will be developed by the evaluation team and reported in the interim and final reports. Modifications of planned analyses may occur if alternative approaches are decided to better support addressing the research questions. Planned model specifications, statistical tests, and units of analyses are included in section A.3.3.

The Design Table (**Table**) summarizes the key features of the evaluation design.

Table 4. Provision 1: Summary of Hypotheses, Questions, Data Sources, and Analytic Approaches for Evaluation of the Expansion of Medicaid Benefits to Childless Adults (CLAs)

Comparison Strategy	Outcome Measures	Data Sources	Analytic Approach
Hypothesis 1.1: The expansion of benefits to non-elderly childless adults will reduce the state’s uninsured rate.			
Primary Research Question 1.1: Did the expansion of benefits to CLAs reduce the state’s uninsured rate?			
Question 1.1a: What are the trends in Wisconsin’s adult uninsured rate and uninsured rate among CLAs?			
CLAs in prior waiver periods	No source of insurance coverage	American Community Survey	Descriptive
	Covered by Medicaid/BadgerCare		
	Covered by private insurance	Family Health Survey	
	Other public coverage		
Question 1.1b: How much did the change in the number of CLAs due to the benefit expansion contribute to the overall change in the adult uninsured rate in Wisconsin?			
CLAs in other states	No source of insurance coverage	American Community Survey	Difference-in-differences
	Covered by Medicaid/BadgerCare		
	Covered by private insurance	Behavioral Risk Factor Surveillance System	
	Other public coverage		
Adults in counties that neighbor Wisconsin	No source of insurance coverage	Small Area Health Insurance Estimates	Panel data models based on geographically contiguous and matched border counties
Hypothesis 1.2. The expansion of benefits to CLAs will lead to their increased access to medical care.			
Primary Research Question 1.2: How did the CLA expansion affect the use of health care services?			
Question 1.2a: Is the expansion of benefits to CLAs associated with increased or stable use of medical care among CLAs in Wisconsin since the initial implementation of the coverage provision?			
CLAs in other states	Self-reported utilization and access to care	Behavioral Risk Factor Surveillance System	Difference-in-differences
	Dentist visits		

Comparison Strategy	Outcome Measures	Data Sources	Analytic Approach
	Doctor visits, including primary care	Family Health Survey	
Parents and caregivers in Wisconsin	Emergency department visits	Survey of members	
	Health care access	CARES, State Medicaid Claims	
Question 1.2b: What are the short- and long-term effects of CLA eligibility and coverage policies on Medicaid health service expenditures?			
Parents and caregivers in Wisconsin	Total Medicaid-paid health care expenditures	CARES, State Medicaid Claims	Difference-in-differences
	Per-person Medicaid-paid health care expenditures		
Hypothesis 1.3. The expansion of benefits to CLAs will lead to their improved health.			
Primary Research Question 1.3: How did the CLA expansion affect the health of CLAs?			
Question 1.3a: Is the expansion of benefits to CLAs associated with increased or stable use of medications for common chronic conditions?			
Parents and caregivers in Wisconsin	Validated, commonly used quality measures; example measures include proportion of days covered with appropriate chronic condition medication	Medicaid enrollment, claims, and encounters	Difference-in-differences
CLAs in other states	Validated, commonly used quality measures reported and measurable in other states such as Medicaid Adult Core Set	Aggregate	Descriptive analyses
		Available measures in BRFSS, FHS, and member survey	
Question 1.3b: How did trends in mortality change after expansion of benefits to CLAs?			
Parents and caregivers in Wisconsin	All mortality causes; mortality from preventable causes	Wisconsin death records	Descriptive analyses
CLAs in prior waiver periods			
Hypothesis 1.4. The expansion of benefits to CLAs will lead to lower provision of uncompensated care by hospitals.			
Primary Research Question 1.4: Did the CLA expansion reduce the provision of uncompensated care among Wisconsin hospitals??			
Question 1.4a. What are the trends in the provision of uncompensated care among Wisconsin hospitals and did it change along with the expansion of benefits to CLAs?			

Comparison Strategy	Outcome Measures	Data Sources	Analytic Approach
Acute care and critical access hospitals in prior waiver periods	Dollar amount of charity care provision	CMS Hospital Cost Reports DSH audit data (for years available)	Interrupted time series
	Dollar amount of bad debt		
Question 1.4b. Did hospitals in areas with greater reductions in the number of uninsured CLAs experience differential changes in uncompensated care?			
Acute care and critical access hospitals in other states	Dollar amount of charity care provision	CMS Hospital Cost Reports DSH audit data (for years available)	Difference-in-differences
	Dollar amount of bad debt		
Acute care and critical access hospitals in neighboring geographic areas	Dollar amount of charity care provision	CMS Hospital Cost Reports DSH audit data (for years available)	Two-way fixed effect models based on geographically contiguous and matched border areas
	Dollar amount of bad debt		

A3.2. Evaluation Period

The evaluation period will include the years 2012 (prior to initial CLA coverage expansion), through 2029 as feasible given data sources, including previous waiver periods. The Provision 1 analyses will apply to the current demonstration period while including the timeline of the 2014 initial expansion to the CLA population as relevant contextual background. Effects may differ across these time periods, which we will test for in the analyses.

A3.3. Analytic Methods

We will address each of the primary research questions as follows:

Q1.1. “Did the expansion of benefits to CLAs reduce the state’s uninsured rate?” We will compare trends for CLAs in Wisconsin both pre- and post-expansion. These analyses will be mainly descriptive, but we will test for differences across waiver periods to determine changes in the fraction of CLAs in the state who did not have any source of health insurance and whether those reductions were maintained. An example regression specification would be a time series regression of the following form, which is an interrupted time series model:

$$Y_t = \beta_0 + \beta_1 t + \gamma_1 D_{2t} + \gamma_2 D_{3t} + \gamma_3 D_{4t} + \delta_1((t - t_2) \cdot D_{2t}) + \delta_2((t - t_3) \cdot D_{3t}) + \delta_3((t - t_4) \cdot D_{4t}) + \epsilon_t$$

where Y_t is the dependent variable at time t , the time trend is represented by t , the D variables represent dummy variables for the waiver periods (2014-2018, 2019-2023, and 2024+, beginning at times t_1 , t_2 , t_3 , and t_4) and ϵ_t is the error term. The γ and δ coefficients are of interest, as they test for a change in the slope and intercept for each period relative to the baseline period. To determine if reductions were maintained or if trends differed between waiver periods, we will conduct F-tests on the coefficients (e.g., testing the hypothesis $\delta_1 = \delta_3$). To ensure valid statistical inference, we will estimate the model with Newey-West standard errors, which are robust to both heteroskedasticity and autocorrelation, using an appropriately selected lag length.

Additional outcomes we will examine include sources of insurance coverage, including Medicaid/BadgerCare, private insurance, and other sources of public coverage (such as Medicare). We can construct these outcomes using data from the American Community Survey, the Behavioral Risk Factor Surveillance System survey, and from Wisconsin’s Family Health Survey.

We will also compare CLAs in Wisconsin with CLAs in other states using difference-in-differences. In particular, we will use the ACS to compare the change in the fraction of CLAs in Wisconsin without health insurance with the change in the fraction of CLAs in states that did not expand Medicaid and, similarly, with the change in states that fully expanded Medicaid. Since no other state policy mirrors Wisconsin’s unique CLA coverage expansion, this approach allows us to fully contextualize the policy

reflected in the waiver. This analysis will also examine changes in sources of coverage (Medicaid/BadgerCare, private, other public). Model specifications will be of the following form:

$$Y_{ist} = \beta_1(WI_s \times Post_t) + \alpha_s + \delta_t + X'_{ist}\gamma + \varepsilon_{ist}$$

where Y_{ist} represents the outcome for individual i in state s at year t , WI_s represents an indicator for living in Wisconsin, $Post_t$ represents an indicator for the period after the waiver was implemented (with some specifications separating this indicator into the distinct waiver periods 2014-2018, 2019-2023, and 2024+) and X'_{ist} representing a vector of appropriate individual-level control variables. The sample will alternatively include CLAs living in Wisconsin and states that did or did not choose to expand Medicaid, so that the coefficient β_1 represents the difference in Wisconsin relative to the comparison group of states in the post period vs. the pre-period. Standard errors will be clustered at the state level and comparisons of coefficients will be made using F-tests or using interaction terms in pooled models as appropriate.

We will compare adults in counties that border Wisconsin with adults in Wisconsin by geographically matching border counties in Wisconsin to their contiguous border counties in neighboring states and estimating panel data models using data from the Census Small Area Health Insurance Estimates program. These models will enable us to determine the effect of the CLA expansion on the fraction of adults without health insurance. These will be specified as county-level difference-in-differences (DiD) models with two-way fixed effects, as exemplified in the following:

$$Y_{ct} = \beta_1(WI_Border_c \times Post_t) + \alpha_c + \delta_t + \varepsilon_{ct}$$

where Y_{ct} represents the outcome for county c at time t , WI_Border_c is an indicator for a Wisconsin border county, $Post_t$ is an indicator for the post-policy time period, α_c represents county fixed effects, and δ_t represents year fixed effects with β_1 the coefficient of interest in the difference-in-differences estimator. Standard errors will be clustered by matched county sets. In some specifications, we will divide $Post_t$ into the different waiver periods (2014-2018, 2019-2023, 2024+) and test for differences in the coefficient across these time periods using F-tests.

Q1.2. “How did the CLA expansion affect the use of health care services?” We will compare CLAs in Wisconsin with CLAs in other states using difference-in-differences and data from BRFSS, in specifications that mirror the difference-in-differences specification described in Q1.1. We will undertake a similar comparison between parents and caregivers enrolled in Medicaid in Wisconsin and CLAs using the Family Health Survey as well as using the Medicaid claims and encounter data. We will perform descriptive analyses taking advantage of the historical data available in the Wisconsin Medicaid member surveys from previous waiver periods using z-tests and chi-square tests or interaction terms in pooled models to examine differences in responses over time.

Q1.3 “How did the CLA expansion affect the health of CLAs?”

High quality medication use is believed to lead to positive health outcomes over time. In order to assess the quality of medication use in the CLA coverage expansion, we will apply a variety of commonly used quality measures endorsed by CMS (e.g., Medicaid Adult Core Set), and other national quality organizations as appropriate. We will compare CLAs in Wisconsin with parents and with CLAs in other states where data are available using difference-in-differences methods using a similar specification as in Q1.1. As available, we will incorporate data from the BRFSS, Family Health Survey, and Wisconsin Medicaid member surveys.

Mortality is a slow-moving outcome with many determinants outside of health care coverage. We will undertake a descriptive analysis of parents and caregivers enrolled in Medicaid in Wisconsin and CLAs over time using CARES data linked to Wisconsin death records to examine trends in all-cause and preventable mortality. This will include time series modeling as proposed in Q1.1.

Q1.4. “Did the CLA expansion reduce the provision of uncompensated care among Wisconsin hospitals?” We will employ interrupted time series, difference-in-differences using hospitals in selected comparison states, and panel data models on hospitals in geographically matched areas to determine the impact of the CLA expansion on the provision of charity care and on bad debt by hospitals using data from the CMS hospital cost reports and from DSH audits (for available years). The regression specifications will mirror those proposed in Q1.1 with the exception of being estimated at the hospital level rather than individual or county.

A4. Methodological Limitations

Because the CLA expansion was implemented at a single time statewide and without randomized controls, the evaluation relies on descriptive and quasi-experimental methods which may limit causal inference potential. More specific further limitations will be specified as the data are examined and specific statistical specifications are developed; all statistical results will be presented with appropriate caveats in context.

IIB. Provision 2: Emergency Department Co-Payments

B1. General Background Information


The driver diagram in **Figure 2** below displays how the ED copayment policy is designed to achieve its outcomes. In the logic of the driver diagram, the immediate outcomes are necessary mechanisms or conditions to achieve the secondary outcomes which in turn contribute directly to realizing the overall Medicaid program goal of the ED copayment policy: *To ensure that CLA Medicaid members use ED and related services appropriately to facilitate the provision of the appropriate level of care.*

For CLAs, an \$8 copayment for non-emergent use of the hospital ED was implemented November 2, 2020. The provider is responsible for using a “prudent layperson” standard in the determination of whether a member has an emergency medical condition. Prior to providing non-emergency services subject to the copayment, hospitals must provide a medical screening, inform the member of the potential cost sharing, and provide the name and location of an alternative provider who could provide services with a lesser or no cost share, including a referral. Providers cannot refuse treatment for nonpayment.

The provider screening for an emergent need and \$8 copayment is designed to educate the CLA member on the appropriate use of the ED and reduce future non-emergent uses of the ED as an immediate outcome. Secondly, the screening may also redirect visits to alternative sites such as primary care or urgent care. Yet another goal of the policy is to provide CLA members experience with a coverage copayment policy that more closely aligns with commercial coverage policies and hypothetically may increase readiness to transition to commercial coverage.

B1.1. Driver Diagram

Figure 2. Driver Diagram: Emergency Department Co-Payment Requirements



B2. Evaluation Questions and Hypotheses

B2.1. Hypotheses & Research Questions

Hypothesis 2.1. The imposition of a copayment for non-emergent use of the emergency department will lead to more appropriate uses of medical care among CLAs enrolled in Medicaid.

Primary Research Question 2.1: Did the imposition of a copayment for non-emergent use of the emergency department reduce the number of non-emergency visits to the emergency department among CLAs enrolled in Medicaid?

Q 2.1a. What was the number of total, emergent, and non-emergent visits to the emergency department among CLAs prior to the imposition of copayments?

Q 2.1b. How did the numbers of emergency department visits and non-emergent visits change among CLAs after the imposition of copayments?

Q 2.1c. How did the use of primary care change among CLAs after the imposition of copayments for non-emergent visits to the emergency department?

Q 2.1d. Do members with copayment requirements understand their payment obligations?

B3. Methodology

B3.1. Evaluation Design Summary

The main analytic approach used in evaluation will be difference-in-differences. The details of the statistical specifications and controls will be developed by the evaluation team and reported in the interim and final reports. Modifications of planned analyses may occur if alternative approaches are decided to better support addressing the research questions. The Design Table (**Table 5**) summarizes the key features of the evaluation design. Planned model specifications, statistical tests, and units of analyses are included in section B.3.3.

Table 5. Provision 2: Summary of Hypotheses, Questions, Data Sources, and Analytic Approaches for Evaluation of Emergency Department Copayment Requirements for CLAs

Comparison Strategy		Outcome Measures	Data Sources	Analytic Approach
Hypothesis 2.1: The imposition of a co-payment for non-emergent use of the emergency department will lead to more appropriate uses of medical care among CLAs enrolled in Medicaid.				
<i>Primary research question 2.1: Did the imposition of a co-payment for non-emergent use of the emergency department reduce the number of non-emergency visits to the emergency department among CLAs enrolled in Medicaid?</i>				
<i>Question 2.1a: What was the number of total, emergent, and non-emergent visits to the emergency department among CLAs prior to the imposition of copayments?</i>				
No comparison strategy is required	Total, emergent, and non-emergent number of ED visits	CARES and WI Medicaid Claims and Encounter Data	Descriptive	
<i>Question 2.1b: How did the numbers of emergency department visits and non-emergent visits change among CLAs after the imposition of copayments?</i>				
Parents and caregiver adults	Total, emergent, and non-emergent number of ED visits	CARES and WI Medicaid Claims and Encounter Data	Difference-in-differences	
Commercially insured adults		WHIO or another comparable data source		
<i>Question 2.1c: How did the use of primary care change among CLAs after the imposition of copayments for non-emergent visits to the emergency department?</i>				
Parents and caregiver adults	Total primary care and urgent care number of visits	CARES and WI Medicaid Claims and Encounter Data	Difference-in-differences	
Commercially insured adults		WHIO or another comparable data source		
<i>Question 2.1d: Do members with co-payment requirements understand their payment obligations?</i>				
No comparison strategy is required	Knowledge and understanding of payment obligations	Member survey	Descriptive	

B3.2. Evaluation Period

The evaluation period will include the years 2016 through 2029, which includes the previous waiver period when copayments began as well as baseline data, through the end of the evaluation period. We will test for differences in potential impact over time as described below. The planned sample frame for the Medicaid data begins in 2016 through the most current available data, and the planned sample frame for the WHIO data is 2018 through the most current available data.

B3.3. Analytic Methods

Q2.1. “Did the imposition of a co-payment for non-emergent use of the emergency department reduce the number of non-emergency visits to the emergency department among CLAs enrolled in Medicaid?” We will employ difference-in-differences designs comparing parents and caretakers in Wisconsin to CLAs in Wisconsin in the Medicaid claims and encounter data, and comparing Medicaid members in Wisconsin to commercial members in Wisconsin using the WHIO data. Non-emergent visits will be measured using a probabilistic method developed for claims data.⁹ By using this method, we will ensure that we will identify non-emergent visits in a consistent manner. We also will examine the total number of ED visits to help determine how any observed changes in non-emergent visits compares to any relative changes in the number of emergent visits. We will examine primary care to consider substitution to other types of visits. The models will be of the following form:

$$Y_{igt} = \beta_0 + \beta_1(CLA_g \times Post_t) + \beta_2(CLA_g) + \beta_3(Post_t) + X'_{igt}\gamma + \varepsilon_{igt}$$

where Y_{igt} represents the outcome for individual i in group g at time t , CLA_g represents an indicator for being in the childless adult group (alternatively, the Medicaid group in models comparing Medicaid to commercial), $Post_t$ represents an indicator for the period after the co-payment was implemented, and β_1 is the coefficient of interest in the difference-in-differences estimator, with X'_{igt} representing a vector of individual-level control variables. Standard errors will be clustered at the individual level or alternatively, we may estimate models aggregated to the group-time level. In some models, we will divide the post period into distinct waiver periods (2020-2023, 2024+) and test for potential changes in impact across periods using F-tests. As appropriate, we will include models that assess changes within-person over time (using individual fixed effects). Descriptive analyses, including reporting average outcomes over time by group will provide context for these findings.

Using the member surveys, we will assess changes over time in reported knowledge of the provision and experience with it. The main statistical approach will be to test for differences in response rates over

⁹ Codes available here: <https://wagner.nyu.edu/faculty/billings/acs-algorithm>

See, for reference: Billings J, Parikh N, Mijanovich T. Emergency Department Use: The New York Story. New York (NY): Commonwealth Fund; 2000 Nov. (Issue Brief). Available at:

https://www.commonwealthfund.org/sites/default/files/documents/_media_files_publications_issue_brief_2000_nov_emergency_room_use_the_new_york_story_billings_nystory_pdf.pdf

time in measures using z-tests and chi-square tests. We will assess the need to adjust for demographic differences and, if needed, will provide adjusted tests using ordinary least squares regression analysis.

B4. Methodological Limitations

Because the ED copays were implemented at a single time statewide and without randomized controls, the methods we propose are all quasi-experimental. It is possible that there are other factors that are not fully accounted for in the design that may have a more direct effect on outcomes. The timing of the ED copay implementation was during COVID and the marginal impact of ED copays on utilization is likely to be overshadowed by COVID impacts. We will employ best practices in accounting for such effects including robustness to different time periods and controls.

IIC. Provision 3: Substance Use Disorder – Expansion of Covered Services

C1. General Background Information

Provision: Modify the benefit package for substance use disorder (SUD) treatment for all Medicaid members. Specifically, the demonstration waiver authorizes federal funding for treatment provided to all Wisconsin Medicaid members in Institutions for Mental Disease (IMD) allowing Wisconsin Medicaid to make two significant programmatic changes: 1) to establish a residential treatment benefit for SUD; and 2) to cover existing services when they are provided in an IMD specifically including medically supervised withdrawal management, inpatient services, and medication-assisted treatment (MAT). This provision took effect on February 1, 2021.

Additionally, the demonstration waiver includes several new or revised policies to support the implementation and quality of these newly covered services. These policies, which took effect on February 1, 2021, are as follows: updated licensure/certification requirements for providers (ongoing); ensuring ASAM-consistent placement criteria (ongoing); utilization management (prior authorization) for the residential treatment benefit; residential treatment provider qualifications that align with national standards (ongoing); requirement that residential treatment facilities offer MAT (onsite or offsite).

The new residential treatment benefit builds on the existing robust set of services currently covered by the Wisconsin Medicaid program to treat substance use disorders (SUDs) for all members, including outpatient counseling, day treatment, psychosocial rehabilitation, MAT, telehealth services (expanded with the onset of the COVID-19 PHE) and inpatient treatment.

Medicaid program goal: To reduce the incidence of drug overdose deaths, including opioid-related deaths, by improving access to the full continuum of treatment.


C1.1. Driver Diagram

Figure 3 displays the driver diagram. In the logic of a driver diagram, secondary drivers are mechanisms or conditions that are necessary to achieve the primary drivers which in turn contribute directly to realizing the overall purpose of the demonstration waiver. **Figure 3** also includes the specific programmatic changes that the Wisconsin Medicaid program will implement under the SUD demonstration waiver. We do so to show how these changes hypothetically relate to the demonstration waiver’s overall goal of reducing drug overdose deaths in the Medicaid population.

The programmatic changes fall within three functional categories: supply of Medicaid SUD providers at all levels of care; coverage for SUD services; and quality of SUD services. These changes have the potential to impact the rate of drug overdose deaths through a sequence of mechanisms. Most directly, the programmatic changes have the potential to increase the supply of SUD providers that accept and treat Medicaid members, and to increase Medicaid members’ use of SUD services. These mechanisms are represented in **Figure 3** as secondary drivers.

These secondary drivers may, in turn, influence the primary drivers: 1) members’ health care needs and preferences, and 2) their capacity to seek care that is suited to their needs. For example, increased access to SUD providers and increased use of SUD services may reduce symptoms of SUD, increase the likelihood of recovery, increase engagement in health care, and foster knowledge and awareness of treatment needs. These changes may thus enable members to remain in SUD treatment, reduce hospital-based SUD service use, and/or address previously ignored physical and mental health co-morbidities. Improvements in outcomes considered primary drivers then have the potential to influence the waiver’s overall goal of reducing drug overdose deaths among Medicaid members.

Figure 3. Driver Diagram: Substance use Disorder Waiver Provision



**Goal for SUD treatment reform per Wisconsin Medicaid’s SUD Implementation Protocol, June 2019

C2. Evaluation Questions and Hypotheses

The following section of the evaluation design report follows the format and guidance that CMS issued specifically for evaluation of SUD demonstration waivers.¹⁰ For this reason, the format of this section of the design report and its related tables/figures differs in some respects from the sections of the evaluation design that are focused on other provisions in the demonstration waiver.

C2.1. Hypotheses and Research Questions

SUD Demonstration Waiver: Expands coverage for SUD treatment in IMD settings including a new residential treatment benefit and coverage for inpatient and medically supervised withdrawal management services, and adopts new or revised policies to support implementation of this coverage expansion.

Question 3.1. Does the SUD demonstration waiver increase the supply of SUD providers for Medicaid members?

H3.1a. The SUD demonstration waiver will increase the supply of SUD providers that accept and/or treat Medicaid members.

Question 3.2. Does the SUD demonstration waiver increase access to, and use of, newly covered SUD services for Medicaid members?

H3.2a. After implementation of the SUD demonstration waiver, members' awareness of available SUD treatment services will increase over time.

H3.2b. The SUD demonstration waiver will increase use of SUD treatment in IMD settings including residential treatment, inpatient treatment, medically supervised withdrawal services and MAT for opioid use disorder.

H3.2c. The SUD demonstration waiver will increase initiation and engagement in SUD treatment.

Question 3.3. Does the SUD demonstration waiver change Medicaid members' use of existing covered SUD services?

H3.3a. The SUD demonstration waiver will increase or have no effect on SUD outpatient services, including in-person and telehealth, and pharmacotherapy treatment provided outside IMD settings.

H3.3b. The SUD demonstration waiver will reduce use of hospital-based SUD services.

H3.3c. The SUD demonstration waiver will increase access to health care for co-morbid physical and mental health conditions among members with a SUD.

H3.3d. The SUD demonstration waiver will increase adherence to SUD treatment.

Question 3.4. Does the SUD demonstration waiver reduce the rate of drug overdose deaths among Medicaid members including opioid-related deaths?

¹⁰ Centers for Medicare and Medicaid Services. Substance Use Disorder Section 1115 Demonstration Evaluation Design- Technical Assistance. March 6, 2019. Available at: <https://www.medicaid.gov/medicaid/section-1115-demo/downloads/evaluation-reports/smi-sed-sud-1115-eval-guide.pdf>

H3.4a. The SUD demonstration waiver will reduce the rate of drug overdose deaths among Medicaid members, including opioid-related overdose deaths.

Question 3.5. What are the patterns and trends in Medicaid costs associated with the SUD demonstration waiver?

The final research question, Q3.5, follows from the recommendations in the CMS technical assistance guidance on SUD demonstration waiver evaluations. Consistent with this guidance, there are no accompanying hypotheses.

C3. Methodology

C3.1. Evaluation Design Summary

We will use descriptive analyses to characterize changes over time in evaluation outcomes and to identify key correlates associated with the outcomes including member characteristics, county-level SUD prevention and treatment resources, and potential changes in state and federal policy or events within and beyond the Medicaid program that are related to SUD prevention and treatment. (e.g., expanded coverage of telehealth services for SUD treatment, allocation of opioid settlement funds, etc.) Where possible, we will employ techniques that allow for causal inference. Planned model specifications, statistical tests, and units of analyses are included in section C3.2.

The provisions in the SUD demonstration waiver affect the full Wisconsin Medicaid population. The evaluation focuses specifically on non-elderly adult Medicaid members, ages 21-64, the Medicaid population in Wisconsin with the highest rates of SUD. We exclude adults who are dually enrolled in Medicaid and Medicare because we cannot observe all of their health care use in Medicaid claims and encounters.

The Design Table (**Table 6**) summarizes the key features of the evaluation design, including evaluation questions, hypotheses, data sources and analytic approaches. As noted above, the format of this table conforms to CMS guidance for evaluation of the SUD provision and differs from the form of the table presented in prior sections.

Table 6. Provision 3: Summary of Questions, Hypotheses, Data Sources, and Analytic Approaches for Evaluation of the SUD Demonstration Waiver

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
Q3.1 Does the demonstration waiver increase the supply of SUD providers for Medicaid members?						
<i>H3.1a. The SUD demonstration waiver will increase the supply of SUD providers that accept and/or treat Medicaid members.</i>						
Secondary Driver (Increase Supply of Providers)	Number of residential treatment facilities that accept Medicaid patients [n/a]	Facility reports willingness to accept Medicaid patients	Federal, state, and local government and private residential treatment facilities that provide substance abuse treatment services	National Substance Use and Mental Health Services Survey (N-SUMHSS)	All treatment facilities in Wisconsin and in selected comparison states for the measurement period	Time series
Q3.2 Does the demonstration waiver increase access to, and use of, newly covered SUD services for Medicaid members?						
<i>H3.2a. After implementation of the SUD demonstration waiver, members' awareness of available SUD treatment services will increase over time</i>						
Secondary Driver (Increase Utilization)	Awareness of Medicaid coverage for SUD services [n/a]	Member Survey	Member Survey	Member Survey	Cross-sectional sample of members at two post-implementation time points	Descriptive analysis comparing changes over time in member awareness.
<i>H3.2b. The SUD demonstration waiver will increase use of SUD treatment in IMD settings including residential treatment, inpatient treatment, medically supervised withdrawal services and MAT for opioid use disorder.</i>						
Secondary Driver (Increase Utilization)	Rate of residential SUD treatment use	Any SUD residential treatment use	Full-benefit, non-elderly adult Medicaid member population.	Wisconsin Medicaid claims and encounters	Comparison of use rates across subgroups and time. Subgroups may include eligibility category, admission diagnosis, and demographics.	Time Series; Event Study

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
Secondary Driver (Increase Utilization)	Receipt of medication for opioid use disorder (MOUD) [MODRN] ¹¹	Any claim for MOUD during residential treatment episode	Residential OUD treatment episodes among full-benefit, non-elderly adult Medicaid member population.	Wisconsin Medicaid claims and encounters.	All OUD residential treatment episodes included.	Descriptive Analysis
Secondary Driver (Increase Utilization)	Any use of residential SUD treatment	Any residential SUD treatment use	Full-benefit, non-elderly adult Medicaid member population with an SUD diagnosis.	Wisconsin Medicaid claims and encounters	Non-elderly full benefit Medicaid members with an SUD who do not have a residential SUD treatment use	Use predictive modeling to identify health care trajectories associated with residential SUD treatment use.
<i>H3.2c. The SUD demonstration waiver will increase initiation and engagement in SUD treatment.</i>						
Secondary Driver (Increase Utilization)	Initiation and engagement of alcohol and other drug dependence treatment [NCQA-IET & MODRN] ¹²	Initiation- # of members who initiated treatment w/in 14 days of the index episode. Engagement- # of members who initiated treatment & had ≥2 additional services with a diagnosis of AOD w/in 30 days of initiation visit	Members with a new diagnosis of AOD received between 1/1-11/15 of the measurement year, and continuous enrollment 60 days before new diagnosis and 44 days post.	Medicaid enrollment, claims, and encounters (MODRN Common Data Model)	Adult, non-elderly, full-benefit Medicaid members in WI and participating MODRN states	Descriptive analysis

¹¹ Donohue JM, Jarlenski MP, Kim JY, Tang L, Ahrens K, Allen L, Austin A, Barnes AJ, Burns M, Chang CH, Clark S, Cole E, Crane D, Cunningham P, Idala D, Junker S, Lanier P, Mauk R, McDuffie MJ, Mohamoud S, Pauly N, Sheets L, Talbert J, Zivin K, Gordon AJ, Kennedy S. Use of Medications for Treatment of Opioid Use Disorder among US Medicaid Enrollees in 11 states, 2014-2018.” Journal of the American Medical Association. 2021;326(2):154-164. doi:10.1001/jama.2021.7374.

¹² Austin AE, Tang L, Kim JY, Allen L, Barnes AJ, Chang CH, Clark S, Cole ES, Durrance CP, Donohue JM, Gordon AJ, Huskamp HA, McDuffie MJ, Mehrotra A, Burns ME. Telehealth supported medications to treat opioid use disorder during the COVID-19 pandemic in 10 state Medicaid programs. JAMA Health Forum. 2023;4(6):e231422. Doi.org/10.1001/jamahealthforum.2023.1422.

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
Q3.3 Does the demonstration waiver change Medicaid members' use of existing covered SUD services?						
<i>H3.3a. The SUD demonstration waiver will increase or have no effect on SUD outpatient services, including in-person and telehealth, and pharmacotherapy treatment provided outside of IMD settings.</i>						
Secondary Driver (Increase Utilization)	Any outpatient visits for SUD treatment, and volume of outpatient visits for SUD treatment. [MODRN]	Any, and # of non-emergency department, outpatient claims with a SUD diagnosis and of an OUD diagnosis. Outpatient visits include in-person and telehealth visits.	All member-months observed for target population and comparison group during the measurement period	WHIO; WI Medicaid claims and encounter	Non-elderly adults enrolled in Medicaid and non-elderly adults enrolled in private insurance.	Difference-in-differences
Secondary Driver (Increase Utilization)	Any medication assisted treatment for opioid use disorder [MODRN]	Any claim for buprenorphine, naltrexone (oral), injectable naltrexone, buprenorphine/Naloxone or a HCPCS code for buprenorphine or buprenorphine/naloxone, methadone administration, or naltrexone	All member-months observed for members with at least one encounter with a diagnosis of OUD in inpatient, outpatient, and professional claims during the measurement period	Medicaid enrollment, claims, and encounters (MODRN Common Data Model)	Adult, non-elderly, full-benefit Medicaid members in WI and participating MODRN states	Descriptive analysis
Secondary Driver (Increase Utilization)	Any SUD treatment [n/a]	Member Survey	Member Survey	Member Survey	Cross-sectional sample of members at two post-implementation time points	Descriptive analysis comparing changes over time in SUD treatment
<i>H3.3b. The SUD demonstration waiver will reduce use of hospital-based services.</i>						
Primary Driver (Reduce)	Any emergency department visit with a SUD-	Any, and # of ED visits with a SUD diagnosis of any	All member-months observed for target population and	WHIO; WI Medicaid claims and encounter	Non-elderly adults enrolled in Medicaid and non-	Difference-in-differences

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
Hospital-Based SUD Service Use)	diagnosis, and volume of emergency department visits with an SUD diagnosis [MODRN]	kind; any and # of ED visits with an OUD diagnosis	comparison group during the measurement period		elderly adults enrolled in private insurance	
	Any hospitalization with a SUD diagnosis, and number of hospitalizations with a SUD diagnosis [MODRN]	Any, and # of hospitalizations with a SUD diagnosis of any kind; any, and # of hospitalizations with an OUD diagnosis	All member-months observed for target population and comparison group during the measurement period	WHIO; WI Medicaid claims and encounter	Non-elderly adults enrolled in Medicaid and non-elderly adults enrolled in private insurance	Difference-in-differences
Primary Driver (Reduce Hospital-Based SUD Service Use)	Any, and volume of readmissions within 30-days following hospitalization for a SUD diagnosis [n/a]	Any, and # of readmissions to the hospital within 30-days for an SUD diagnosis of any kind; any and # of readmissions to the hospital within 30-days for an OUD diagnosis	Hospital discharges with a diagnosis of SUD in the measurement period among members with continuous enrollment for a least 31 days post-hospitalization.	WHIO; WI Medicaid claims and encounter	Non-elderly adults enrolled in Medicaid and non-elderly adults enrolled in private insurance	Difference-in-differences
<i>H3.3c The SUD demonstration waiver will increase use of health care for co-morbid physical and mental health conditions among members with a SUD.</i>						
Primary Driver (Increase Use of Health Care for Co-Morbid Conditions)	Any outpatient visits for a non-SUD diagnosis; Quantity of outpatient visits for a non-SUD diagnosis [n/a]. Outpatient visit includes in-	Any, and # of non-emergency department, outpatient claim with a non-SUD diagnosis; any, and # of non-emergency department outpatient claims	All member-months observed for target population and comparison group members with at least one inpatient, outpatient, emergency department or IMD claim with an SUD diagnosis	WHIO; WI Medicaid claims and encounter	Non-elderly adults enrolled in Medicaid and non-elderly adults enrolled in private insurance	Difference-in-differences

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
	person and telehealth visits.	with a non-SUD diagnosis				
Primary Driver (Increase Use of Health Care for Co-Morbid Conditions)	Health status and chronic conditions; access and use of general medical care; Problematic substance use and SUD	Member Survey	Member Survey	Member Survey	Cross-sectional sample of members at two post-implementation time points	Descriptive analysis of changes in outcomes over time
<i>H3.3d. The SUD demonstration waiver will increase adherence to SUD treatment.</i>						
Primary Driver (Increase adherence to SUD treatment)	Continuity of pharmacotherapy for OUD [MODRN]	Members who have at least a) 90 days, and b) 180 days of continuous pharmacotherapy with a medication prescribed for OUD without a gap of more than 7 days.	Members that meet Inclusion criteria: individuals with a diagnosis of OUD in inpatient, outpatient or professional claims; and at least one claim for an oral OUD medication during the measurement period received with at least 180 days before the end of the final calendar year; and continuously enrolled for at least 6 months after the month with the first OUD medication claim with no gap in that enrollment.	Medicaid enrollment, claims, and encounters (MODRN Common Data Model)	Adult, non-elderly, full-benefit Medicaid members in WI and participating MODRN states	Descriptive analysis
Primary Driver (Increase adherence to SUD treatment)	Outpatient follow-up and use of MOUD within 7 and 30 days post-discharge from residential	Members who have an outpatient visit within 7(14) days of discharge; Members who have a claim for MOUD within 7(14) days of discharge.	Residential SUD treatment episodes.	Medicaid enrollment, claims, and encounters (MODRN Common Data Model)	Adult, non-elderly, full-benefit Medicaid members in WI and participating MODRN states	Descriptive analysis

Driver	Measure Description [steward]	Numerator	Denominator	Data Source	Comparison Group(S)	Analytical Approach
	treatment [MODRN] ¹³					
Primary Driver (Increase adherence to SUD treatment)	Outpatient follow-up within 7 and 14 days post-discharge from SUD-related ED visit	Members who have an outpatient visit within 7(14) days of an SUD-related ED visit	SUD-related ED visits	Medicaid enrollment, claims, and encounters (MODRN Common Data Model)	Adult, non-elderly, full-benefit Medicaid members in WI and participating MODRN states	Descriptive analysis
Q3.4 Does the demonstration waiver reduce the rate of drug overdose deaths among Medicaid members including opioid-related deaths?						
<i>H3.4a. The SUD demonstration waiver will reduce the rate of drug overdose deaths among Medicaid members.</i>						
Purpose (Reduce drug overdose deaths including opioid-related deaths)	Rate of drug overdose death, and opioid-related drug overdose death [WIDHS - Technical Notes Annual Death Report, 2017, P-01170-19]	# of deaths due to any type of drug overdose; # of deaths due to opioid drug overdose; # of deaths all cause	Medicaid non-elderly adult population; Estimated Wisconsin non-elderly adult population not enrolled in Medicaid; Estimated Wisconsin non-elderly population.	WI Death Records; Census Estimates; Medicaid Enrollment	Wisconsin non-elderly adult population not enrolled in Medicaid during the measurement period	Time series
Q3.5 What are the patterns and trends in Medicaid costs associated with the SUD demonstration waiver?						
	Total health care costs; SUD and non-SUD costs; category-specific costs (inpatient, pharmacy, outpatient non-ED, outpatient ED, residential treatment).	Medicaid amount paid for each outcome noted.	All member-months observed during the measurement period for the target population.	Medicaid claims and encounter data.	Non-elderly adult Medicaid members	Descriptive analyses of patterns and trends in total and SUD-specific Medicaid expenditures
Note: MODRN refers to the Medicaid Outcomes Distributed Research Network's Opioid Use Disorder workgroup. https://www.academyhealth.org/MODRN						

¹³ The Medicaid Outcomes Distributed Research Network (MODRN). Outpatient follow-up and use of medications for opioid use disorder after residential treatment among Medicaid enrollees in 10 states. Drug and Alcohol Dependence 241 (2022): 109670

C3.2. Analytic Methods

We will address the evaluation questions as follows:

Q 3.1. “Does the SUD demonstration waiver increase the supply of SUD providers for Medicaid members?” To understand whether the waiver has an ongoing impact on the supply of residential treatment facilities that accept Medicaid members, we will use the N-SUMHSS to compare trends in Medicaid acceptance for residential treatment facilities in Wisconsin from 2021–2029 relative to states without an SUD IMD waiver (“non-waiver states”). These analyses will be mainly descriptive. We will describe changes in the percentage of facilities that accept Medicaid in Wisconsin and test whether the trend in Medicaid acceptance in Wisconsin is increasing over time relative to non-waiver states. An example regression specification would be a time series regression of the following form:

$$Y_{it} = \beta_0 + \beta_1 t + \gamma WI_t + \delta(t \cdot WI_t) + X'_{it}\varphi + \alpha S_t + \epsilon_{ist}$$

where Y_{it} is the dependent variable for unit i at time t . In this case, i represents a facility and t represents a year. The time trend is represented by t , and WI is a dummy variable equal to one for facilities in Wisconsin. Non-waiver states serve as the comparison group. The vector X' represents characteristics that vary by unit i and time t ; the vector S represents a vector of state-year characteristics, and ϵ_{ist} is the error term clustered at the state level. The coefficient of interest, δ , represents the change in the trend in WI relative to the comparison group. To determine if the trend in facility acceptance rate in WI differed from non-waiver states, we will conduct a Wald test on this coefficient (e.g., testing the hypothesis $\delta = 0$).

The composition of the comparison group will change over time to the extent that state SUD IMD status changes between 2021–2029. We will assess the sensitivity of results to these potential changes by restricting the analyses to the subset of comparison states that have unvarying SUD IMD waiver status over the study period

Q 3.2. “Does the SUD demonstration waiver increase access to, and use of, newly covered SUD services for Medicaid members?” First, to determine the magnitude of increase in member awareness of SUD treatment services in the years following its implementation (H3.2a), we will compare responses to the surveys of Medicaid members that the team will field over time. To address the hypotheses regarding increases in utilization of treatment, we will use the Wisconsin Medicaid claims and in addition to examining trends over time, we will use event study analysis to estimate the impacts of room and board grants on utilization rates and use predictive modeling techniques to identify drivers of residential treatment. To address the hypothesis within question 3.2 pertaining to an expected increase in initiation and engagement in SUD treatment (H3.2c), we will take advantage of IRP and investigator participation in the MODRN Common Data model to compare adults in Wisconsin to trends in these outcomes in other states participating in MODRN over time. For the analysis of survey data, we will rely on four waves, and utilize a cross-sectional, pre-post analysis to compare the percentage of respondents that believe residential treatment for SUD is

covered, from 2020 (prior to coverage) to 2024, 2026, and 2029 (all post coverage). Specifically, we will estimate models of the form:

$$Y_{it} = \beta_0 + \sum_{\tau \in \{2024, 2026, 2029\}} \beta_{\tau}(\text{wave}_t = \tau) + X'_{it}\theta + \epsilon_{it}.$$

The dependent variable Y_{it} is an indicator for “believes residential SUD treatment is covered.” We include a set of covariates indicating survey strata and potentially other factors. Our interest is in the post-implementation coefficient β_{τ} . To test the null hypothesis that (adjusting for composition) awareness of residential coverage has not increased, we test the hypothesis using a Wald test that $\beta_{\tau} = 0$, for each post-period τ . Rejecting this null hypothesis would indicate that awareness has increased (or decreased). We will also jointly test the null hypothesis of no change in awareness with an F-test for joint significance of the β_{τ} s. We will weigh the estimation appropriately given the survey design.

We will use Medicaid enrollment and claims data to test whether the rate of SUD residential treatment admissions among Wisconsin Medicaid members remains stable or increases from 2021 through 2029. We will first describe and plot the changes in the rate of residential treatment admissions in the member population and then test for potential differences in admission rates across selected subgroups (e.g., defined by mutually exclusive categories such as eligibility category). An example regression specification for the overall test of trend would be a simplified version of the time series regression shown in Q3.1:

$$Y_t = \beta_0 + \beta_1 t + X'_t \varphi + \epsilon_t$$

where Y_t is the dependent variable, the number of admissions to residential treatment per 10,000 beneficiaries in the month-year t . The time trend is represented by t , the vector X represents beneficiary population characteristics that vary by time, and ϵ_t is the error term. The coefficient of interest, β_1 , is the mean change in the monthly admission rate relative to baseline conditional on the other terms in the model. We will test the hypothesis that $\beta_1 \geq 0$ using a Wald test.

To test for differential changes over time in the admission rate by subgroup, we will include dummy variables for the subgroups of interest in the model and interact each of those dummy variables with the time trend as shown in the model specification for Q3.1. To determine if the change over time in baseline admission rate differs for one subgroup relative to another, we will conduct an F-test on the coefficients for the interaction terms. We will consider alternative units of time (e.g., quarter, annual) for this analysis based on the frequency of the outcome and to facilitate interpretability. To ensure valid statistical inference, we will estimate the model with Newey-West standard errors, which are robust to both heteroskedasticity and autocorrelation, using an appropriately selected lag length.

Thirteen-months after implementation of the SUD waiver, in April 2022, the state began allocating opioid settlement funds received through the National Prescription Opiate Litigation in the form of grants to counties and tribal nations to pay for the costs of room and board associated with residential treatment for Medicaid beneficiaries who receive residential treatment for opioid use disorder. The room and board grants have continued with the latest round issued for 2026. Using Medicaid enrollment and claims data, we will implement an event study to test for an increase in the likelihood of a residential treatment admission following the provision of these grants. An example regression specification is below:

$$Y_{it} = \sum_{\tau \in \{-m, \dots, 0, \dots, n\}} \gamma_j D_{i,t-j} + X'_{it} \theta + \epsilon_{it}.$$

where Y_{it} is the outcome, a residential treatment admission, for individual i in month t . The term, $D_{i,t-j}$, is an indicator variable for event time, j . Event time is time relative to the event which is the number of months before or after the event - April 2022, in this case. A separate indicator variable is included for each event time (i.e., 2 months before the event, 3 months before the event, etc.). The constants m and n define the endpoints for the event study terms. A vector of control variables, X_{it} , and an error term complete the model. The coefficients of interest, γ_j , reflect the effects of the treatment (in this case, introduction of grants for room and board). The coefficients (γ_j for $j \geq 0$) represent the effects of the treatment over time since the event occurred. We will conduct a F-test of the null hypothesis that the post-event coefficients are jointly = 0. The coefficients (γ_j for $j < 0$) provide a falsification test; we would not expect the pre-event terms to demonstrate a trend and will conduct an F-test that the pre-event coefficients are jointly = 0. We will repeat this analysis with a subsample of the member population, individuals with any non-nicotine, substance use diagnosis in the preceding six months. Additionally, for context, we will plot the rate of residential treatment admissions for Medicaid members where the X-axis represents event time rather than calendar time as described above.

We will quantify the associations between member characteristics and receipt of medication for opioid use disorder during a residential treatment episode among all residential treatment episodes that occur from 2021-2029. An example regression specification would be the following cross-sectional model:

$$Y_{it} = X'_{it} \varphi + \pi_t + e_{it}$$

where Y is the dependent variable for unit i , a residential treatment episode, at time t . The vector X' represents member-episode characteristics including demographics, health-related measures assessed during episode (e.g., a diagnosis of OUD), and receipt of MOUD before the episode; π_t is a vector of time fixed effects; and e_{it} represent the error term. We will use Wald tests to test the hypothesis that the coefficient for the member-episode characteristic of interest is equal to zero. We will adjust standard errors for multiple observations within person over time.

We will conduct descriptive analyses of the health care trajectories associated with beginning residential SUD treatment. A health care trajectory is a specific sequence of health care encounters. For example, a patient might have an emergency department visit for SUD, a detox admission, and then a residential SUD treatment. Our study team will define trajectories leading up to residential treatment that we expect to be common, drawing on our clinical expertise. Then we will estimate two sets of predictive models, for the probability that patient i in month t initiates residential SUD treatment:

$$\Pr(\text{Res SUD}_{it}) = F\left(\theta_t + X'_i\beta + \sum_{\tau=0}^{\tau=2} \sum_c \eta_{\tau c} 1\{\text{HadCareType } c\}_{it-\tau}\right)$$

$$\Pr(\text{Res SUD}_{it}) = F\left(\theta_t + X'_i\beta + \sum_j \eta_j 1\{\text{Trajectory} = j\}_{it}\right)$$

The sample will be limited to full-benefit adult patients with a diagnosis of SUD in month $t - 1$ or earlier, and months where the waiver is in effect so that residential SUD treatment is well-measured. The F function here is the probit functional form. The first model relates residential SUD treatment to encounter types in the current and prior two months. The care types c will include health care encounters such as emergency department visits for SUD and inpatient visits for SUD. This model will enable assessment of time-based patterns in the data, such as whether emergency department SUD encounters are associated with subsequent residential SUD treatment. To measure the importance of particular trajectories in predicting residential treatment (e.g. ED then detox vs. detox alone or ED alone), we will estimate the second model which relates residential SUD treatment to defined, mutually exclusive trajectories (ED visit followed by detox, for example). Both models adjust for patient characteristics X'_i and time fixed effects θ_t .

This analysis will point to trajectories that are and are not predictive of initiating residential SUD treatment. Understanding these trajectories is valuable for assessing the degree to which residential SUD treatment reflects types of preceding health care verse types of patient characteristics and clinical indications, and whether there are opportunities to optimize access to residential SUD treatment by leveraging key transitions of care. For example, underutilization of residential SUD treatment among patients experiencing inpatient SUD admissions could indicate opportunity for state Medicaid policies and programs to tailor navigation towards these services.

We will conduct cross sectional, descriptive comparisons of the annual rates of medication for opioid use disorder (OUD) initiation and the rates for engagement in additional OUD treatment services from 2018-2029 in Wisconsin and two de-identified comparison states. The comparison states, like Wisconsin, belong to the Medicaid Outcomes Distributed Research Network (MODRN), a network of 15 state and university partnerships described previously in section 1D. Both comparison states implemented their SUD IMD waivers approximately two years before the Wisconsin Medicaid waiver

was implemented. Comparison states have agreed to contribute to this 1115 waiver evaluation on the condition of remaining unidentified.

Each state will generate identically defined annual measures of initiation and engagement rates for their full-benefit, state Medicaid populations overall and for the following strata within each state and year: age group, sex, race/ethnicity, eligibility category, and urbanicity. Comparison states will provide their outcome data to the Wisconsin evaluation team. We will summarize these annual outcomes by state in table and graphic formats including trends over time. Comparison of outcomes across states provides a benchmark and resource to identify anomalous or exceptional outcomes. We will not use statistical tests to identify differences in outcomes across states because the outcomes represent population parameters rather than parameter estimates.

Q 3.3. “Does the SUD demonstration waiver change Medicaid members’ use of existing covered SUD services?”

Using a DiD design, we will compare the likelihood and the volume of health care service use among Medicaid members before (2017-2019) versus after implementation of the residential treatment benefit (2021-2029) to the comparison group of commercially insured adults observed in the WHIO data. The models will be of the following form, mirroring those described in Q3.1:

$$Y_{igt} = \beta_0 + \beta_1(MCD_g \times Post_t) + \beta_2(MCD_g) + \beta_3(Post_t) + X'_{igt}\gamma + \varepsilon_{igt}$$

where Y_{igt} represents the outcome for individual i in group g at time t , MCD_g represents an indicator for being in the Medicaid group, $Post_t$ represents an indicator for the period after the SUD waiver was implemented, and β_1 is the coefficient of interest in the difference-in-differences estimator with X'_{igt} representing a vector of individual-level control variables. Standard errors will be clustered at the individual level or, alternatively, we may estimate models aggregated to the group-time level. In some models, we will divide the post period into distinct waiver periods (2021-2024, 2025+) and test for potential changes in impact across periods using F-tests. As appropriate, we will include models that assess changes within-person over time (using individual fixed effects). Descriptive analyses, including reporting average outcomes over time by group will provide context for these findings.

Identifying a strong comparison group for the Medicaid population from within the commercially insured population can be difficult to the extent that there are time-varying differences between the groups related to outcomes. We will attempt to account for such differences through several strategies including the use of diagnostically similar subpopulations and propensity score weighting as appropriate. We will test for the plausibility of the parallel trends assumption. If those results do not support that assumption, we will not interpret the results causally.

For the analysis of survey data, we will use the specification described in Q3.2 (“details-awareness”). The outcome metric here will be indicators for receipt of any SUD treatment; overall health status

and indicators for chronic conditions; measures of access and general use of medical care; and indicators for problematic substance use, and prevalence of SUD.

We will implement the analytical approach outlined in Q3.2 to describe and compare annual outcomes in Wisconsin and comparison MODRN states for the Q3.3 measures: any medication for opioid use disorder (MOUD), continuity of MOUD for 90 and 180 days, outpatient follow-up within 7 and 14 days after discharge from residential SUD treatment, and outpatient follow-up within 7 and 14 days of an SUD-related emergency department visit.

Q 3.4. “Does the SUD demonstration waiver reduce the rate of drug overdose deaths among Medicaid members including opioid-related deaths?” We will combine Medicaid enrollment data and Wisconsin death records, and we will compare adult Medicaid members to non-Medicaid members in a statewide, population-level analysis. We will estimate the size of the non-Medicaid group from census data and the Medicaid population from Medicaid enrollment data in order to measure rates.

We will summarize in table and graphic forms the unadjusted and age-adjusted monthly mortality rates for each group from 2017 – 2029 including all-cause, overdose, and opioid-related overdose. We will then compare trends in the age-adjusted mortality rates for Medicaid and non-Medicaid populations. These analyses will be mainly descriptive. The general form of the model follows the time series in Q3.1. To test for differences in the outcome trend across the two groups, we will conduct a Wald test on the coefficient for the interaction term between time and the study group (e.g., testing the hypothesis $\delta = 0$). In some models, we will estimate separate trends for distinct waiver periods (e.g., 2017-2020, 2021-2024, 2025+). To ensure valid statistical inference, we will estimate the model with Newey-West standard errors, which are robust to both heteroskedasticity and autocorrelation, using an appropriately selected lag length.

Q 3.5. “What are the patterns and trends in Medicaid costs associated with the SUD demonstration waiver?” We use the Medicaid enrollment data to construct a sample that includes all non-elderly adult Medicaid members enrolled at any point during the evaluation period. We will use descriptive analysis to summarize and plot the trend in health care costs during the evaluation period. We will report overall costs as well as costs by relevant subcomponents. The relevant subcomponents include, but are not limited to: residential SUD treatment, total SUD costs, non-SUD costs, and category-specific costs (e.g. inpatient, pharmacy, outpatient non-ED, outpatient ED, long-term care).

C3.3. Evaluation Period

The implementation of the residential treatment benefit and the implementation date for coverage of existing services within an IMD setting (i.e., inpatient services and medically supervised withdrawal services) took effect on February 1, 2021. The evaluation period for the SUD waiver is February 1, 2017 – January 31, 2029. This allows up to 3 years of observation before (2017-2019)

implementation. The specific duration of the evaluation period may vary according to the question and hypothesis. Effects may differ across these time periods, which we will test for in the analyses.

C4. Methodological Limitations

Implementation of the SUD provision for all adult Medicaid members at the same points in time during the prior waiver period precludes the inclusion of a concurrent, within-state Medicaid comparison group that is exposed to all other potential changes in Medicaid policies during the observation period except the SUD demonstration waiver provisions. By comparing to other states using national surveys or the MODRN data model, we mitigate but do not eliminate concerns about drawing causal conclusions. In addition, policy changes may alter the composition of the adult member population in ways that are relevant to our outcomes to the extent that individuals newly enroll in Medicaid because of the availability of expanded SUD services. Such individuals, for example, may be more likely to have an SUD and a desire for treatment. It is important to distinguish the potential effects of the demonstration waiver on study outcomes, from changes in study outcomes that are attributable to compositional changes in the member population. To assess and mitigate this possibility, as our data permit, we will execute sensitivity analyses that hold the analytic sample constant over time as our data allow to rule out the potential confounding effects of changes in the characteristics of the member population.

III. ATTACHMENTS

Attachment A: Waiver approval letter, waiver provisions, and Special Terms and Conditions (STCs)

Attachment B: Independent Evaluator Assurance of No Conflict

Attachment C: Timelines of Major Evaluation Milestones

Attachment D: Budget and Budget Narrative

Attachment A: Waiver Approval Letter, Waiver Provisions, and STCs

DEPARTMENT OF HEALTH & HUMAN SERVICES
CENTERS FOR MEDICARE & MEDICAID SERVICES
7500 SECURITY BOULEVARD, MAIL STOP S2-26-12
BALTIMORE, MARYLAND 21244-1850



October 29, 2024

Bill Hanna
State Medicaid Director
Wisconsin Department of Health Services
1 W. Wilson St.
Madison, WI 53703

Dear Director Hanna:

The Centers for Medicare & Medicaid Services (CMS) is approving Wisconsin's request for a five-year extension of the "Wisconsin BadgerCare Reform" section 1115 demonstration (Project Number 11-W-00293/5), in accordance with section 1115(a) of the Social Security Act ("the Act"). CMS's approval of this extension is based on the determination that the demonstration is likely to assist with promoting the objectives of title XIX of the Act because it will provide benefits to low-income childless adults and former foster care youth populations. During the temporary extension and amendment approved on November 17, 2023, the following authorities were removed from the demonstration: disenrollment lockout periods, monthly premiums, health behavior assessments, health risk assessments, and the requirement for beneficiaries to answer questions about substance use treatment needs to remain eligible. This demonstration extension approval is effective as of the date of this letter through December 31, 2029, upon which date, unless extended or otherwise amended, all authorities granted to operate this demonstration will expire.

CMS's approval of this section 1115(a) demonstration is subject to the limitations specified in the attached expenditure authorities, special terms and conditions (STC), and any supplemental attachments defining the nature, character, and extent of federal involvement in this project. The state may deviate from the Medicaid state plan requirements only to the extent those requirements have been specifically listed not applicable to expenditures under the demonstration.

Extent and Scope of Demonstration Extension

This demonstration extension allows Wisconsin to maintain current components of the demonstration, including providing substance use disorder (SUD) benefits to cover short-term residential services in facilities that qualify as institutions for mental diseases (IMDs); providing coverage to out-of-state former foster care youth (FFCY) up to 26 years of age, who turned 18 on

or before December 31, 2022; and extending coverage to non-pregnant, non-disabled, non-elderly childless adults with incomes of up to and including 100 percent of the federal poverty level (FPL). The BadgerCare Reform demonstration will also continue to allow the state to charge childless adult beneficiaries in the demonstration an \$8 copayment for non-emergency use of the emergency department (ED). The extension does not include any substantive changes to the approved demonstration authorities.

Section 1002(a) of the Substance Use Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities (SUPPORT) Act created a new Former Foster Care Children (FFCC) Medicaid state plan eligibility group, providing coverage for individuals who were receiving Medicaid while in foster care under the responsibility of any state; however, the new requirements apply exclusively to those who turn 18 on or after January 1, 2023. As a result, states still need section 1115 demonstration authority to continue coverage for individuals who turned 18 years old before January 1, 2023, until a beneficiary reaches age 26. Therefore, Wisconsin's FFCY demonstration eligibility will be limited to beneficiaries who turned 18 on or before December 31, 2022.

Budget Neutrality¹

CMS has long required, as a condition of demonstration approval, that demonstrations be “budget neutral,” meaning the federal costs of the state’s Medicaid program with the demonstration cannot exceed what the federal government’s Medicaid costs in that state likely would have been without the demonstration. The demonstration extension is projected to be budget neutral to the federal government. The state will be held to the budget neutrality monitoring and reporting requirements as outlined in the STCs.

In requiring demonstrations to be budget neutral, CMS is constantly striving to achieve a balance between its interest in preserving the fiscal integrity of the Medicaid program and its interest in facilitating state innovation through section 1115 demonstration approvals.

Under this approval, CMS calculated the “without waiver” (WOW) baseline (which refers to the projected expenditures that could have occurred absent the demonstration and which is the basis for the budget neutrality expenditure limit for each approval period) by using a weighted average of the state’s historical WOW per-member-per-month (PMPM) baseline and its recent actual PMPM costs. The projected demonstration expenditures associated with each Medicaid Eligibility Group in the WOW baseline have been trended forward using the President’s Budget trend rate to determine the maximum expenditure authority for the new approval period. Using the President’s Budget trend rate aligns the demonstration trend rate with federal budgeting principles and assumptions.

CMS has also updated its approach to mid-course corrections to budget neutrality calculations in this demonstration extension approval to provide flexibility and stability for the state over the life of a demonstration. This update identifies, in the STCs, a list of circumstances under which a state’s baseline may be adjusted based on actual expenditure data to accommodate circumstances

¹ For more information on CMS’s current approach to budget neutrality, see <https://www.medicaid.gov/medicaid/section-1115-demonstrations/budget-neutrality/index.html>

that are either out of the state’s control (for example, if expensive new drugs that the state is required to cover enter the market); and/or the effect is not a condition or consequence of the demonstration (for example, unexpected costs due to a public health emergency); and/or the new expenditure (while not a new demonstration-covered service or population that would require the state to propose an amendment to the demonstration) is likely to further strengthen access to care (for example, a legislated increase in provider rates). CMS also explains in the STCs what data and other information the state should submit to support a potentially approvable request for an adjustment. CMS considers this a more rational, transparent, and standardized approach to permitting budget neutrality modifications during the course of a demonstration.

CMS has determined the extension of the FFCY demonstration authority to be budget neutral because the demonstration authority to cover the FFCY population is needed for only a temporary period, through 2030, when all FFCY will be covered via the Medicaid state plan FFCC population. Further, through monitoring budget neutrality, CMS determined that the actual experience of states’ covering out-of-state FFCY resulted in limited total expenditures and low enrollment within the demonstrations. CMS generally believes that this FFCY demonstration coverage poses minimal financial risk to the federal government since FFCY demonstration spending is miniscule across states. This decision will increase the administrative ease of maintaining FFCY demonstration coverage in Wisconsin.

The state will be required to report total expenditures and member months in its demonstration monitoring reports. The state must still report quarterly claims and report expenditures on the CMS 64.9 WAIVER form. Failure to report FFCY expenditures and member months will result in reinstatement of the budget neutrality requirement.

Monitoring and Evaluation

Consistent with the demonstration STCs, the state submitted its draft Interim Evaluation Report for the prior demonstration approval period (October 2018 to December 2021), and it was approved on August 28, 2023. The findings from the Interim Evaluation Report were mixed. The SUD-specific findings from the evaluation period with data analyzed through December 2021 were in alignment with the demonstration’s goals. For example, the state experienced an increase in insurance rates for low-income childless adults, however this increase was consistent with other states during the same time period. Additionally, the state experienced an increased use of residential SUD treatment, but did not experience increases in other SUD services.

CMS will continue to collaborate with the state to ensure the demonstration is monitored and evaluated comprehensively during the extension period to support a comprehensive assessment of whether the initiatives are effective in producing the desired outcomes for beneficiaries and the state’s overall Medicaid program. The demonstration evaluation must outline and address well-crafted hypotheses and research questions for all key demonstration policy components—including those that were authorized in the initial approval of the demonstration. The state must evaluate the overall impact of the coverage components, including assessing hypotheses that address the program’s cost-effectiveness and its effects on beneficiary health and outcomes. Additionally, the state’s monitoring and evaluation efforts must facilitate understanding the

extent to which the demonstration extension might support reducing existing disparities in access to and quality of care and health outcomes.

Consideration of Public Comments

The federal comment period was open from December 2, 2022, through January 1, 2023, for the application submitted November 22, 2022, during which CMS received 12 comments. Two comments were from individuals, one of which was not relevant to the demonstration request, and 10 were from organizations. While some commenters supported Wisconsin's request to extend the BadgerCare Reform demonstration, others were against the proposal.

One organization supports the proposal to expand access to SUD care for Wisconsin Medicaid beneficiaries. Several organizations noted that while they support the continuation of Medicaid coverage for childless adults, they oppose several provisions of the proposal including disenrollment lockout periods, emergency room copayments, monthly premiums, health behavior assessments, health risk assessments, and the requirement for beneficiaries to answer questions about substance use treatment needs to remain eligible. All these demonstration provisions, except for copayments for non-emergency use of the ED, were removed from the demonstration during the temporary extension and amendment approved on November 17, 2023.

After carefully reviewing the demonstration proposal and the public comments submitted during the federal comment period, CMS has concluded that the demonstration is likely to assist in promoting the objectives of Medicaid.

Other Information

CMS's approval of this extension is conditioned upon compliance with the enclosed set of expenditure authorities and the STCs defining the nature, character, and extent of anticipated federal involvement in the demonstration. The award is subject to CMS receiving written acceptance of this award and acceptance of these STCs within 30 days of the date of this approval letter.

Your CMS project officer for this demonstration is Amy Schlom. She is available to answer any questions concerning your section 1115 demonstration. Ms. Schlom's contact information is as follows:

Centers for Medicare & Medicaid Services
Center for Medicaid and CHIP Services
7500 Security Boulevard
Baltimore, Maryland 21244-1850
Email: amy.schlom@cms.hhs.gov

We look forward to our continued partnership on the Wisconsin BadgerCare Reform demonstration. If you have any questions regarding this approval, please contact Ms. Jacey Cooper, Director, State Demonstrations Group, Center for Medicaid and CHIP Services, at (410) 786-9686.

Sincerely,



Daniel Tsai
Deputy Administrator and Director

Enclosure

cc: Mai Le-Yuen, State Monitoring Lead, Medicaid and CHIP Operations Group

**CENTERS FOR MEDICARE & MEDICAID SERVICES
EXPENDITURE AUTHORITY**

NUMBER: 11-W-00293/5

TITLE: Wisconsin BadgerCare Reform Section 1115 Demonstration

AWARDEE: Wisconsin Department of Health Services

Under the authority of section 1115(a)(2) of the Social Security Act (“the Act”), expenditures made by Wisconsin for the items identified below, which are not otherwise included as expenditures under section 1903 of the Act shall, for the period from October 29, 2024 through December 31, 2029, unless otherwise specified, be regarded as expenditures under the state’s title XIX plan.

The following expenditure authorities may only be implemented consistent with the approved Special Terms and Conditions (STC) and shall enable Wisconsin to operate the above-identified section 1115(a) demonstration.

- 1. Childless Adults Demonstration Population.** Expenditures for health care-related costs for eligible non-pregnant, uninsured adults ages 19 through 64 years who have family incomes up to 95 percent of the federal poverty level (FPL) (effectively 100 percent of the FPL including the five percent disregard), who are not otherwise eligible under the Medicaid State plan, other than for family planning services or for the treatment of Tuberculosis, and who are not otherwise eligible for Medicare, Medical Assistance, or the State Children’s Health Insurance Program (CHIP).
- 2. Former Foster Care Youth from Another State.** Expenditures to extend eligibility for full Medicaid state plan benefits to former foster care youth are under age 26, who turned 18 on or before December 31, 2022, who were in foster care under the responsibility of another state or tribe on the date of attaining 18 years of age (or such higher age as the state has elected for termination of Federal foster care assistance under title IV-E of the Act), were enrolled in Medicaid on the date of aging out of foster care, and are now applying for Medicaid in Wisconsin.
- 3. Residential and Inpatient Treatment Services for Individuals with Substance Use Disorder.** Expenditures for Medicaid state plan services furnished to otherwise eligible individuals who are primarily receiving treatment and/or withdrawal management services for substance use disorder (SUD) who are short-term residents in facilities that meet the definition of an institution for mental diseases (IMD).

All requirements of the Medicaid program expressed in law, regulation, and policy statement, not expressly identified as not applicable in the list below, shall apply to the Childless Adults Demonstration Population.

Title XIX Requirements Not Applicable to the Demonstration Population:

1. Freedom of Choice

Section 1902(a)(23)(A)

To the extent necessary to enable the state to require enrollment of the childless adult population in managed care organizations.

2. Comparability

Section 1902(a)(17)/Section 1902(a)(10)(B)

To the extent necessary to enable the state to establish a non-emergency use of the emergency department copayment of \$8 for the childless adult population.

**CENTERS FOR MEDICARE AND MEDICAID SERVICES
SPECIAL TERMS AND CONDITIONS**

NUMBER: 11-W-00293/5

TITLE: Wisconsin BadgerCare Reform

AWARDEE: Wisconsin Department of Health Services

1. PREFACE

The following are the Special Terms and Conditions (STCs) for the “Wisconsin BadgerCare Reform” section 1115(a) Medicaid demonstration (hereinafter “demonstration”), to enable the Wisconsin Department of Health Services (hereinafter “state”) to operate this demonstration. The Centers for Medicare & Medicaid Services (CMS) has granted expenditure authorities authorizing federal matching of demonstration costs not otherwise matchable, which are separately enumerated. These STCs set forth conditions and limitations on those expenditure authorities, and describe in detail the nature, character, and extent of federal involvement in the demonstration and the state’s obligations to CMS related to the demonstration. These STCs neither grant additional waivers or expenditure authorities, nor expand upon those separately granted.

The STCs related to the programs for those populations affected by the demonstration are effective from October 29, 2024 through December 31, 2029, unless otherwise specified. The STCs have been arranged into the following subject areas:

1. Preface
2. Program Description and Objectives
3. General Program Requirements
4. Eligibility and Enrollment
5. Benefits
6. Cost Sharing
7. Delivery System
8. Monitoring and Reporting Requirements
9. Evaluation of the Demonstration
10. General Financial Requirements
11. Monitoring Budget Neutrality for the Demonstration
12. Schedule of Deliverables for the Demonstration Period

Additional attachments have been included to provide supplementary information and guidance for specific STCs.

Attachment A. Substance Use Disorder Implementation Plan Protocol (Approved)
Attachment B. Substance Use Disorder Monitoring Protocol (Reserved)
Attachment C. Developing the Evaluation Design
Attachment D. Preparing the Interim and Summative Evaluation Reports

2. PROGRAM DESCRIPTION AND OBJECTIVES

With the implementation of the Affordable Care Act provisions that provided federally-funded subsidies to help individuals and families purchase private health insurance, Wisconsin saw the BadgerCare Reform demonstration as an opportunity to reduce the uninsured rate and encourage beneficiaries to access coverage in the private market.

The Wisconsin BadgerCare Reform demonstration provides state plan benefits, other than family planning services and tuberculosis-related services, to childless adults who have effective family incomes up to 100 percent of the Federal Poverty Level (FPL) (effective income is defined to include the five (5) percent disregard). Coverage for this population focuses on improving health outcomes, reducing unnecessary services, and improving the cost- effectiveness of Medicaid services.

In accordance with CMS' November 21, 2016, CMCS Informational Bulletin (CIB), Section 1115 Demonstration Opportunity to Allow Medicaid Coverage to Former Foster Care Youth Who Have Moved to a Different State, the BadgerCare Reform demonstration was amended in December 2017 to add coverage of former foster care youth defined as individuals under age 26 who were in foster care in another state or tribe of such other state when they turned 18 (or such higher age as the state has elected for termination of federal foster care assistance under title IV-E of the Act), were enrolled in Medicaid at that time or at some point while in such foster care, and are now applying for Medicaid in Wisconsin. With the addition of this population, Wisconsin has a new demonstration goal to increase and strengthen overall coverage of former foster care youth and improve health outcomes for this population.

On October 29, 2024, CMS approved a five-year extension of the demonstration to allow the state to continue the existing demonstration authorities, which provide authority for the expansion of eligibility to childless adults, former foster care youth, services for substance use disorders in an institution for mental disease, and the \$8 copay for non-emergency use of the emergency department. The extension does not include any changes to the approved demonstration authorities.

During the demonstration period, the state seeks to achieve the following goals:

SUD Goals:

1	Increase rates of identification, initiation, and engagement in treatment for SUD
2	Increase adherence to and retention in treatment
3	Reduce overdose deaths, particularly those due to opioids
4	Reduce utilization of emergency departments and inpatient hospital settings for treatment where the utilization is preventable or medically inappropriate through improved access to other continuum of care services
5	Fewer readmissions to the same or higher level of care where the readmission is preventable or medically inappropriate

3. GENERAL PROGRAM REQUIREMENTS

- 3.1. **Compliance with Federal Non-Discrimination Statutes.** The state must comply with all applicable federal statutes relating to non-discrimination. These include, but are not limited to, the Americans with Disabilities Act of 1990 (ADA), Title VI of the Civil Rights Act of 1964, section 504 of the Rehabilitation Act of 1973 (Section 504), the Age Discrimination Act of 1975, and section 1557 of the Patient Protection and Affordable Care Act (Section 1557).
- 3.2. **Compliance with Medicaid and Children’s Health Insurance Program (CHIP) Law, Regulation, and Policy.** All requirements of the Medicaid and CHIP programs expressed in federal law, regulation, and policy statement, not expressly waived or identified as not applicable in the waiver and expenditure authority documents (of which these terms and conditions are part), apply to the demonstration.
- 3.3. **Changes in Medicaid and CHIP Law, Regulation, and Policy.** The state must, within the timeframes specified in federal law, regulation, or written policy, come into compliance with changes in law, regulation, or policy affecting the Medicaid or CHIP programs that occur during this demonstration approval period, unless the provision being changed is expressly waived or identified as not applicable. In addition, CMS reserves the right to amend the STCs to reflect such changes and/or changes as needed without requiring the state to submit an amendment to the demonstration under STC 3.7 CMS will notify the state 30 business days in advance of the expected approval date of the amended STCs to allow the state to provide comment. Changes will be considered in force upon issuance of the approval letter by CMS. The state must accept the changes in writing.
- 3.4. **Impact on Demonstration of Changes in Federal Law, Regulation, and Policy.**
 - a. To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in federal financial participation (FFP) for expenditures made under this demonstration, the state must adopt, subject to CMS approval, a modified budget neutrality agreement for the demonstration as necessary to comply with such change, as well as a modified allotment neutrality worksheet as necessary to comply with such change. The trend rates for the budget neutrality agreement are not subject to change under this subparagraph. Further, the state may seek an amendment to the demonstration (as per STC 3.7 of this section) as a result of the change in FFP.
 - b. If mandated changes in the federal law require state legislation, unless otherwise prescribed by the terms of the federal law, the changes must take effect on the earlier of the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the law, whichever is sooner.
- 3.5. **State Plan Amendments.** The state will not be required to submit title XIX or XXI state plan amendments (SPAs) for changes affecting any populations made eligible solely through the demonstration. If a population eligible through the Medicaid or CHIP state plan is affected by a change to the demonstration, a conforming amendment to the appropriate state plan is required,

except as otherwise noted in these STCs. In all such cases, the Medicaid and CHIP state plans govern.

- 3.6. **Changes Subject to the Amendment Process.** Changes related to eligibility, enrollment, benefits, beneficiary rights, delivery systems, cost sharing, sources of non-federal share of funding, budget neutrality, and other comparable program elements must be submitted to CMS as amendments to the demonstration. All amendment requests are subject to approval at the discretion of the Secretary in accordance with section 1115 of the Act. The state must not implement changes to these elements without prior approval by CMS either through an approved amendment to the Medicaid or CHIP state plan or amendment to the demonstration. Amendments to the demonstration are not retroactive and no FFP of any kind, including for administrative or medical assistance expenditures, will be available under changes to the demonstration that have not been approved through the amendment process set forth in STC 3.7 below, except as provided in STC 3.3.
- 3.7. **Amendment Process.** Requests to amend the demonstration must be submitted to CMS for approval no later than 120 calendar days prior to the planned date of implementation of the change and may not be implemented until approved. CMS reserves the right to deny or delay approval of a demonstration amendment based on non-compliance with these STCs, including but not limited to the failure by the state to submit required elements of a complete amendment request as described in this STC, and failure by the state to submit required reports and other deliverables according to the deadlines specified therein. Amendment requests must include, but are not limited to, the following:
- a. An explanation of the public process used by the state, consistent with the requirements of STC 3.12. Such explanation must include a summary of any public feedback received and identification of how this feedback was addressed by the state in the final amendment request submitted to CMS;
 - b. A detailed description of the amendment, including impact on beneficiaries, with sufficient supporting documentation;
 - c. A data analysis which identifies the specific “with waiver” impact of the proposed amendment on the current budget neutrality agreement. Such analysis must include current total computable “with waiver” and “without waiver” status on both a summary and detailed level through the current approval period using the most recent actual expenditures, as well as summary and detailed projections of the change in the “with waiver” expenditure total as a result of the proposed amendment, which isolates (by Eligibility Group) the impact of the amendment;
 - d. An up-to-date CHIP allotment worksheet, if necessary;
 - e. The state must identify how it will modify its evaluation design to incorporate the amendment provisions..
- 3.8. **Extension of the Demonstration.** States that intend to request an extension of the demonstration must submit an application to CMS at least 12 months in advance from the Governor of the state in accordance with the requirements of 42 CFR 431.412(c). States that do not intend to request an extension of the demonstration beyond the period authorized in these STCs must submit phase-out plan consistent with the requirements of STC 3.9.

- 3.9. **Demonstration Phase Out.** The state may only suspend or terminate this demonstration in whole, or in part, consistent with the following requirements:
- a. Notification of Suspension or Termination. The state must promptly notify CMS in writing of the reason(s) for the suspension or termination, together with the effective date and a transition and phase-out plan. The state must submit a notification letter and a draft transition and phase-out plan to CMS no less than six months before the effective date of the demonstration's suspension or termination. Prior to submitting the draft transition and phase-out plan to CMS, the state must publish on its website the draft transition and phase-out plan for a 30-day public comment period. In addition, the state must conduct tribal consultation in accordance with STC 3.12, if applicable. Once the 30-day public comment period has ended, the state must provide a summary of the issues raised by the public during the comment period and how the state considered the comments received when developing the revised transition and phase-out plan.
 - b. Transition and Phase-out Plan Requirements. The state must include, at a minimum, in its phase-out plan the process by which it will notify affected beneficiaries, the content of said notices (including information on the beneficiary's appeal rights), the process by which the state will conduct redeterminations of Medicaid or CHIP eligibility prior to the termination of the demonstration for the affected beneficiaries, and ensure ongoing coverage for eligible beneficiaries, as well as any community outreach activities the state will undertake to notify affected beneficiaries, including community resources that are available.
 - c. Transition and Phase-out Plan Approval. The state must obtain CMS approval of the transition and phase-out plan prior to the implementation of transition and phase-out activities. Implementation of transition and phase-out activities must be no sooner than 14 calendar days after CMS approval of the transition and phase-out plan.
 - d. Transition and Phase-out Procedures. The state must redetermine eligibility for all affected beneficiaries in order to determine if they qualify for Medicaid eligibility under a different eligibility category prior to making a determination of ineligibility as required under 42 CFR 435.916(f)(1). For individuals determined ineligible for Medicaid and CHIP, the state must determine potential eligibility for other insurance affordability programs and comply with the procedures set forth in 42 CFR 435.1200(e). The state must comply with all applicable notice requirements found in 42 CFR, part 431 subpart E, including sections 431.206 through 431.214. In addition, the state must assure all applicable appeal and hearing rights are afforded to beneficiaries in the demonstration as outlined in 42 CFR, part 431 subpart E, including sections 431.220 and 431.221. If a beneficiary in the demonstration requests a hearing before the date of action, the state must maintain benefits as required in 42 CFR 431.230.
 - e. Exemption from Public Notice Procedures, 42 CFR Section 431.416(g). CMS may expedite the federal and state public notice requirements under circumstances described in 42 CFR 431.416(g).
 - f. Enrollment Limitation during Demonstration Phase-Out. If the state elects to suspend, terminate, or not extend this demonstration, during the last six months of the demonstration, enrollment of new individuals into the demonstration must be suspended. The limitation of enrollment into the demonstration does not impact the

state's obligation to determine Medicaid eligibility in accordance with the approved Medicaid state plan.

- g. **Federal Financial Participation (FFP).** If the project is terminated or any relevant waivers are suspended by the state, FFP must be limited to normal closeout costs associated with the termination or expiration of the demonstration including services, continued benefits as a result of beneficiaries' appeals, and administrative costs of disenrolling beneficiaries.

- 3.10. **Withdrawal of Waiver or Expenditure Authority.** CMS reserves the right to withdraw waivers and/or expenditure authorities at any time it determines that continuing the waiver or expenditure authorities would no longer be in the public interest or promote the objectives of title XIX and title XXI. CMS will promptly notify the state in writing of the determination and the reasons for the withdrawal, together with the effective date, and afford the state an opportunity to request a hearing to challenge CMS's determination prior to the effective date. If a waiver or expenditure authority is withdrawn, FFP is limited to normal closeout costs associated with terminating the waiver or expenditure authority, including services, continued benefits as a result of beneficiary appeals, and administrative costs of disenrolling beneficiaries.
- 3.11. **Adequacy of Infrastructure.** The state must ensure the availability of adequate resources for implementation and monitoring of the demonstration, including education, outreach, and enrollment; maintaining eligibility systems; compliance with cost sharing requirements; and reporting on financial and other demonstration components.
- 3.12. **Public Notice, Tribal Consultation, and Consultation with Interested Parties.** The state must comply with the state notice procedures as required in 42 CFR section 431.408 prior to submitting an application to extend the demonstration. For applications to amend the demonstration, the state must comply with the state notice procedures set forth in 59 Fed. Reg. 49249 (September 27, 1994) prior to submitting such request. The state must also comply with the Public Notice Procedures set forth in 42 CFR 447.205 for changes in statewide methods and standards for setting payment rates.
- 3.13. **Federal Financial Participation (FFP).** No federal matching funds for expenditures for this demonstration, including for administrative and medical assistance expenditures, will be available until the effective date identified in the demonstration approval letter, or if later, as expressly stated within these STCs.
- 3.14. **Administrative Authority.** When there are multiple entities involved in the administration of the demonstration, the Single State Medicaid Agency must maintain authority, accountability, and oversight of the program. The State Medicaid Agency must exercise oversight of all delegated functions to operating agencies, MCOs, and any other contracted entities. The Single State Medicaid Agency is responsible for the content and oversight of the quality strategies for the demonstration.
- 3.15. **Common Rule Exemption.** The state must ensure that the only involvement of human subjects in research activities that may be authorized and/or required by this demonstration is

for projects which are conducted by or subject to the approval of CMS, and that are designed to study, evaluate, or otherwise examine the Medicaid or CHIP program – including public benefit or service programs, procedures for obtaining Medicaid or CHIP benefits or services, possible changes in or alternatives to Medicaid or CHIP programs and procedures, or possible changes in methods or levels of payment for Medicaid benefits or services. CMS has determined that this demonstration as represented in these approved STCs meets the requirements for exemption from the human subject research provisions of the Common Rule set forth in 45 CFR 46.104(d)(5).

4. ELIGIBILITY AND ENROLLMENT

- 4.1. **State Plan Eligibility Groups Affected by the Demonstration.** The state plan populations affected by this demonstration are outlined in Table 1, which summarizes each specific group of individuals and specifies the authority under which they are eligible for coverage and the name of the eligibility and expenditure group under which expenditures are reported to CMS and the budget neutrality expenditure agreement is constructed.
- 4.2. **Demonstration Expansion Eligibility Groups.** Table 1 summarizes the specific groups of individuals, and specifies the authority under which they are eligible for coverage. Demonstration Populations 1 and 2 in Table 1 is made eligible for the demonstration by virtue of the expenditure authorities expressly granted in this demonstration. Coverage of Demonstration Populations 1 and 2 are subject to Medicaid laws and regulations unless otherwise specified in the “Title XIX Requirements Not Applicable to the Demonstration Population” section of the expenditure authorities document for this demonstration.

Table 1: Eligibility Groups Affected by the Demonstration

Demonstration Expansion Groups	Eligibility Criteria	Funding Stream
Population 1. Childless Adult Demonstration Population	<ul style="list-style-type: none"> • Ages 19 through 64 • Effective monthly income at or below 100 percent of the FPL • Not pregnant • Do not qualify for any other full-benefit Medicaid or CHIP eligibility group • Are not receiving Medicare • Childless adults may have children, but do not qualify as a parent or caretaker relative (e.g., either the children are not currently living with them or those children living with them are 19 years of age or older) 	Title XIX

Population 2. Former Foster Care Youth (FFCY) from Another State	<ul style="list-style-type: none"> • Under age 26 • Were in foster care under the responsibility of a state other than Wisconsin or a tribe in such other state when they turned 18 or such higher age as the state has elected for termination of federal foster care assistance under title IV-E of the Act) • Were enrolled in Medicaid at the time of aging out of foster care • Turned 18 on or before December 31, 2022 • Are now applying for Medicaid in Wisconsin, and • Are not otherwise eligible for Medicaid 	Title XIX
--	---	-----------

5. BENEFITS

5.1. **Wisconsin BadgerCare Demonstration.** All enrollees in this demonstration (as described in Section 4) will receive benefits as specified in the Medicaid state plan, to the extent that such benefits apply to those individuals. Beneficiaries in Demonstration Population 1 will not receive family planning services or tuberculosis-related services. In addition, beneficiaries in the Demonstration Population 1 will not receive pregnancy related services, but instead must be administratively transferred to the pregnant women group in the state plan if they are pregnant. Refer to the state plan for additional information on benefits. Out-of-state former foster care youth will receive the same Medicaid State Plan benefits and be subject to the same cost-sharing requirements effectuated by the state for the mandatory title IV-E foster care youth eligibility category enacted by the Adoption Assistance and Child Welfare Act of 1980 (Pub. L. 96-272).

5.2. **Opioid Use Disorder (OUD)/Substance Use Disorder (SUD) Program.** Effective upon CMS's approval of the SUD Implementation Plan, the demonstration benefit package for Medicaid beneficiaries will include OUD/SUD treatment services, including services provided in residential and inpatient treatment settings that qualify as an IMD, which are not otherwise matchable expenditures under section 1903 of the Act. The state will be eligible to receive FFP for Medicaid beneficiaries who are short-term residents in IMDs under the terms of this demonstration for coverage of medical assistance, including OUD/SUD treatment services, that would otherwise be matchable if the beneficiary were not residing in an IMD once CMS approves the state's Implementation Plan. CMS approved the SUD Implementation Plan on October 22, 2019. The state will aim for a statewide average length of stay of 30 days or less in residential treatment settings, to be monitored pursuant to the SUD Monitoring Protocol as outlined in STC 8.5, to ensure short-term residential stays.

Under this demonstration beneficiaries will have access to high quality, evidence-based OUD/SUD treatment services across a comprehensive continuum of care, ranging from residential and inpatient treatment to ongoing chronic care for these conditions in cost-effective community-based settings.

The coverage of OUD/SUD treatment services and withdrawal management during short term residential and inpatient stays in IMDs will expand Wisconsin's current SUD benefit package

available to all Wisconsin Medicaid recipients as outlined in Table 2. Room and board costs are not considered allowable costs for residential treatment service providers unless they qualify as inpatient facilities under section 1905(a) of the Act.

Table 2: Wisconsin OUD/SUD Benefits Coverage with Expenditure Authority

SUD Benefits	Wisconsin Medicaid Authority	Expenditure Authority
Outpatient Services	State Plan	n/a
Intensive Outpatient Services	State Plan	n/a
Medication Assisted Treatment	State Plan (Individual services covered)	Services provided to individuals in IMDs
Residential Treatment Services	State Plan (Individual services covered)	Services provided to individuals in IMDs
Inpatient Services	State Plan (Individual services covered)	Services provided to individuals in IMDs
Medically Supervised Withdrawal Management	State Plan	Services provided to individuals in IMDs

- 5.3. **SUD Implementation Plan and Health IT Plan.** The state's SUD Implementation Plan initially approved for the period from June 7, 2019 through December 31, 2023 (and temporarily extended through December 31, 2024) remains in effect for the approval period from October 29, 2024, through December 31, 2029, and is affixed to the STCs as Attachment A. Any future modifications to the approved Implementation Plan will require CMS approval. Failure to progress in meeting the milestone goals agreed upon by the state and CMS will result in a funding deferral. The approved SUD Implementation Plan describes the strategic approach and a detailed project implementation plan, including timetables and programmatic content where applicable, for meeting the following milestones which reflect the key goals and objectives of this SUD demonstration project:

- Access to Critical Levels of Care for OUD and other SUDs. Coverage of OUD/SUD treatment services across a comprehensive continuum of care including: outpatient; intensive outpatient; medication assisted treatment (medication as well as counseling and other services with sufficient provider capacity to meet needs of Medicaid beneficiaries in the state); intensive levels of care in residential and inpatient settings; and medically supervised withdrawal management, within 12-24 months of demonstration approval;
- Use of Evidence-based SUD-specific Patient Placement Criteria. Establishment of a requirement that providers assess treatment needs based on SUD-specific, multidimensional assessment tools, such as the American Society of Addiction Medicine (ASAM) Criteria or other assessment and placement tools that reflect evidence-based clinical treatment guidelines within 12-24 months of OUD/SUD program demonstration approval;
- Patient Placement. Establishment of a utilization management approach such that beneficiaries have access to SUD services at the appropriate level of care and that the interventions are appropriate for the diagnosis and level of care, including an independent process for reviewing placement in residential treatment settings within 12-24 months of demonstration approval;
- Use of Nationally Recognized SUD-specific Program Standards to set Provider Qualifications for Residential Treatment Facilities. Currently, residential treatment

- service providers must be a licensed organization, pursuant to the residential service provider qualifications described in Wisconsin administrative code. The state must establish residential treatment provider qualifications in licensure, policy or provider manuals, managed care contracts or credentialing, or other requirements or guidance that meet program standards in the ASAM Criteria or other nationally recognized, SUD-specific program standards regarding in particular the types of services, hours of clinical care, and credentials of staff for residential treatment settings within 12-24 months of demonstration approval;
- e. Standards of Care. Establishment of a provider review process to ensure that residential treatment providers deliver care consistent with the specifications in the ASAM Criteria or other comparable, nationally recognized SUD program standards based on evidence-based clinical treatment guidelines for types of services, hours of clinical care, and credentials of staff for residential treatment settings within 12-24 months of demonstration approval;
 - f. Standards of Care. Establishment of a requirement that residential treatment providers offer Medication Assisted Treatment (MAT) on-site or facilitate access to MAT off-site within 12-24 months of demonstration approval;
 - g. Sufficient Provider Capacity at each Level of Care, including Medication Assisted Treatment for SUD/ODU. An assessment of the availability of providers in the critical levels of care throughout the state, or in the regions of the state participating under this demonstration, including those that offer MAT within 12 months of demonstration approval;
 - h. Implementation of Comprehensive Treatment and Prevention Strategies to Address Opioid Abuse and SUD/ODU. Implementation of opioid prescribing guidelines along with other interventions to prevent prescription drug abuse and expand coverage of and access to naloxone for overdose reversal as well as implementation of strategies to increase utilization and improve functionality of prescription drug monitoring programs;
 - i. Improved Care Coordination and Transitions between Levels of Care. Establishment and implementation of policies to ensure residential and inpatient facilities link beneficiaries with community-based services and supports following stays in these facilities within 24 months of demonstration approval;
 - j. SUD Health IT Plan. Implementation of a Substance Use Disorder Health Information Technology Plan which describes technology that will support the aims of the demonstration. Further information which describes milestones and metrics are detailed in STC 5.4 and Attachment A.
 - k. SUD Health Information Technology Plan (“Health IT Plan”). The SUD Health IT plan applies to all states where the Health IT functionalities are expected to impact beneficiaries within the demonstration. As outlined in SMDL #17-003, states must submit to CMS the applicable Health IT Plan(s), to be included as a section(s) of the associated Implementation Plan(s) (see STC 5.2(j) and STC 5.2), to develop infrastructure and capabilities consistent with the requirements outlined in each demonstration-type.
 - l. The Health IT Plan should describe how technology can support outcomes through care coordination; linkages to public health and prescription drug monitoring programs; establish data and reporting structure to monitor outcomes and support data

driven interventions. Such technology should, per 42 CFR 433.112(b), use open interfaces and exposed application programming interfaces and ensure alignment with, and incorporation of, industry standards adopted by the Office of the National Coordinator for Health IT in accordance with 42 CFR part 170, subpart B.

- i. The state must include in its Monitoring Protocol (see STC 10.5) an approach to monitoring its SUD Health IT Plan which will include performance metrics to be approved in advance by CMS.
- ii. The state must monitor progress, each DY, on the implementation of its SUD Health IT Plan in relationship to its milestones and timelines—and report on its progress to CMS within its Annual Report (see STC 10.6).
- iii. As applicable, the state should advance the standards identified in the ‘Interoperability Standards Advisory—Best Available Standards and Implementation Specifications’ (ISA) in developing and implementing the state’s SUD Health IT policies and in all related applicable State procurements (e.g., including managed care contracts) that are associated with this demonstration.
- iv. Where there are opportunities at the state- and provider-level (up to and including usage in MCO or ACO participation agreements) to leverage federal funds associated with a standard referenced in 45 CFR 170 Subpart B, the state should use the federally recognized standards.
- v. Where there are opportunities at the state- and provider-level to leverage federal funds associated with a standard not already referenced in 45 CFR 170 but included in the ISA, the state should use the federally recognized ISA standards.
- vi. Components of the Health IT Plan include:
 1. The Health IT Plan must describe the state’s alignment with Section 5042 of the SUPPORT Act requiring Medicaid providers to query a Qualified Prescription Drug Monitoring Program (PDMP)¹.
 2. The Health IT Plan must address how the state’s Qualified PDMP will enhance ease of use for prescribers and other state and federal stakeholders.² States should favor procurement strategies that incorporate qualified PDMP data into electronic health records as discrete data without added interface costs to Medicaid providers, leveraging existing federal investments in RX Check for Interstate data sharing.
 3. The Health IT Plan will describe how technology will support substance use disorder prevention and treatment outcomes described by the demonstration.
 4. In developing the Health IT Plan, states should use the following resources:

– ¹ 1Prescription drug monitoring programs (PDMP) are electronic databases that track controlled substance prescriptions in states. PDMPs can provide health authorities timely information about prescribing and patient behaviors that contribute to the “opioid” epidemic and facilitate a nimble and targeted response.

- States may use federal resources available on Health IT.Gov (<https://www.healthit.gov/topic/behavioral-health>) including but not limited to “Behavioral Health and Physical Health Integration” and “Section 34: Opioid Epidemic and Health IT” (<https://www.healthit.gov/playbook/health-information-exchange/>).
- States may also use the CMS 1115 Health IT resources available on “Medicaid Program Alignment with State Systems to Advance HIT, HIE and Interoperability” at <https://www.medicaid.gov/medicaid/data-and-systems/hie/index.html>. States should review the “1115 Health IT Toolkit” for health IT considerations in conducting an assessment and developing their Health IT Plans.
- States may request from CMS technical assistance to conduct an assessment and develop plans to ensure they have the specific health IT infrastructure with regards to PDMP interoperability, electronic care plan sharing, care coordination, and behavioral health-physical health integration, to meet the goals of the demonstration.
- States should review the Office of the National Coordinator’s Interoperability Standards Advisory (<https://www.healthit.gov/isa/>) for information on appropriate standards which may not be required per 45 CFR part 170, subpart B for enhanced funding, but still should be considered industry standards per 42 CFR 433.112(b)(12).

5.4. **SUD Evaluation.** The SUD Evaluation will be subject to the same requirements as the overall demonstration evaluation, as described in Sections 8 (Monitoring and Reporting Requirements) and 9 (Evaluation of the Demonstration) of these STCs.

5.5. **Unallowable Expenditures Under the SUD Expenditure Authority.** In addition to the other unallowable costs and caveats already outlined in these STCs, the state may not receive FFP under any expenditure authority approved under this demonstration for any of the following:

- a. Room and board costs for residential treatment service providers unless they qualify as inpatient facilities under section 1905(a) of the Act.

6. COST SHARING

6.1. **Cost Sharing.** Cost sharing imposed upon individuals enrolled in the demonstration is consistent with the provisions of the approved state plan.

6.2. **Copayments for Use of the Emergency Department.** Individuals in Demonstration Population 1 are required to pay a copayment for each non-emergent use of the emergency room (ER). This copayment shall be charged consistent with 1916A(e)(1) of the Act and 42 CFR 447.54.

- a. Under the provisions of section 1916A(e) of the Act, the state has the authority to impose a copayment for services received at a hospital emergency room if the services are not emergency services.

- b. As provided under 42 CFR 447.54, the amount of this co-pay will be \$8 for each non-emergent use of the emergency department.
- c. The individual must receive an appropriate medical screening examination under section 1867—the Emergency Medical Treatment and Labor Act, or EMTALA provision of the Act.
- d. Providers cannot refuse treatment for nonpayment of the co-payment.
- e. AI/AN who are currently receiving or who have ever received an item or services furnished by an Indian health care provider or through referral under contract health services are exempt from the copayment requirements outlined above, consistent with section 1916(j) of the Act and 42 CFR 447.56.

7. DELIVERY SYSTEM

- 7.1. **General.** Demonstration Population 1 will be enrolled in managed care organizations (MCO) that are currently contracted to provide health care services to the state’s existing Medicaid and BadgerCare programs. As a condition of eligibility, demonstration enrollees will be required to join a MCO, as long as there is at least two MCOs available in their county of residence unless the rural exception is met in accordance with 42 CFR 438.52.(b). If the county has not been granted a rural exception, the state must offer the option of either MCO enrollment or Medicaid fee-for-service. All demonstration eligible beneficiaries must be provided a Medicaid card, regardless of MCO enrollment. MCOs may elect to provide a MCO specific card to MCO enrollees as well. The state must comply with the managed care regulations published at 42 CFR part 438. Capitation rates shall be developed and certified as actuarially sound, in accordance with 42 CFR 438.4, 438.5 and 438.7. No FFP is available for activities covered under contracts and/or modifications to existing contracts that are subject to 42 CFR part 438 requirements prior to CMS approval of this demonstration authority as well as such contracts and/or contract amendments. The state shall submit any supporting documentation deemed necessary by CMS. The state must provide CMS with a minimum of sixty (60) days to review and approve changes. CMS reserves the right, as a corrective action, to withhold FFP (either partial or full) for the demonstration, until the contract compliance requirement is met.

8. MONITORING AND REPORTING REQUIREMENTS

- 8.1. **Deferral for Failure to Submit Timely Demonstration Deliverables.** CMS may issue deferrals in the amount of \$5,000,000 per deliverable (federal share) when items required by these STCs (e.g., required data elements, analyses, reports, design documents, presentations, and other items specified in these STCs (hereafter singularly or collectively referred to as “deliverable(s)”) are not submitted timely to CMS or found to not be consistent with the requirements approved by CMS. The state does not relinquish its rights provided under 42 CFR part 430 subpart C to challenge any CMS finding that the state materially failed to comply with the terms of this agreement. Specifically:
- a. The following process will be used: 1) thirty (30) calendar days after the deliverable was due if the state has not submitted a written request to CMS for approval of an extension as described in subsection (8.1.3) below; or 2) thirty (30) calendar days after CMS has notified the state in writing that the deliverable was not accepted for being inconsistent with the requirements of this agreement and the information

- needed to bring the deliverable into alignment with CMS requirements.
- b. CMS will issue a written notification to the state providing advance notification of a pending deferral for late or non-compliant submissions of required deliverables
- c. For each deliverable, the state may submit to CMS a written request for an extension to submit the required deliverable that includes a rationale for the cause(s) of the delay and the state's anticipated date of submission. Extension requests that extend beyond the current fiscal quarter must include a Corrective Action Plan (CAP). Should CMS agree in writing to the state's request, a corresponding extension of the deferral process described below can be provided. If the state's request for an extension includes a CAP, CMS may agree to or further negotiate the CAP as an interim step before applying the deferral.
- d. If CMS agrees to an interim corrective plan in accordance with subsection 8.1.2, and the state fails to comply with the corrective action plan or, despite the corrective action plan, still fails to submit the overdue deliverable(s) with all required contents in satisfaction of the terms of this agreement, the deferral would be issued against the next Quarterly Statement of Expenditure reported in Medicaid Budget and Expenditure System (MBES/CBES) following a written deferral notification to the state. following the written deferral notification.
- e. If the CMS deferral process has been initiated for state non-compliance with the terms of this agreement with respect to required deliverable(s), and the state submits the overdue deliverable(s), and such deliverable(s) are accepted by CMS as meeting the requirements specified in these STCs, the deferral(s) will be released. When the state submits the overdue deliverable(s) that are accepted by CMS, the deferral(s) will be released.
- f. As the purpose of a section 1115 demonstration is to test new methods of operation or services, a state's failure to submit all required deliverables may preclude a state from renewing a demonstration or obtaining a new demonstration.

8.2. Deferral of Federal Financial Participation (FFP) from IMD Claiming for Insufficient Progress Toward Milestone. Up to \$5,000,000 in FFP for services in IMDs may be deferred if the state is not making adequate progress on meeting the milestones and goals as evidenced by reporting on the milestones in the Implementation Plan and the required performance measures in the Monitoring Protocol agreed upon by the state and CMS. Once CMS determines that state has not made adequate progress, up to \$5,000,000 will be deferred in the next calendar quarter and each calendar thereafter until CMS has determined sufficient progress has been made.

8.3. Submission of Post-approval Deliverables. The state must submit all deliverables as stipulated by CMS and within the timeframes outlined within these STCs.

8.4. Compliance with Federal Systems Updates. As federal systems continue to evolve and incorporate additional 1115 waiver reporting and analytics functions, the state will work with CMS to:

- a. Revise the reporting templates and submission processes to accommodate timely compliance with the requirements of the new system;

- b. Ensure all 1115, Transformed Medicaid Statistical Information System (T-MSIS), and other data elements that have been agreed to for reporting and analytics are provided by the state; and
- c. Submit deliverables to the appropriate system as directed by CMS.

8.5. **Monitoring Protocol.** The state must submit to CMS a Monitoring Protocol no later than 150 calendar days after approval of the demonstration. The Monitoring Protocol must be developed in cooperation with CMS and is subject to CMS approval. The state must submit a revised Monitoring Protocol with 60 calendar days after receipt of CMS's comments, if any. Once approved, the Monitoring Protocol will be incorporated into the STCs, as Attachment F. Progress on the performance measures identified in the Monitoring Protocol must be reported via the Quarterly and Annual Monitoring Reports. Components of the Monitoring Protocol must include:

- a. An assurance of the state's commitment and ability to report information relevant to each of the program implementation areas listed in STC 5.2 and reporting relevant information to the state's Health IT plan described in STC 5.2.
- b. A description of the methods of data collection and timeframes for reporting on the state's progress on required measures as part of the general reporting requirements described in Section 8 (Monitoring and Reporting Requirements) of the demonstration; and
- c. A description of baselines and targets to be achieved by the end of the demonstration. Where possible, baselines will be informed by state data, and target will be benchmarked against performance in best practice settings.

8.6. **Monitoring Reports.** The state must submit three Quarterly Monitoring Reports and one Annual Monitoring Report each DY. The fourth quarter information that would ordinarily be provided in a separate report should be reported as distinct information within the Annual Report. The Quarterly Monitoring Reports are due no later than 60 calendar days following the end of each demonstration quarter. The Annual Monitoring Report (including the fourth quarter information) is due no later than 90 calendar days following the end of the DY. The reports will include all required elements as per 42 CFR 431.428, and must not direct readers to links outside the report. Additional links not referenced in the document may be listed in a Reference/Bibliography section. The Monitoring Reports must follow the framework to be provided by CMS, which is subject to change as monitoring systems are developed/evolve, and be provided in a structured manner that supports federal tracking and analysis.

- a. Operational Updates - Per 42 CFR 431.428, the Monitoring Reports must document any policy or administrative difficulties in operating the demonstration. The reports shall provide sufficient information to document key operational and other challenges, underlying causes of challenges, how challenges are being addressed, as well as key achievements and to what conditions and efforts successes can be attributed. The discussion should also include any issues or complaints identified by beneficiaries; lawsuits or legal actions; unusual or unanticipated trends; legislative updates; and descriptions of any public forums held. Monitoring Reports should also include a summary of all public comments received through post-award public forums regarding the progress of the demonstration.

- b. Performance Metrics – Per applicable CMS guidance and technical assistance, the performance metrics will provide data to support tracking the state’s progress toward meeting the demonstration’s annual goals and overall targets as identified in the approved Monitoring Protocol and will cover key policies under this demonstration. The performance metrics will reflect all components of the state’s demonstration, and may include, but are not limited to, measures associated with eligibility and coverage. Per 42 CFR 431.428, the Monitoring Reports must document the impact of the demonstration on beneficiaries’ outcomes of care, quality and cost of care, and access to care. Such reporting must also be stratified by key demographic subpopulations of interest (e.g., by sex, age, race/ethnicity, primary language, disability status, and geography) and by demonstration component, to the extent feasible. Subpopulation reporting will support identifying any existing shortcomings or disparities in quality of care and health outcomes and help track whether the demonstration’s initiatives help improve outcomes for the state’s Medicaid population, including the narrowing of any identified disparities. This may also include the results of beneficiary satisfaction surveys, if conducted, and grievances and appeals. The required monitoring and performance metrics must be included in the Monitoring Reports, and will follow the framework provided by CMS to support federal tracking and analysis.
- c. Budget Neutrality and Financial Reporting Requirements – Per 42 CFR 431.428, the Monitoring Reports must document the financial performance of the demonstration. The state must provide an updated budget neutrality workbook with every Monitoring Report that meets all the reporting requirements for monitoring budget neutrality set forth in the General Financial Requirements section of these STCs, including the submission of corrected budget neutrality data upon request. In addition, the state must report quarterly and annual expenditures associated with the populations affected by this demonstration on the Form CMS-64. Administrative costs should be reported separately.
- d. Evaluation Activities and Interim Findings - Per 42 CFR 431.428, the Monitoring Reports must document any results of the demonstration to date per the evaluation hypotheses. Additionally, the state shall include a summary of the progress of evaluation activities, including key milestones accomplished, as well as challenges encountered and how they were addressed.
- e. SUD Health IT - The state will include a summary of progress in regards to SUD Health IT requirements outlined in STC 5.

- 8.7. **SUD Mid-Point Assessment** - The state must contract with an independent entity to conduct a Mid-Point Assessment by December 31, 2026. This timeline will allow for the Mid-Point Assessment to capture approximately the first two-and-a-half years of demonstration program data, accounting for data run-out and data completeness. In the design, planning and conduction of the Mid-Point Assessment, the state must require that the independent assessor consult with key stakeholders including, but not limited to: representatives of MCOs, health care providers (including SUD treatment providers), beneficiaries, community groups, and other key partners.

The state must require that the assessor provide a Mid-Point Assessment to the state that includes the methodologies used for examining progress and assessing risk, the limitations of the methodologies, its determinations and any recommendations. The state must provide a copy of the report to CMS no later than 60 days after December 31, 2026. If requested, the state must brief CMS on the report. The state must submit a revised Mid-Point Assessment with 60 calendar days after receipt of CMS's comments, if any.

For milestones and measure targets at medium to high risk of not being achieved, the state must submit to CMS proposed modifications to the SUD Implementation Plan and the SUD Monitoring Protocol, for ameliorating these risks. Modifications to any of these plans or protocols are subject to CMS approval.

Elements of the Mid-Point Assessment must include:

1. An examination of progress toward meeting each milestone and timeframe approved in the SUD Implementation Plan and toward meeting the targets for performance measures as approved in the SUD Monitoring Protocol.
2. A determination of factors that affected achievement on the milestones and performance measure gap closure percentage points to date.
3. A determination of factors likely to affect future performance in meeting milestones and targets not yet met and information about the risk of possibly missing those milestones and performance targets.
4. For milestones or targets at medium to high risk of not being met, recommendations for adjustments in the state's SUD Implementation Plans or to other pertinent factors that the state can influence that will support improvement; and
5. An assessment of whether the state is on track to meet the budget neutrality requirements.

8.8. Corrective Action Plan Related to Demonstration Monitoring - If monitoring indicates that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS reserves the right to require the state to submit a corrective action plan to CMS for approval. A state corrective action plan could include a temporary suspension of implementation of demonstration programs in circumstances where monitoring data indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. This may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 3.10. CMS will withdraw an authority, as described in STC 3.10 when metrics indicate substantial and sustained directional change inconsistent with the state's demonstration goals, and the state has not implemented corrective action. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.

8.9. Close-Out Report. Within 120 calendar days after the expiration of the demonstration, the state must submit a draft Close-Out Report to CMS for comments.

- a. The Close-Out Report must comply with the most current guidance from CMS.
- b. In consultation with CMS, and per the guidance from CMS, the state will include an evaluation of the demonstration (or demonstration components) that are to phase out

or expire without extension along with the Close-Out Report. Depending on the timeline of the phase-out during the demonstration approval period, in agreement with CMS, the evaluation requirement may be satisfied through the Interim and/or Summative Evaluation Reports stipulated in STCs 9.7 and 9.8, respectively.

- c. The state will present to and participate in a discussion with CMS on the Close-Out report.
- d. The state must take into consideration CMS' comments for incorporation into the final Close-Out Report.
- e. A revised Close-Out Report is due to CMS no later than 30 days after receipt of CMS' comments.
- f. A delay in submitting the draft or final version of the Close-Out Report may subject the state to penalties described in STC 8.1.

8.10. Monitoring Calls. CMS will convene periodic conference calls with the state.

- a. The purpose of these calls is to discuss ongoing demonstration operation, including (but not limited to), any significant actual or anticipated developments affecting the demonstration. Examples include implementation activities, trends in reported data on metrics and associated mid-course adjustments, enrollment and access, budget neutrality, and progress on evaluation activities.
- b. CMS will provide updates on any pending actions, as well as federal policies and issues that may affect any aspect of the demonstration.
- c. The state and CMS will jointly develop the agenda for the calls.

8.11. Post Award Forum. Pursuant to 42 CFR 431.420(c), within six months of the demonstration's implementation, and annually thereafter, the state must afford the public with an opportunity to provide meaningful comment on the progress of the demonstration. At least 30 days prior to the date of the planned public forum, the state must publish the date, time, and location of the forum in a prominent location on its website. The state must also post the most recent Annual Monitoring Report on its website with the public forum announcement. Pursuant to 42 CFR 431.420(c), the state must include a summary of the comments in the Monitoring Report associated with the quarter in which the forum was held, as well as in its compiled Annual Monitoring Report.

9. EVALUATION OF THE DEMONSTRATION

9.1. Cooperation with Federal Evaluators. As required under 42 CFR 431.420(f), the state shall cooperate fully and timely with CMS and its contractors in any federal evaluation of the demonstration or any component of the demonstration. This includes, but is not limited to, commenting on design and other federal evaluation documents and providing data and analytic files to CMS, including entering into a data use agreement that explains how the data and data files will be exchanged, and providing a technical point of contact to support specification of the data and files to be disclosed, as well as relevant data dictionaries and record layouts. The state shall include in its contracts with entities who collect, produce or maintain data and files for the demonstration, that they shall make such data available for the federal evaluation as is required under 42 CFR 431.420(f) to support federal evaluation. The state may claim

administrative match for these activities. Failure to comply with this STC may result in a deferral being issued as outlined in STC 8.1.

- 9.2. **Independent Evaluator.** Upon approval of the demonstration, the state must begin to arrange with an independent party to conduct an evaluation of the demonstration to ensure that the necessary data is collected at the level of detail needed to research the approved hypotheses. The independent party must sign an agreement to conduct the demonstration evaluation in an independent manner in accord with the CMS-approved, draft Evaluation Design. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.
- 9.3. **Draft Evaluation Design.** The state must submit, for CMS comment and approval, a draft Evaluation Design, no later than one hundred eighty (180) calendar days after approval of the demonstration. Any modifications to an existing approved Evaluation Design will not affect previously established requirements and timelines for report submission for the demonstration, if applicable.
 - a. The draft Evaluation Design must be developed in accordance with the following CMS guidance (including but not limited to):
 - b. Attachment C (Developing the Evaluation Design) of these STCs, technical assistance for developing SUD Evaluation Designs (as applicable, and as provided by CMS), and all applicable technical assistance on how to establish comparison groups to develop a draft Evaluation Design.
- 9.4. **Evaluation Design Approval and Updates.** The state must submit a revised draft Evaluation Design within sixty (60) calendar days after receipt of CMS' comments. Upon CMS approval, the approved Evaluation Design will be included as an attachment to these STCs. Per 42 CFR 431.424(c), the state will publish the approved Evaluation Design within thirty (30) calendar days of CMS approval. The state must implement the Evaluation Design and submit a description of its evaluation progress in each of the Monitoring Reports. Once CMS approves the Evaluation Design, if the state wishes to make changes, the state must submit a revised Evaluation Design to CMS for approval if the changes are substantial in scope; otherwise, in consultation with CMS, the state may include updates to the evaluation design in monitoring reports.
- 9.5. **Evaluation Questions and Hypotheses.** Consistent with Attachments C and D (Developing the Evaluation Design and Preparing the Interim and Summative Evaluation Reports) of these STCs, the evaluation documents must include a discussion of the evaluation questions and hypotheses that the state intends to test. Each demonstration component should have at least one evaluation question and hypothesis. The hypothesis testing should include, where possible, assessment of both process and outcome measures. Proposed measures should be selected from nationally-recognized sources and national measures sets, where possible. Measures sets could include CMS's Core Set of Health Care Quality Measures for Children in Medicaid and CHIP, CMS' measure sets for eligibility and coverage, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Initial Core Set of Health Care Quality Measures for Medicaid-Eligible Adults and/or measures endorsed by National Quality Forum (NQF).

- 9.6. **Evaluation Budget.** A budget for the evaluation shall be provided with the draft Evaluation Design. It will include the total estimated cost, as well as a breakdown of estimated staff, administrative, and other costs for all aspects of the evaluation such as any survey and measurement development, quantitative and qualitative data collection and cleaning, analyses, and report generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the design or if CMS finds that the design is not sufficiently developed, or if the estimates appear to be excessive.
- 9.7. **Interim Evaluation Report.** The state must submit an Interim Evaluation Report for the completed years of the demonstration, and for each subsequent renewal or extension of the demonstration, as outlined in 42 CFR 431.412(c)(2)(vi). When submitting an application for renewal, the Interim Evaluation Report should be posted to the state's website with the application for public comment.
- a. The Interim Evaluation Report will discuss evaluation progress and present findings to date as per the approved Evaluation Design.
 - b. For demonstration authority that expires prior to the overall demonstration's expiration date, the Interim Evaluation Report must include an evaluation of the authority as approved by CMS.
 - c. If the state is seeking to renew or extend the demonstration, the draft Interim Evaluation Report is due when the application for renewal is submitted. If the state made changes to the demonstration in its application for renewal, the research questions and hypotheses, and how the design was adapted should be included. If the state is not requesting a renewal for a demonstration, an Interim Evaluation Report is due one (1) year prior to the end of the demonstration. For demonstration phase outs prior to the expiration of the approval period, the draft Interim Evaluation Report is due to CMS on the date that will be specified in the notice of termination or suspension.
 - d. The state must submit a revised Interim Evaluation Report sixty (60) calendar days after receiving CMS comments on the draft Interim Evaluation Report. Once approved by CMS, the state must post the final Interim Evaluation Report to the state's website.
 - e. The Interim Evaluation Report must comply with Attachment D (Preparing the Interim and Summative Evaluation Reports) of these STCs.
- 9.8. **Summative Evaluation Report.** The state must submit to CMS a draft Summative Evaluation Report for the demonstration's current approval period within 18 months of the end of the approval period represented by these STCs.
- a. The Summative Evaluation Report, in alignment with the Evaluation Design, must evaluate the entirety of the demonstration period.
 - b. Unless otherwise agreed upon in writing by CMS, the state shall submit a revised Summative Evaluation Report within sixty (60) calendar days of receiving comments from CMS on the draft, if any.
 - c. Once approved by CMS, the state must post the final Summative Evaluation Report to the state's Medicaid website within 30 calendar days.

- d. The Summative Evaluation Report must comply with Attachment B (Preparing the Interim and Summative Evaluation Report) of these STCs.

- 9.9. **Corrective Action Plan Related to Evaluation.** If evaluation findings indicate that demonstration features are not likely to assist in promoting the objectives of Medicaid, CMS reserves the right to require the state to submit a corrective action plan to CMS for approval. These discussions may also occur as part of a renewal process when associated with the state's Interim Evaluation Report. A state corrective action plan could include a temporary suspension of implementation of demonstration programs, in circumstances where evaluation findings indicate substantial and sustained directional change inconsistent with demonstration goals, such as substantial and sustained trends indicating increased difficulty accessing services. This may be an interim step to withdrawing waivers or expenditure authorities, as outlined in STC 3.10. CMS further has the ability to suspend implementation of the demonstration should corrective actions not effectively resolve these concerns in a timely manner.
- 9.10. **State Presentations for CMS.** CMS reserves the right to request that the state present and participate in a discussion with CMS on the Evaluation Design, the Interim Evaluation Report, and/or the summative evaluation. Presentations may be conducted remotely.
- 9.11. **Public Access.** The state shall post the final documents (e.g., Monitoring Reports, Close Out Report, Approved Evaluation Design, Interim Evaluation Report, and Summative Evaluation Report) on the state's Medicaid website within thirty (30) calendar days of approval by CMS.
- 9.12. **Additional Publications and Presentations.** For a period of twelve (12) months following CMS approval of the final reports, CMS will be notified prior to presentation of these reports or their findings, including in related publications (including, for example, journal articles), by the state, contractor, or any other third party directly connected to the demonstration over which the state has control. Prior to release of these reports, articles, or other publications, CMS will be provided a copy including any associated press materials. CMS will be given ten (10) business days to review and comment on publications before they are released. CMS may choose to decline to comment or review some or all of these notifications and reviews. This requirement does not apply to the release or presentation of these materials to state or local government officials.

10. GENERAL FINANCIAL REQUIREMENTS

- 10.1. **Allowable Expenditures.** This demonstration project is approved for authorized demonstration expenditures applicable to services rendered and for costs incurred during the demonstration approval period designated by CMS. CMS will provide FFP for allowable demonstration expenditures only so long as they do not exceed the pre-defined limits as specified in these STCs.
- 10.2. **Standard Medicaid Funding Process.** The standard Medicaid funding process will be used for this demonstration. The state will provide quarterly expenditure reports through the Medicaid and CHIP Budget and Expenditure System (MBES/CBES) to report total expenditures under this Medicaid section 1115 demonstration following routine CMS-37 and

CMS-64 reporting instructions as outlined in section 2500 of the State Medicaid Manual. The state will estimate matchable demonstration expenditures (total computable and federal share) subject to the budget neutrality expenditure limit and separately report these expenditures by quarter for each federal fiscal year on the form CMS-37 for both the medical assistance payments (MAP) and state and local administration costs (ADM). CMS shall make federal funds available based upon the state's estimate, as approved by CMS. Within 30 days after the end of each quarter, the state shall submit form CMS-64 Quarterly Medicaid Expenditure Report, showing Medicaid expenditures made in the quarter just ended. If applicable, subject to the payment deferral process, CMS shall reconcile expenditures reported on form CMS-64 with federal funding previously made available to the state, and include the reconciling adjustment in the finalization of the grant award to the state.

- 10.3. **Sources of Non-Federal Share.** As a condition of demonstration approval, the state certifies that its funds that make up the non-federal share are obtained from permissible state and/or local funds that, unless permitted by law, are not other federal funds. The state further certifies that federal funds provided under this section 1115 demonstration must not be used as the non-federal share required under any other federal grant or contract, except as permitted by law. CMS approval of this demonstration does not constitute direct or indirect approval of any underlying source of non-federal share or associated funding mechanisms and all sources of non-federal funding must be compliant with section 1903(w) of the Act and applicable implementing regulations. CMS reserves the right to deny FFP in expenditures for which it determines that the sources of non-federal share are impermissible.
- a. If requested, the state must submit for CMS review and approval documentation of any sources of non-federal share that would be used to support payments under the demonstration.
 - b. If CMS determines that any funding sources are not consistent with applicable federal statutes or regulations, the state must address CMS's concerns within the time frames allotted by CMS.
 - c. Without limitation, CMS may request information about the non-federal share sources for any amendments that CMS determines may financially impact the demonstration.
- 10.4. **State Certification of Funding Conditions.** As a condition of demonstration approval, the state certifies that the following conditions for non-federal share financing of demonstration expenditures have been met:
- a. If units of state or local government, including health care providers that are units of state or local government, supply any funds used as non-federal share for expenditures under the demonstration, the state must certify that state or local monies have been expended as the non-federal share of funds under the demonstration in accordance with section 1903(w) of the Act and applicable implementing regulations.
 - b. To the extent the state utilizes certified public expenditures (CPE) as the funding mechanism for the non-federal share of expenditures under the demonstration, the state must obtain CMS approval for a cost reimbursement methodology. This methodology must include a detailed explanation of the process, including any necessary cost reporting protocols, by which the state identifies those costs eligible for purposes of certifying public expenditures. The certifying unit of government that

- incurs costs authorized under the demonstration must certify to the state the amount of public funds allowable under 42 CFR 433.51 it has expended. The federal financial participation paid to match CPEs may not be used as the non-federal share to obtain additional federal funds, except as authorized by federal law, consistent with 42 CFR 433.51(c).
- c. The state may use intergovernmental transfers (IGT) to the extent that the transferred funds are public funds within the meaning of 42 CFR 433.51 and are transferred by units of government within the state. Any transfers from units of government to support the non-federal share of expenditures under the demonstration must be made in an amount not to exceed the non-federal share of the expenditures under the demonstration.
 - d. Under all circumstances, health care providers must retain 100 percent of their payments for or in connection with furnishing covered services to beneficiaries. Moreover, no pre-arranged agreements (contractual, voluntary, or otherwise) may exist between health care providers and state and/or local governments, or third parties to return and/or redirect to the state any portion of the Medicaid payments in a manner inconsistent with the requirements in section 1903(w) of the Act and its implementing regulations. This confirmation of Medicaid payment retention is made with the understanding that payments that are the normal operating expenses of conducting business, such as payments related to taxes, including health care provider-related taxes, fees, business relationships with governments that are unrelated to Medicaid and in which there is no connection to Medicaid payments, are not considered returning and/or redirecting a Medicaid payment.
 - e. The State Medicaid Director or his/her designee certifies that all state and/or local funds used as the state's share of the allowable expenditures reported on the CMS-64 for this demonstration were in accordance with all applicable federal requirements and did not lead to the duplication of any other federal funds.

10.5. Financial Integrity for Managed Care Delivery Systems. As a condition of demonstration approval, the state attests to the following, as applicable:

- a. All risk-based managed care organization, prepaid inpatient health plan (PIHP), and prepaid ambulatory health plan (PAHP) payments, comply with the requirements on payments in 42 CFR 438.6(b)(2), 438.6(c), 438.6(d), 438.60, and 438.74.

10.6. Requirements for Health Care-Related Taxes and Provider Donations. As a condition of demonstration approval, the state attests to the following, as applicable:

- a. Except as provided in paragraph (c) of this STC, all health care-related taxes as defined by Section 1903(w)(3)(A) of the Act and 42 CFR 433.55 are broad-based as defined by Section 1903(w)(3)(B) of the Act and 42 CFR 433.68(c).
- b. Except as provided in paragraph (c) of this STC, all health care-related taxes are uniform as defined by Section 1903(w)(3)(C) of the Act and 42 CFR 433.68(d).
- c. If the health care-related tax is either not broad-based or not uniform, the state has applied for and received a waiver of the broad-based and/or uniformity requirements as specified by 1903(w)(3)(E)(i) of the Act and 42 CFR 433.72.
- d. The tax does not contain a hold harmless arrangement as described by Section 1903(w)(4) of the Act and 42 CFR 433.68(f).

- e. All provider-related donations as defined by 42 CFR 433.52 are bona fide as defined by Section 1903(w)(2)(B) of the Social Security Act, 42 CFR 433.66, and 42 CFR 433.54.

- 10.7. **State Monitoring of Non-federal Share.** If any payments under the demonstration are funded in whole or in part by a locality tax, then the state must provide a report to CMS regarding payments under the demonstration no later than 60 days after demonstration approval. This deliverable is subject to the deferral as described in STC 8.1. This report must include:
- a. A detailed description of and a copy of (as applicable) any agreement, written or otherwise agreed upon, regarding any arrangement among the providers including those with counties, the state, or other entities relating to each locality tax or payments received that are funded by the locality tax;
 - b. Number of providers in each locality of the taxing entities for each locality tax;
 - c. Whether or not all providers in the locality will be paying the assessment for each locality tax;
 - d. The assessment rate that the providers will be paying for each locality tax;
 - e. Whether any providers that pay the assessment will not be receiving payments funded by the assessment;
 - f. Number of providers that receive at least the total assessment back in the form of Medicaid payments for each locality tax;
 - g. The monitoring plan for the taxing arrangement to ensure that the tax complies with section 1903(w)(4) of the Act and 42 CFR 433.68(f); and
 - h. Information on whether the state will be reporting the assessment on the CMS form 64.11A as required under section 1903(w) of the Act.
- 10.8. **Extent of Federal Financial Participation for the Demonstration.** Subject to CMS approval of the source(s) of the non-federal share of funding, CMS will provide FFP at the applicable federal matching rate for the following demonstration expenditures, subject to the budget neutrality expenditure limits described in the STCs in section 11:
- a. Administrative costs, including those associated with the administration of the demonstration;
 - b. Net expenditures and prior period adjustments of the Medicaid program that are paid in accordance with the approved Medicaid state plan; and
 - c. Medical assistance expenditures and prior period adjustments made under section 1115 demonstration authority with dates of service during the demonstration extension period; including those made in conjunction with the demonstration, net of enrollment fees, cost sharing, pharmacy rebates, and all other types of third party liability.
- 10.9. **Program Integrity.** The state must have processes in place to ensure there is no duplication of federal funding for any aspect of the demonstration. The state must also ensure that the state and any of its contractors follow standard program integrity principles and practices including retention of data. All data, financial reporting, and sources of non-federal share are subject to audit.

- 10.10. **Medicaid Expenditure Groups.** Medicaid Expenditure Groups (MEG) are defined for the purpose of identifying categories of Medicaid or demonstration expenditures subject to budget neutrality, components of budget neutrality expenditure limit calculations, and other purposes related to monitoring and tracking expenditures under the demonstration. The Master MEG Chart table provides a master list of MEGs defined for this demonstration.

Table 3: Master MEG Chart					
MEG	Which BN Test Applies?	WOW Per Capita	WOW Aggregate	WW	Brief Description
Childless Adult	Hypothetical	X		X	All expenditures for services provided to non-pregnant, uninsured adults ages 19 through 64 years who have family incomes up to 100 percent of the FPL.
SUD	Hypothetical	X		X	All expenditures for services provided to an individual while they are a patient in an IMD for SUD treatment.
ADM	N/A				All additional administrative costs that are directly attributable to the demonstration and not described elsewhere and are not subject to budget neutrality.

BN – budget neutrality; MEG – Medicaid expenditure group; WOW – without waiver; WW – with waiver

- 10.11. **Reporting Expenditures and Member Months.** The state must report all demonstration expenditures claimed under the authority of title XIX of the Act and subject to budget neutrality each quarter on separate forms CMS-64.9 WAIVER and/or 64.9P WAIVER, identified by the demonstration project number assigned by CMS (11-W-00293/5). Separate reports must be submitted by MEG (identified by Waiver Name) and Demonstration Year (identified by the two-digit project number extension). Unless specified otherwise, expenditures must be reported by DY according to the dates of service associated with the expenditure. All MEGs identified in the Master MEG Chart as WW must be reported for expenditures, as further detailed in the MEG Detail for Expenditure and Member Month Reporting table below. To enable calculation of the budget neutrality expenditure limits, the state also must report member months of eligibility for specified MEGs.
- Cost Settlements.** The state will report any cost settlements attributable to the demonstration on the appropriate prior period adjustment schedules (form CMS-64.9P WAIVER) for the summary sheet line 10b (in lieu of lines 9 or 10c), or line 7. For any cost settlement not attributable to this demonstration, the adjustments should

- be reported as otherwise instructed in the State Medicaid Manual. Cost settlements must be reported by DY consistent with how the original expenditures were reported.
- b. **Premiums and Cost Sharing Collected by the State.** The state will report any premium contributions collected by the state from demonstration enrollees quarterly on the form CMS-64 Summary Sheet line 9D, columns A and B. In order to assure that these collections are properly credited to the demonstration, quarterly premium collections (both total computable and federal share) should also be reported separately by demonstration year on form CMS-64 Narrative, and on the Total Adjustments tab in the Budget Neutrality Monitoring Tool. In the annual calculation of expenditures subject to the budget neutrality expenditure limit, premiums collected in the demonstration year will be offset against expenditures incurred in the demonstration year for determination of the state's compliance with the budget neutrality limits.
 - c. **Pharmacy Rebates.** Because pharmacy rebates are included in the base expenditures used to determine the budget neutrality expenditure limit, the state must report the portion of pharmacy rebates applicable to the demonstration on the appropriate forms CMS-64.9 WAIVER and 64.9P waiver for the demonstration, and not on any other CMS-64.9 form (to avoid double counting). The state must have a methodology for assigning a portion of pharmacy rebates to the demonstration in a way that reasonably reflects the actual rebate-eligible pharmacy utilization of the demonstration population, and which identifies pharmacy rebate amounts with DYs. Use of the methodology is subject to the approval in advance by the CMS Regional Office, and changes to the methodology must also be approved in advance by the Regional Office. Each rebate amount must be distributed as state and federal revenue consistent with the federal matching rates under which the claim was paid.
 - d. **Administrative Costs.** The state will separately track and report additional administrative costs that are directly attributable to the demonstration. All administrative costs must be identified on the forms CMS-64.10 WAIVER and/or 64.10P WAIVER. Unless indicated otherwise on the MEG Charts and in the STCs in section 11, administrative costs are not counted in the budget neutrality tests; however, these costs are subject to monitoring by CMS.
 - e. **Member Months.** As part of the Quarterly and Annual Monitoring Reports described in section 8, the state must report the actual number of “eligible member months” for all demonstration enrollees for all MEGs identified as WOW Per Capita in the Master MEG Chart table above, and as also indicated in the MEG Detail for Expenditure and Member Month Reporting table below. The term “eligible member months” refers to the number of months in which persons enrolled in the demonstration are eligible to receive services. For example, a person who is eligible for three months contributes three eligible member months to the total. Two individuals who are eligible for two months each contribute two eligible member months per person, for a total of four eligible member months. The state must submit a statement accompanying the annual report certifying the accuracy of this information.
 - f. **Budget Neutrality Specifications Manual.** The state will create and maintain a Budget Neutrality Specifications Manual that describes in detail how the state will compile data on actual expenditures related to budget neutrality, including methods used to extract and compile data from the state’s Medicaid Management Information

System, eligibility system, and accounting systems for reporting on the CMS-64, consistent with the terms of the demonstration. The Budget Neutrality Specifications Manual will also describe how the state compiles counts of Medicaid member months. The Budget Neutrality Specifications Manual must be made available to CMS on request.

Table 4: MEG Detail for Expenditure and Member Month Reporting

MEG (Waiver Name)	Detailed Description	Exclusions	CMS-64.9 or 64.10 Line(s) To Use	How Expend. Are Assigned to DY	MAP or ADM	Report Member Months (Y/N)	MEG Start Date	MEG End Date
Childless Adult	All expenditures for services provided to non-pregnant, uninsured adults ages 19 through 64 years who have family incomes up to 100 percent of the FPL		Follow standard CMS 64.10 Category of Service Definitions	Date of service	MAP	Y	10/29/24	12/31/29
SUD	All expenditures for services provided to an individual while they are a patient in an IMD for SUD treatment.		Follow standard CMS 64.9 Category of Service Definitions	Date of service	MAP	N	10/29/14	12/31/29
ADM	All additional administrative costs that are directly attributable to the demonstration and not described elsewhere and are not subject to budget neutrality.		Follow standard CMS 64.10 Category of Service Definitions	Date of payment	ADM	N	10/29/24	12/31/29

ADM – administration; DY – demonstration year; MAP – medical assistance payments; MEG – Medicaid expenditure group;

- g. **Demonstration Year Definition.** The Demonstration Years (DYs) will be defined as follows:

October 29, 2024 through December 31, 2025	Demonstration Year 12 (DY12)
January 1, 2026 through December 31, 2026	Demonstration Year 13 (DY13)
January 1, 2027 through December 31, 2027	Demonstration Year 14 (DY14)
January 1, 2028 through December 31, 2028	Demonstration Year 15 (DY15)
January 1, 2029 through December 31, 2029	Demonstration Year 16 (DY16)

- h. **Budget Neutrality Monitoring Tool.** The state must provide CMS with quarterly budget neutrality status updates, including established baseline and member months data, using the Budget Neutrality Monitoring Tool provided through the performance metrics database and analytics (PMDA) system. The tool incorporates the “Schedule C Report” for comparing the demonstration’s actual expenditures to the budget neutrality expenditure limits described in section 11. CMS will provide technical assistance, upon request.
- i. **Claiming Period.** The state will report all claims for expenditures subject to the budget neutrality agreement (including any cost settlements) within two years after the calendar quarter in which the state made the expenditures. All claims for services during the demonstration period (including any cost settlements) must be made within two years after the conclusion or termination of the demonstration. During the latter two-year period, the state will continue to identify separately net expenditures related to dates of service during the operation of the demonstration on the CMS-64 waiver forms in order to properly account for these expenditures in determining budget neutrality.
- j. **Future Adjustments to Budget Neutrality.** CMS reserves the right to adjust the budget neutrality expenditure limit:
- To be consistent with enforcement of laws and policy statements, including regulations and guidance, regarding impermissible provider payments, health care related taxes, or other payments. CMS reserves the right to make adjustments to the budget neutrality limit if any health care related tax that was in effect during the base year, or provider-related donation that occurred during the base year, is determined by CMS to be in violation of the provider donation and health care related tax provisions of section 1903(w) of the Act. Adjustments to annual budget targets will reflect the phase out of impermissible provider payments by law or regulation, where applicable.
 - To the extent that a change in federal law, regulation, or policy requires either a reduction or an increase in FFP for expenditures made under this demonstration. In this circumstance, the state must adopt, subject to CMS approval, a modified budget neutrality agreement as necessary to comply with such change. The modified agreement will be effective upon the implementation of the change. The trend rates for the budget neutrality agreement are not subject to change under this STC. The state agrees that if mandated changes in the federal law require state legislation, the changes shall

take effect on the day such state legislation becomes effective, or on the last day such legislation was required to be in effect under the federal law.

- iii. The state certifies that the data it provided to establish the budget neutrality expenditure limit are accurate based on the state's accounting of recorded historical expenditures or the next best available data, that the data are allowable in accordance with applicable federal, state, and local statutes, regulations, and policies, and that the data are correct to the best of the state's knowledge and belief. The data supplied by the state to set the budget neutrality expenditure limit are subject to review and audit, and if found to be inaccurate, will result in a modified budget neutrality expenditure limit.
- k. **Budget Neutrality Mid-Course Correction Adjustment Request.** No more than once per demonstration year, the state may request that CMS make an adjustment to its budget neutrality agreement based on changes to the state's Medicaid expenditures that are unrelated to the demonstration and/or outside the state's control, and/or that result from a new expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.
- l. **Contents of Request and Process.** In its request, the state must provide a description of the expenditure changes that led to the request, together with applicable expenditure data demonstrating that due to these expenditures, the state's actual costs have exceeded the budget neutrality cost limits established at demonstration approval. The state must also submit the budget neutrality update described in STC 10.11(n). If approved, an adjustment could be applied retrospectively to when the state began incurring the relevant expenditures, if appropriate. Within 120 days of acknowledging receipt of the request, CMS will determine whether the state needs to submit an amendment pursuant to STC 3.7. CMS will evaluate each request based on its merit and will approve requests when the state establishes that an adjustment to its budget neutrality agreement is necessary due to changes to the state's Medicaid expenditures that are unrelated to the demonstration and/or outside of the state's control, and/or that result from a new expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.
- m. **Types of Allowable Changes.** Adjustments will be made only for actual costs as reported in expenditure data. CMS will not approve mid-demonstration adjustments for anticipated factors not yet reflected in such expenditure data. Examples of the types of mid-course adjustments that CMS might approve include the following:
 - i. Provider rate increases that are anticipated to further strengthen access to care;
 - ii. CMS or State technical errors in the original budget neutrality formulation applied retrospectively, including, but not limited to the following: mathematical errors, such as not aging data correctly; or unintended omission of certain applicable costs of services for individual MEGs;
 - iii. Changes in federal statute or regulations, not directly associated with Medicaid, which impact expenditures;
 - iv. State legislated or regulatory change to Medicaid that significantly affects the costs of medical assistance;
 - v. When not already accounted for under Emergency Medicaid 1115 demonstrations, cost impacts from public health emergencies;
 - vi. High cost innovative medical treatments that states are required to cover; or,

- vii. Corrections to coverage/service estimates where there is no prior state experience (e.g., SUD) or small populations where expenditures may vary widely.
- n. **Budget Neutrality Update.** The state must submit an updated budget neutrality analysis with its adjustment request, which includes the following elements:
 - i. Projected without waiver and with waiver expenditures, estimated member months, and annual limits for each DY through the end of the approval period; and,
 - ii. Description of the rationale for the mid-course correction, including an explanation of why the request is based on changes to the state's Medicaid expenditures that are unrelated to the demonstration and/or outside the state's control, and/or is due to a new expenditure that is not a new demonstration-covered service or population and that is likely to further strengthen access to care.

11. MONITORING BUDGET NEUTRALITY FOR THE DEMONSTRATION

- 11.1. **Former Foster Care Youth (FFCY) Budget Neutrality.** CMS has determined that the FFCY demonstration population is budget neutral based on CMS's assessment that the FFCY expenditure authority granted for the demonstration has minimal federal Medicaid expenditures and this population could have been covered through waiver only authority. The state will not be allowed to obtain budget neutrality "savings" from this authority. This population will not include a budget neutrality expenditure limit; however, the state is required to report total expenditures and member months in their demonstration monitoring reports, per STC 8.6. The state must report quarterly claims and report expenditures on the CMS 64.9 WAIVER form. Failure to report FFCY expenditures and member months will result in reinstatement of the budget neutrality requirement. CMS reserves the right to request budget neutrality worksheets, requirements, limits, and analyses from the state at any time, or whenever the state seeks a change to the demonstration, per STC 3.7.
- 11.2. **Limit on Title XIX Funding.** The state will be subject to limits on the amount of federal Medicaid funding the state may receive over the course of the demonstration approval. The budget neutrality expenditure limits are based on projections of the amount of FFP that the state would likely have received in the absence of the demonstration. The limit consists of one or more Hypothetical Budget Neutrality Tests, and a Capped Hypothetical Budget Neutrality Test as described below. CMS's assessment of the state's compliance with these tests will be based on the Schedule C CMS-64 Waiver Expenditure Report, which summarizes the expenditures reported by the state on the CMS-64 that pertain to the demonstration.
- 11.3. **Risk.** The budget neutrality expenditure limits are determined on either a per capita or aggregate basis as described in Table 3, Master MEG Chart and Table 4, MEG Detail for Expenditure and Member Month Reporting. If a per capita method is used, the state is at risk for the per capita cost of state plan and hypothetical populations, but not for the number of participants in the demonstration population. By providing FFP without regard to enrollment in the demonstration for all demonstration populations, CMS will not place the state at risk for changing economic conditions, however, by placing the state at risk for the per capita costs of

the demonstration populations, CMS assures that the demonstration expenditures do not exceed the levels that would have been realized had there been no demonstration. If an aggregate method is used, the state accepts risk for both enrollment and per capita costs.

- 11.4. **Calculation of the Budget Neutrality Limit.** To calculate the budget neutrality limits for the demonstration, separate annual budget limits are determined for each DY on a total computable basis. Each annual budget limit is the sum of one or more components: per capita components, which are calculated as a projected without-waiver PMPM cost times the corresponding actual number of member months, and aggregate components, which project fixed total computable dollar expenditure amounts. The annual limits for all DYs are then added together to obtain a budget neutrality limit for the entire demonstration period. The federal share of this limit will represent the maximum amount of FFP that the state may receive during the demonstration period for the types of demonstration expenditures described below. The federal share will be calculated by multiplying the total computable budget neutrality expenditure limit by the appropriate Composite Federal Share.
- 11.5. **Hypothetical Budget Neutrality.** When expenditure authority is provided for coverage of populations or services that the state could have otherwise provided through its Medicaid state plan or other title XIX authority (such as a waiver under section 1915 of the Act), or when a WOW spending baseline for certain WW expenditures is difficult to estimate due to variable and volatile cost data resulting in anomalous trend rates, CMS considers these expenditures to be “hypothetical,” such that the expenditures are treated as if the state could have received FFP for them absent the demonstration. For these hypothetical expenditures, CMS makes adjustments to the budget neutrality test which effectively treats these expenditures as if they were for approved Medicaid state plan services. Hypothetical expenditures, therefore, do not necessitate savings to offset the expenditures on those services. When evaluating budget neutrality, however, CMS does not offset non-hypothetical expenditures with projected or accrued savings from hypothetical expenditures; that is, savings are not generated from a hypothetical population or service. To allow for hypothetical expenditures, while preventing them from resulting in savings, CMS currently applies separate, independent Hypothetical Budget Neutrality Tests, which subject hypothetical expenditures to pre-determined limits to which the state and CMS agree, and that CMS approves, as a part of this demonstration approval. If the state’s WW hypothetical spending exceeds the Hypothetical Budget Neutrality Test’s expenditure limit, the state agrees (as a condition of CMS approval) to offset that excess spending through savings elsewhere in the demonstration or to refund the FFP to CMS.
- 11.6. **Hypothetical Budget Neutrality Test.** The table below identifies the MEGs that are used for Hypothetical Budget Neutrality Test 1. MEGs that are designated “WOW Only” or “Both” are the components used to calculate the budget neutrality expenditure limit. The Composite Federal Share for the Hypothetical Budget Neutrality Test is calculated based on all MEGs indicated as “WW Only” or “Both.” MEGs that are indicated as “WW Only” or “Both” are counted as expenditures against this budget neutrality expenditure limit.

Table 5: Hypothetical Budget Neutrality Test

MEG	PC or Agg	WOW Only, WW Only, or Both	Trend Rate	DY 12	DY 13	DY 14	DY 15	DY 16
Childless Adults	PC	Both	5.20%	\$611.53	\$643.33	\$676.78	\$711.97	\$748.99
SUD	PC	Both	5.10%	\$4,274.05	\$4,492.12	\$4,721.32	\$4,962.21	\$5,215.39

- 11.7. **Composite Federal Share Ratio.** The Composite Federal Share is the ratio that will be used to convert the total computable budget neutrality limit to federal share. The Composite Federal Share is the ratio calculated by dividing the sum total of FFP received by the state on actual demonstration expenditures during the approval period by total computable demonstration expenditures for the same period, as reported through MBES/CBES and summarized on Schedule C. Since the actual final Composite Federal Share will not be known until the end of the demonstration's approval period, for the purpose of interim monitoring of budget neutrality, a reasonable estimate of Composite Federal Share may be developed and used through the same process or through an alternative mutually agreed to method. Each Budget Neutrality Test has its own Composite Federal Share, as defined in the paragraph pertaining to each particular test.
- 11.8. **Exceeding Budget Neutrality.** CMS will enforce the budget neutrality agreement over the demonstration period, which extends from October 29, 2024 to December 31, 2029. If at the end of the demonstration approval period a Capped Hypothetical Budget Neutrality Test has been exceeded, the excess federal funds will be returned to CMS. If the Demonstration is terminated prior to the end of the budget neutrality agreement, the budget neutrality test shall be based on the time elapsed through the termination date. date
- 11.9. **Corrective Action Plan.** If at any time during the demonstration approval period CMS determines that the demonstration is on course to exceed its budget neutrality expenditure limit, CMS will require the state to submit a corrective action plan for CMS review and approval. CMS will use the threshold levels in the tables below as a guide for determining when corrective action is required.

Table 6: Budget Neutrality Test Corrective Action Plan Calculation		
Demonstration Year	Cumulative Target Definition	Percentage
DY 12	Cumulative budget neutrality limit plus:	2.0 percent
DY 12 through DY 13	Cumulative budget neutrality limit plus:	1.5 percent
DY 13 through DY 14	Cumulative budget neutrality limit plus:	1.0 percent
DY 14 through DY 15	Cumulative budget neutrality limit plus:	0.5 percent
DY 15 through DY 16	Cumulative budget neutrality limit plus:	0.0 percent

12. SCHEDULE OF DELIVERABLES FOR THE DEMONSTRATION PERIOD

Table 7: Schedule of Deliverables for the Demonstration Period

Date	Deliverable	STC
30 calendar days after demonstration approval	State acceptance of demonstration Waivers, STCs, and Expenditure Authorities	Approval letter
90 calendar days after demonstration approval	SUD Implementation Plan (including Health IT Plan)	STC 5.3
60 calendar days after receipt of CMS comments	Revised SUD Implementation Plan (including Health IT Plan)	STC 5.3
150 calendar days after demonstration approval	Monitoring Protocol	STC 8.5
60 calendar days after receipt of CMS comments	Revised Monitoring Protocol	STC 8.5
180 calendar days after demonstration approval	Draft Evaluation Design	STC 9.3
60 days after receipt of CMS comments	Revised Evaluation Design	STC 9.4
No later than 60 calendar days after December 31, 2026	Mid-Point Assessment	STC 8.7
60 calendar days after receipt of CMS comments	Revised Mid-Point Assessment	STC 8.7
December 31, 2028, or with renewal application	Draft Interim Evaluation Report	STC 9.7(c)
60 calendar days after receipt of CMS comments	Revised Interim Evaluation Report	STC 9.7(d)
Within 18 months after December 31, 2029	Draft Summative Evaluation Report	STC 9.8
60 calendar days after receipt of CMS comments	Revised Summative Evaluation Report	STC 9.8
Monthly Deliverables	Monitoring Calls	STC 8.10
Quarterly monitoring reports due 60 calendar days after end of each quarter, except 4 th quarter.	Quarterly Monitoring Reports, including implementation updates	STC 8.6
	Quarterly Expenditure Reports	STC 10.11
Annual Deliverables - Due 90 calendar days after end of each 4 th quarter	Annual Monitoring Reports	STC 8.6

ATTACHMENT A
Substance Use Disorder Implementation Plan Protocol (Approved)

State of Wisconsin
BadgerCare Reform Demonstration Project

Substance Use Disorder Implementation
Protocol

September 24, 2019

Table of Contents

1.0 Introduction.....	3
2.0 Milestone Completion.....	4
2.1 Access to Critical Levels of Care for OUD and Other SUDs	4
2.2 Use of Evidence-based, SUD-specific Patient Placement Criteria	6
2.3 Use of Nationally Recognized SUD-Specific Program Standards to Set Provider Qualifications for Residential Treatment Facilities 10	
2.4 Sufficient Provider Capacity at Critical Levels of Care including for Medication Assisted Treatment for OUD 12	
2.5 Implementation of Comprehensive Treatment and Prevention Strategies to Address Opioid Abuse and OUD 13	
2.6 Improved Care Coordination and Transitions between Levels of Care.....	16
3.0 Implementation Administration	16
4.0 Relevant Documents	18
Attachment A – SUD Health Information Technology (IT) Plan	22

1.0 Introduction

Wisconsin's Section 1115 BadgerCare Reform Demonstration Waiver was approved on October 31, 2018. The approved waiver includes expansion of coverage for the continuum of Substance Use Disorder (SUD) treatment. Although Wisconsin Medicaid currently covers a robust array of treatment for members with SUD, including outpatient counseling, day treatment, psychosocial rehabilitation, medication-assisted treatment (MAT), and inpatient treatment, some gaps remain in the availability of clinically-appropriate, evidence-based treatment.

The waiver authorizes federal funding for treatment provided to Medicaid members in Institutions for Mental Diseases (IMD), allowing Wisconsin Medicaid to establish a residential treatment benefit that provides coverage in all state-certified residential programs, regardless of size. As a result, Wisconsin Medicaid members will have access to high quality, evidence-based opioid use disorder (OUD) and other SUD treatment services.

This document serves as the BadgerCare Reform Demonstration Waiver Implementation Protocol. In accordance with Standard Terms and Conditions (STC) #20 in the waiver, the implementation protocol describes the strategic approach and project plan to meet required milestones for SUD treatment reform in Wisconsin.

Specifically, Wisconsin Medicaid's overall goals for SUD treatment reform include:

1. Increased rates of identification, initiation and engagement in treatment for OUD and other SUDs;
2. Increased adherence to and retention in treatment for OUD and other SUDs;
3. Reductions in overdose deaths, particularly those due to opioids;
4. Reduced utilization of emergency departments and inpatient hospital settings for OUD and other SUD treatment where the utilization is preventable or medically inappropriate through improved access to other continuum of care services;
5. Fewer readmissions to the same or higher level of care where readmissions is preventable or medically inappropriate for OUD and other SUD; and
6. Improved access to care for physical health conditions among beneficiaries with OUD or other SUDs.

Wisconsin Medicaid has identified the following milestones to meet during the project implementation:

1. Access to critical levels of care for OUD and other SUDs;
2. Widespread use of evidence-based, SUD-specific patient placement criteria;
3. Use of nationally recognized, evidence-based, SUD program standards to set residential treatment provider qualifications;

4. Sufficient provider capacity at each level of care, including MAT;
5. Implementation of comprehensive treatment and prevention strategies to address opioid abuse and OUD; and
6. Improved care coordination and transitions between levels of care.

2.0 Milestone Completion

Over the course of the demonstration, Wisconsin Medicaid will work with internal and external stakeholders to develop, implement, and monitor SUD treatment initiatives designed to achieve the following milestones:

2.1 Access to Critical Levels of Care for OUD and Other SUDs

Wisconsin Medicaid will establish new coverage policies and enhance existing benefits to provide members access to the full continuum of care for SUD treatment. Currently, Wisconsin Medicaid's largest coverage gap is for the residential level of care. Under this demonstration, Wisconsin will develop coverage policies for residential facilities, including IMD facilities that are not otherwise eligible for matched expenditures under Section 1903 of the Social Security Act.

Following implementation of the new residential benefit by February 2020, Wisconsin Medicaid will reassess coverage for each level of care to identify any additional gaps or barriers to treatment. Initiatives to remove treatment barriers will be prioritized so that Wisconsin Medicaid members can access SUD treatment at the appropriate level of care.

The following table provides an overview of each critical level of care with current Wisconsin Medicaid coverage along with proposed changes.

Level of Care	Current State	Future State	Summary of Actions Needed
Outpatient Services	This is an existing service under the State Plan.	Continue to monitor and evaluate services and expenditures.	No immediate action. Will review coverage policies following implementation of residential benefit and update to State regulations.
Intensive Outpatient Services	This is an existing service under the State Plan.	Continue to monitor and evaluate services and expenditures.	No immediate action. Will review coverage policies following implementation of residential benefit and update to State regulations.
Medication Assisted Treatment	This is an existing service under the State Plan.	Continue to monitor and evaluate services and expenditures.	No immediate action. Will review coverage policies following implementation of residential benefit and update to State regulations.

Residential Treatment Services	<p>The component services of Residential Treatment (e.g. outpatient counseling) are existing services under the State Plan.</p>	<p>Wisconsin Medicaid will develop a new benefit under this demonstration, designed to establish a bundled coverage and reimbursement approach for Residential Treatment. Wisconsin will enroll providers certified as transitional residential programs (Wisc. Admin. Code DHS 75.14) and medically monitored treatment services (Wisc. Admin. Code DHS 75.11).</p> <p>Although the regulations for these programs are not explicitly tied to ASAM guidelines, they align with the ASAM Level of Care 3. Transitional residential programs are most closely aligned with sub-level 3.1 and medically monitored treatment programs are most closely aligned with sub-level 3.7. Wisconsin's new benefit will cover both types of treatment programs.</p>	<p>Wisconsin Medicaid will establish coverage and reimbursement policies aligned with American Society of Addiction Medicine (ASAM) criteria and state regulations, including but not limited to: eligible provider criteria, medical necessity criteria, claims submission and reimbursement guidelines, and utilization management. Benefit design and implementation will be completed by February 2020.</p>
--------------------------------	---	--	---

Inpatient Services	This is an existing service under the State Plan.	Coverage for inpatient services will expand to include any previously excluded IMD providers.	Wisconsin Medicaid will provide coverage and reimbursement policy guidance to any facilities previously excluded from providing treatment due to categorization as an IMD. Policy guidance will be distributed to providers by November 2020.
Medically Supervised Withdrawal Management	This is an existing service under the State Plan.	Coverage for medically supervised withdrawal management will expand to include any previously excluded IMD providers.	Wisconsin Medicaid will provide coverage and reimbursement policy guidance to any facilities previously excluded from providing treatment due to categorization as an IMD. Policy guidance will be distributed to providers by November 2020.

2.2 Use of Evidence-based, SUD-specific Patient Placement Criteria

Wisconsin Medicaid establishes standards for the use of patient placement criteria in Administrative Code Chapter DHS 75, “Community Substance Abuse Service Standards.” These standards already establish requirements for certified SUD treatment programs to use approved patient placement criteria. Further, the Wisconsin Department of Health Services (DHS) is currently drafting language to revise ch., DHS 75, including updated references to ASAM guidelines.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Implementation of requirement that providers assess treatment needs based on SUD-specific, multi-dimensional assessment tools that reflect evidence-based clinical treatment guidelines	<p>Wis. Admin. Code ch. DHS 75 requires all certified programs to use the Wisconsin-Uniform Placement Criteria (UPC), ASAM patient placement criteria, or other similar patient placement criteria approved by the department. In practice, many certified programs are using the ASAM placement criteria.</p> <p>The WI UPC is a SUD-specific, multidimensional assessment tool first implemented in 1996. This tool established uniform definitions of levels of care, improved patient placement consistency, and established adoption of common standards of program admission, continued stay, and discharge criteria.</p> <p>Admission to a program is based on an intake procedure that includes screening, approved patient placement criteria, and initial assessment.</p>	Wisconsin Medicaid will revise Wis. Admin. Code DHS 75 to update references to ASAM patient placement criteria and clarify whether any additional standards are approved.	<p>The revisions to administrative code were authorized by Wisconsin's governor in July 2018. The new regulations will follow the state's rulemaking process.</p> <p>Listening sessions were held on 5/21/19, 5/23/19, 6/17/19, 6/20/19, 6/27/19, and 7/16/19. The input collected through these sessions is incorporated in rule drafting. A rule draft will then be shared with an Advisory Committee for discussion and comment. This phase of rulemaking will continue through 2019.</p> <p>Following revisions suggested by the Advisory Committee, the draft rule will be published for public comment and analysis of economic impact in 2020.</p> <p>Final rule approval by the Wisconsin legislature is anticipated by early 2021, but may occur sooner if comments on the draft are limited.</p>

<p>Implementation of a utilization management approach such that (a) beneficiaries have access to SUD services at the appropriate level of care (b) interventions are appropriate for the diagnosis and level of care (c) there is an independent process for reviewing placement in residential treatment settings</p>	<p>Wis. Admin. Code ch. DHS 75 requires all certified programs to establish intake procedures so that (a) individuals access services at the appropriate level of care and (b) interventions are appropriate for the diagnosis and level of care.</p> <p>DHS Division of Quality Assurance (DQA) (c) conducts site visits and documentation review to ensure providers comply with these standards. Certification reviews take place for the provider's initial application and renewal applications, including a site visit and license holder and employee background checks. Providers must update their program documentation at least annually and apply for certification renewal at least every 2 years.</p> <p>Wisconsin Medicaid requires prior authorization (PA) of SUD treatment for day treatment programs at the intensive outpatient level of care. PA requests are reviewed by licensed behavioral health clinicians to determine medical necessity, including determining that the</p>	<p>DQA will continue to survey certified SUD treatment programs for compliance with provider credentialing standards, including requirements for use of patient placement criteria.</p> <p>Wisconsin Medicaid will develop utilization management policies (e.g. service authorizations) for Medicaid reimbursement in the design of the residential treatment benefit. The benefit design team will establish policies that balance the need to verify a clinically-appropriate assessment has been performed prior to admitting the individual into residential treatment, including the use patient placement criteria, with the need to rapidly connect individuals with treatment to prevent recurrence of use. The Medicaid team consulted with residential treatment providers in July and August 2019 to solicit their input on the referral, screening, assessment, and admissions process for their programs. Using this information, the benefits team is developing</p>	<p>Wisconsin Medicaid will establish utilization management policies.</p> <p>Wisconsin Medicaid will publish authorization requests forms by December 2019 and provide training to residential treatment programs on request submission.</p> <p>Target date to implement coverage is no later than February 2020.</p>
---	---	---	---

	<p>requested treatment is at the appropriate level of care.</p> <p>Managed care organizations contracted with Wisconsin Medicaid can make decisions to provide or deny services on the basis of medical necessity and place appropriate limits on a service for the purpose of utilization management, but cannot define medical necessity in a way that is more restrictive than the definition used by Wisconsin Medicaid.</p>	<p>authorization guidelines for initial admittance to residential treatment and authorization guidelines for continued stays in residential treatment.</p>	
--	--	--	--

2.3 Use of Nationally Recognized SUD-Specific Program Standards to Set Provider Qualifications for Residential Treatment Facilities

Wisconsin Medicaid establishes provider qualifications in Administrative Code ch. DHS 75, “Community Substance Abuse Service Standards”. DHS is currently drafting language to revise ch. DHS 75, including updated references to evidence-based guidelines.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Implementation of residential treatment provider qualifications in licensure requirements, policy manuals, managed care contracts, or other guidance. Qualification should meet program standards in the ASAM Criteria or other nationally recognized, SUD-specific program standards regarding, in particular, the types of services, hours of clinical care, and credentials of staff for residential treatment settings	<p>Wisconsin establishes residential treatment provider qualifications in Wisconsin Administrative Code. State standards currently describe the types of services, hours of clinical care, and credentials of staff for transitional residential treatment programs and medically monitored treatment programs.</p> <p>Wisconsin Medicaid intends to use these provider qualifications to determine provider eligibility to deliver residential treatment aligned with ASAM Level of Care 3.</p>	The Wisconsin Division of Care and Treatment Services (DCTS) has begun work to update state administrative code to further align provider qualifications with nationally recognized standards.	<p>The revisions to administrative code were authorized by Wisconsin’s governor in July 2018. The new regulations will follow the state’s rulemaking process.</p> <p>Listening sessions were held on 5/21/19, 5/23/19, 6/17/19, 6/20/19, 6/27/19, and 7/16/19. The input collected through these sessions is incorporated in rule drafting. A rule draft will then be shared with an Advisory Committee for discussion and comment. This phase of rulemaking will continue through 2019.</p> <p>Following revisions suggested by the Advisory Committee, the draft rule will be published for public comment and analysis of economic impact in 2020.</p> <p>Final rule approval by the Wisconsin legislature is anticipated by early 2021, but may occur sooner if comments on the draft are limited.</p>

Implementation of a state process for reviewing residential treatment providers to ensure compliance with these standards	All community SUD programs seeking certification under Wisconsin's administrative code are certified by (DQA). DQA conducts site visits and documentation review to ensure providers comply with these standards.	DQA will continue to certify SUD treatment programs and monitor their compliance with state regulations.	No immediate action.
Implementation of requirement that residential treatment facilities offer MAT on-site or facilitate access off site.	There are no current requirements that residential treatment facilities offer MAT on-site or facilitate access off site.	The Wisconsin Division of Medicaid Services is working with partners in DCTS and DQA to determine the appropriate regulatory or policy document to establish a requirement for residential treatment facilities to offer MAT on-site or facilitate access off site. Staff will consider available options, including establishing regulatory requirements in state administrative code or reimbursement requirements in Medicaid coverage policies. Staff will assess the impact of the options on current and potential treatment programs and determine which approach will maximize the availability of residential SUD treatment in Wisconsin while ensuring individuals in treatment have access to evidence-based treatment approaches.	DHS staff will implement the requirement by November 2020.

2.4 Sufficient Provider Capacity at Critical Levels of Care including for Medication Assisted Treatment for OUD

Wisconsin Medicaid will use data from the state's Medicaid Management Information System (MMIS) to evaluate provider capacity. Additional information regarding the data collection, reporting, and analytic methodologies will be described in the SUD Monitoring Protocol.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
<p>Completion of assessment of the availability of providers enrolled in Wisconsin Medicaid and accepting new patients in the following critical levels of care throughout the state (or at least in participating regions of the state) including those that offer MAT:</p> <ul style="list-style-type: none"> • Outpatient services • Intensive outpatient services • MAT (medications as well as counseling and other services) • Intensive care in residential and inpatient settings • Medically supervised withdrawal management 	<p>Wisconsin Medicaid currently enrolls healthcare professionals and programs in categories aligned with their state licensure or certification. Wisconsin will use a combination of DEA registration, state program certification, and state licensure information collected during provider enrollment to identify SUD treatment providers, including those that offer MAT.</p>	<p>As Wisconsin Medicaid updates licensure or certification requirements, including revisions to Wis. Admin. Code ch. DHS 75, it will update its methodology to assign the new provider credentials with the appropriate level of care.</p>	<p>Wisconsin will complete baseline measurements for provider capacity at each level of care by November 2019.</p>

2.5 Implementation of Comprehensive Treatment and Prevention Strategies to Address Opioid Abuse and OUD

Wisconsin Medicaid has and continues to make broad efforts across the state to address the drug abuse epidemic sweeping our communities. Initiatives included Medicaid program coverage revisions as well as broader community initiatives to address opioid addiction. The Wisconsin legislature enacted 30 bills for system improvements directly related to substance use disorders under the Heroin, Opioid Prevention and Education (HOPE) Agenda.

In Wisconsin, controlled substance dispensing initiatives resulted in a 29% decline in opioid prescriptions (1.5 million fewer prescriptions), a 19% decline in benzodiazepines (445,000 fewer prescriptions), and a flat trend in stimulant prescriptions from 2015 to 2018.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Implementation of opioid prescribing guidelines along with other interventions to prevent opioid abuse	<p>Wisconsin Medicaid established prescribing guidelines in alignment with Centers for Disease Control and Prevention (CDC) guidance. The Wisconsin Medical Examining Board (MEB) published Opioid Prescribing Guidelines in 2016. The MEB published updated guidelines in 2018.</p> <p>Wisconsin Medicaid's Drug Utilization Review (DUR) Board has been focused on opioid related activities. These activities include targeted intervention focused on opioid prescribing when a member's medication use may be outside of published guidance (i.e., CDC Opioid Prescribing Guidelines). Wisconsin Medicaid has drug/drug related criteria that is used to send physicians education letters alerting them to a clinical concern and pharmacies receive a drug/drug alert informing them of a clinical concern before the medication is dispensed.</p> <p>Wisconsin Medicaid has an opioid script limit of five prescription fills a</p>	Continue to monitor and evaluate.	No immediate action.

	<p>month for opioids and some quantity limits for certain opioid products. There is a process in place for the pharmacy to receive an override in case a member needs to exceed the limits for clinically appropriate reasons.</p>		
Expanded coverage of, and access to, naloxone for overdose reversal.	<p>2013 Wisconsin Act 200 established expanded access to naloxone, allowing pharmacies to dispense naloxone via a standing order. In August 2016, DHS issued a statewide standing order allowing any pharmacy to use the order to dispense naloxone.</p> <p>Wisconsin Medicaid covers Naloxone as a preferred drug and does not require prior authorization for coverage.</p> <p>In 2018, Wisconsin Medicaid expanded reimbursement policy to allow Opioid Treatment Programs to be reimbursed for dispensing naloxone.</p>	Continue to monitor and evaluate.	No immediate action.
Implementation of strategies to increase utilization and improve functionality of prescription drug monitoring programs	See attachment A for additional detail.	See attachment A for additional detail.	See attachment A for additional detail.

2.6 Improved Care Coordination and Transitions between Levels of Care

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Additional policies to ensure coordination of care for co-occurring physical and mental health conditions	<p>Current certification requirements for community SUD treatment programs include requirements for assessment, referral, and aftercare services that are designed to ensure all health needs for an individual in treatment are identified and addressed.</p> <p>Wisconsin Medicaid integrates the majority of behavioral health services into its risk-based contracts for managed care. This approach to contracting ensures the managed care entity meets coverage requirements for both physical and behavioral health conditions and coordinates services across these domains.</p>	<p>Wisconsin Medicaid will continue to evaluate the array of services carved into its risk-based managed care contracts to further integrate physical and mental health services. The new residential SUD benefit will be carved into acute managed care plans effective January 2020 to ensure coordination between physical and behavioral health services.</p> <p>Wisconsin Medicaid will also identify opportunities to develop more intensive care coordination models for individuals with SUD, including health homes or other intensive care coordination models. Initial analysis of the health home model for enhanced core coordination for individuals with SUD will be completed in 2020.</p>	Wisconsin Medicaid will revise acute managed care contracts by January 2020 and conduct ongoing monitoring through managed care provider network and quality monitoring.

3.0 Implementation Administration

Please see below for the Wisconsin Medicaid's point of contact for the Implementation Plan.

Name and Title: Sophia Lee, Behavioral Health Analyst, Division of Medicaid Services
Telephone Number: 608-266-2901

Email Address: sophia.lee@dhs.wisconsin.gov

Relevant Documents

No additional documents.

Attachment A – SUD Health Information Technology (IT) Plan

Section I.

This section is a continuation of milestone 5 to detail the use of the Prescription Drug Monitoring Program (PDMP) and the State Medicaid Health IT Plan (SMHP). As described in Table 1, Wisconsin Medicaid has developed and implemented an enhanced prescription drug monitoring program (ePDMP).

Wisconsin Medicaid recognizes the value of developing new and innovative tools to connect individuals with timely and appropriate SUD treatment and reduce administrative burden for treatment providers and other healthcare partners. The DHS eHealth Team conducts a Health Information Technology (HIT) landscape assessment each year to evaluate current HIT capabilities and define strategies Wisconsin Medicaid can pursue to advance health IT maturity and objectives.

Initial research identified key priorities to assess and further the adoption and use of HIT among treatment providers, including the need to conduct a behavioral health specific HIT landscape assessment, develop consent management tools to facilitate the flow of clinical information, and improve access to care through telehealth delivery of services. Details on Wisconsin Medicaid's strategic approach to these priorities will be included in an upcoming version of the SMHP.

Wisconsin Medicaid provides assurance that there is existing health IT infrastructure that may be leveraged in conjunction with future HIT initiatives to accomplish the goals of this demonstration.

Table 1. State HIT / PDMP Assessment & Plan

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Prescription Drug Monitoring Program (PDMP) Functionalities			
Enhanced interstate data sharing to better track patient specific prescription data	Wisconsin Medicaid is connected to the National Association of Boards of Pharmacy (NABP) Prescription Monitoring Interconnect (PMPi) and is currently sharing data with 18 other states. Wisconsin Medicaid is in the process of connecting to RxCheck, an additional data sharing hub.	Wisconsin Medicaid will be connected to a second interstate data sharing hub in 2019 and will continue to connect with additional compatible states for interstate data sharing. Work is underway to ensure interstate data can be presented to end users who access PDMP reports from within the workflow of their electronic health record (EHR).	PDMP is awaiting determination from NABP about whether there will be a modified memorandum of understanding to address whether it is allowable for interstate data to be presented to end users who access the PDMP reports from within their EHR workflow. The timeline for connecting to the additional data sharing hub is dependent on interstate coordination. Additional information on progress for interstate data sharing will be provided to CMS as Implementation Updates via quarterly monitoring reporting.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Enhanced “ease of use” for prescribers and other state and federal stakeholders	Wisconsin Medicaid developed and launched a new PDMP application in 2017 with extensive input from stakeholders to improve the PDMP’s ease of use. The new web application streamlines registration and reduces the number of clicks for healthcare users to access patient reports. Analytics and visualizations are used in patient reports to bring the most relevant information from a patient’s PDMP prescription history to the immediate attention of the user. Wisconsin has also developed a single sign on service offering for prescribers to be able to access patient reports from within their electronic medical record.	PDMP continues to gather feedback from stakeholders about desirable enhancements to continue to improve ease of use. This feedback has been developed as part of a user-led enhancement grant project through the U.S. Department of Justice, Bureau of Justice Assistance.	The user-led enhancement grant project will finalize the selection of any enhancements by October 2019.
Enhanced connectivity between the state’s PDMP and any statewide, regional or local health information exchange	The Wisconsin Statewide Health Information Network is one of the entities that offer the single sign on connection to the PDMP from within the community health record.	Continue to monitor and evaluate.	No immediate action.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Enhanced identification of long-term opioid use directly correlated to clinician prescribing patterns ¹ (see also “Use of PDMP” #2 below)	Long term opioid therapy is currently one of the data-driven alerts that are included in the patient report to help inform prescribers of concerning elements of their patients’ prescription history. Alerts figure not only on patient reports but also on prescriber metrics reports that are available to prescribers as a self-assessment tool, to medical coordinators who oversee prescribers, and to the boards that review PDMP data to look for outlying prescribing practices.	PDMP is considering inclusion of an analytics-driven alert to flag patients who are opioid naïve/do not have history of long- term opioid use.	No immediate action.
Current and Future PDMP Query Capabilities			
Facilitate the state’s ability to properly match patients receiving opioid prescriptions with patients in the PDMP (i.e. the state’s master patient index (MPI) strategy with regard to PDMP query)	The PDMP uses data quality software to perform patient matching.	Continue to monitor and evaluate.	No immediate action.
Use of PDMP – Supporting Clinicians with Changing Office Workflows / Business Processes			
Develop enhanced provider workflow / business processes to better support clinicians in accessing the PDMP prior to prescribing an opioid or other controlled substance to address the issues which follow	Wisconsin Medicaid has developed a single sign on (SSO) service offering for prescribers to be able to access patient reports from within their electronic medical record. Analytics and visualizations are used in patient reports.	Continue to monitor and evaluate.	No immediate action.

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Develop enhanced supports for clinician review of the patients' history of controlled substance prescriptions provided through the PDMP—prior to the issuance of an opioid prescription	State law requires prescribers to review the PDMP prior to issuing a prescription order for a controlled substance. When prescribers review their patients' reports, they see alerts and visualizations based on analytics bring the most relevant information from a patient's PDMP prescription history to the immediate attention of the user.	Continue to monitor and evaluate.	No immediate action.
Master Patient Index / Identity Management			
Enhance the master patient index (or master data management service, etc.) in support of SUD care delivery.	The PDMP uses data quality software to perform patient matching	Continue to monitor and evaluate.	No immediate action.
Overall Objective for Enhancing PDMP Functionality & Interoperability			

Milestone Criteria	Current State	Future State	Summary of Actions Needed
Leverage the above functionalities / capabilities / supports (in concert with any other state health IT, technical assistance or workflow effort) to implement effective controls to minimize the risk of inappropriate opioid overprescribing—and to ensure that Wisconsin Medicaid does not inappropriately pay for opioids	<p>The Wisconsin Department of Safety and Professional Services sends a monthly data extract to DHS for purposes delineated in a Data Use Agreement between the two agencies.</p> <p>The medical coordinator role in PDMP allows those who oversee prescribers to view non- patient-identifiable prescribing practice assessment metrics for the patients they oversee, which allows them to better identify prescribers that may present an opportunity for education about safe opioid prescribing practices. Prescribers can view their own metrics to see how their prescribing compares to their peers of the same specialty, and prescribing boards review similar metrics to help identify critically dangerous prescribing practices for further investigation and possible disciplinary action.</p>	Continue to monitor and evaluate.	No immediate action.

¹ Shah A, Hayes CJ, Martin BC. Characteristics of Initial Prescription Episodes and Likelihood of Long-Term Opioid Use — United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:265–269. DOI: <http://dx.doi.org/10.15585/mmwr.mm6610a1>.

Attachment A, Section II – Implementation Administration

Please see below for Wisconsin Medicaid's point of contact for the SUD Health IT Plan.

Name and Title: Mitzi Melendez, eHealth Section Chief, Division of Medicaid Services

Telephone Number: 608-261-8871

Email Address: mitzi.melendezprodoehl@dhs.wisconsin.gov

Attachment A, Section III – Relevant Documents

No additional documentation.

ATTACHMENT B
Substance Use Disorder Monitoring Protocol (Reserved)

ATTACHMENT C:

DEVELOPING THE EVALUATION DESIGN

Introduction

For states that are testing new approaches and flexibilities in their Medicaid programs through section 1115 demonstrations, evaluations are crucial to understand and disseminate what is or is not working and why. The evaluations of new initiatives seek to produce new knowledge and direction for programs and inform Medicaid policy for the future. While a narrative about what happened during a demonstration provides important information, the principal focus of the evaluation of a section 1115 demonstration should be obtaining and analyzing data on the process (e.g., whether the demonstration is being implemented as intended), outcomes (e.g., whether the demonstration is having the intended effects on the target population), and impacts of the demonstration (e.g., whether the outcomes observed in the targeted population differ from outcomes in similar populations not affected by the demonstration). Both state and federal governments need rigorous quantitative and qualitative evidence to inform policy decisions.

Expectations for Evaluation Designs

CMS expects Evaluation Designs to be rigorous, incorporate baseline and comparison group assessments, as well as statistical significance testing. Technical assistance resources for constructing comparison groups and identifying causal inferences are available on Medicaid.gov: <https://www.medicaid.gov/medicaid/section-1115-demonstrations/1115-demonstration-monitoring-evaluation/1115-demonstration-state-monitoring-evaluation-resources/index.html>. If the state needs technical assistance using this outline or developing the Evaluation Design, the state should contact its demonstration team.

All states with Medicaid section 1115 demonstrations are required to conduct an evaluation, and the Evaluation Design is the roadmap for conducting the evaluation. The roadmap begins with the stated goals for the demonstration followed by the measurable evaluation questions and quantifiable hypotheses, all to support a determination of the extent to which the demonstration has achieved its goals. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances.


The format for the Evaluation Design is as follows:

- A. General Background Information;
- B. Evaluation Questions and Hypotheses;
- C. Methodology;
- D. Methodological Limitations;
- E. Attachments.

Submission Timelines

There is a specified timeline for the state's submission of Evaluation Design and Reports. (The graphic below depicts an example of this timeline for a 5-year demonstration). In addition, the state should be aware that section 1115 evaluation documents are public records. The state is required to publish the Evaluation Design to the state's website within thirty (30) calendar days

of CMS approval, as per 42 CFR 431.424(e). CMS will also publish a copy to the Medicaid.gov website.



Required Core Components of All Evaluation Designs

The Evaluation Design sets the stage for the Interim and Summative Evaluation Reports. It is important that the Evaluation Design explain the goals and objectives of the demonstration, the hypotheses related to the demonstration, and the methodology (and limitations) for the evaluation. A copy of the state's Driver Diagram (described in more detail in paragraph B2 below) should be included with an explanation of the depicted information.

1. General Background Information – In this section, the state should include basic information about the demonstration, such as:

- a. The issue/s that the state is trying to address with its section 1115 demonstration and/or expenditure authorities, the potential magnitude of the issue/s, and why the state selected this course of action to address the issue/s (e.g., a narrative on why the state submitted an 1115 demonstration proposal).
- b. The name of the demonstration, approval date of the demonstration, and period of time covered by the evaluation;
- c. A brief description of the demonstration and history of the implementation, and whether the draft Evaluation Design applies to an amendment, extension, renewal, or expansion of, the demonstration;
- d. For renewals, amendments, and major operational changes: A description of any changes to the demonstration during the approval period; the primary reason or reasons for the change; and how the Evaluation Design was altered or augmented to address these changes.
- e. Describe the population groups impacted by the demonstration.

2. Evaluation Questions and Hypotheses – In this section, the state should:

- a. Describe how the state’s demonstration goals are translated into quantifiable targets for improvement, so that the performance of the demonstration in achieving these targets could be measured.
- b. Include a Driver Diagram to visually aid readers in understanding the rationale behind the cause and effect of the variants behind the demonstration features and intended outcomes. A driver diagram is a particularly effective modeling tool when working to improve health and health care through specific interventions. The diagram includes information about the goal of the demonstration, and the features of the demonstration. A driver diagram depicts the relationship between the aim, the primary drivers that contribute directly to achieving the aim, and the secondary drivers that are necessary to achieve the primary drivers for the demonstration. For an example and more information on driver diagrams:
<https://innovation.cms.gov/files/x/hciatwoaimsdrvrs.pdf>.
- c. Identify the state’s hypotheses about the outcomes of the demonstration:
 - i. Discuss how the evaluation questions align with the hypotheses and the goals of the demonstration;
 - ii. Address how the research questions / hypotheses of this demonstration promote the objectives of Titles XIX and/or XXI.

2.2. Methodology – In this section, the state is to describe in detail the proposed research methodology. The focus is on showing that the evaluation meets the prevailing standards of scientific and academic rigor, and the results are statistically valid and reliable, and that where appropriate it builds upon other published research (use references).

- a. This section provides the evidence that the demonstration evaluation will use the best available data; reports on, controls for, and makes appropriate adjustments for the limitations of the data and their effects on results; and discusses the generalizability of results. This section should provide enough transparency to explain what will be measured and how. Specifically, this section establishes:
 - i. *Evaluation Design* – Provide information on how the evaluation will be designed. For example, will the evaluation utilize a pre/post comparison? A post-only assessment? Will a comparison group be included?
 - ii. *Target and Comparison Populations* – Describe the characteristics of the target and comparison populations, to include the inclusion and exclusion criteria. Include information about the level of analysis (beneficiary, provider, or program level), and if populations will be stratified into subgroups. Additionally discuss the sampling methodology for the populations, as well as support that a statistically reliable sample size is available.
 - iii. *Evaluation Period* – Describe the time periods for which data will be included.

- iv. *Measures* – List all measures that will be calculated to *Evaluation* evaluate the demonstration. Include the measure stewards (i.e., the organization(s) responsible for the evaluation data elements/sets by “owning”, defining, validating; securing; and submitting for endorsement, etc.) Include numerator and denominator information. Additional items to ensure:
1. The measures contain assessments of both process and outcomes to evaluate the effects of the demonstration during the period of approval.
 2. Qualitative analysis methods may be used, and must be described in detail.
 3. Benchmarking and comparisons to national and state standards, should be used, where appropriate.
 4. Proposed health measures could include CMS’s Core Set of Health Care Quality Measures for Children in Medicaid and CHIP, Consumer Assessment of Health Care Providers and Systems (CAHPS), the Initial Core Set of Health Care Quality Measures for Medicaid-Eligible Adults and/or measures endorsed by National Quality Forum (NQF).
 5. Proposed performance metrics can be selected from nationally recognized metrics, for example from sets developed by the Center for Medicare and Medicaid Innovation or for meaningful use under Health Information Technology (HIT).
 6. Among considerations in selecting the metrics shall be opportunities identified by the state for improving quality of care and health outcomes, and controlling cost of care.
- v. *Data Sources* – Explain where the data will be obtained, and efforts to validate and clean the data. Discuss the quality and limitations of the data sources.

If primary data (data collected specifically for the evaluation) – The methods by which the data will be collected, the source of the proposed question/responses, the frequency and timing of data collection, and the method of data collection. (Copies of any proposed surveys must be reviewed with CMS for approval before implementation).

- vi. *Analytic Methods* – This section includes the details of the selected quantitative and/or qualitative measures to adequately assess the effectiveness of the demonstration. This section should:
1. Identify the specific statistical testing which will be undertaken for each measure (e.g., t-tests, chi-square, odds ratio, ANOVA, regression). Table A is an example of how the state might want to articulate the analytic methods for each research question and measure.

2. Explain how the state will isolate the effects of the demonstration (from other initiatives occurring in the state at the same time) through the use of comparison groups.
3. A discussion of how propensity score matching and difference in differences design may be used to adjust for differences in comparison populations over time (if applicable).
4. The application of sensitivity analyses, as appropriate, should be considered.

vii. *Other Additions* – The state may provide any other information pertinent to the Evaluation Design of the demonstration.

Table A. Example Design Table for the Evaluation of the Demonstration

Research Question	Outcome measures used to address the research question	Sample or population subgroups to be compared	Data Sources	Analytic Methods
Hypothesis 1				
Research question 1a	-Measure 1 -Measure 2 -Measure 3	-Sample e.g. All attributed Medicaid beneficiaries -Beneficiaries with diabetes diagnosis	-Medicaid fee-for-service and encounter claims records	-Interrupted time series
Research question 1b	-Measure 1 -Measure 2 -Measure 3 -Measure 4	-sample, e.g., PPS patients who meet survey selection requirements (used services within the last 6 months)	-Patient survey	Descriptive statistics
Hypothesis 2				
Research question 2a	-Measure 1 -Measure 2	-Sample, e.g., PPS administrators	-Key informants	Qualitative analysis of interview material

- 2.3. **Methodological Limitations** – This section provides detailed information on the limitations of the evaluation. This could include the design, the data sources or collection process, or analytic methods. The state should also identify any efforts to minimize the limitations. Additionally, this section should include any information about features of the demonstration that effectively present methodological constraints that the state would like CMS to take into consideration in its review.
- 2.4. **Special Methodological Considerations** – CMS recognizes that there may be certain instances where a state cannot meet the rigor of an evaluation as expected by CMS. In these instances, the state should document for CMS why it is not able to incorporate key components of a rigorous evaluation, including comparison groups and baseline data analyses. Examples of considerations include:

- a. When the state demonstration is:
 - i. Long-standing, non-complex, unchanged, or
 - ii. Has previously been rigorously evaluated and found to be successful, or
 - iii. Could now be considered standard Medicaid policy (CMS published regulations or guidance)
- b. When the demonstration is also considered successful without issues or concerns that would require more regular reporting, such as:
 - i. Operating smoothly without administrative changes; and
 - ii. No or minimal appeals and grievances; and
 - iii. No state issues with CMS-64 reporting or budget neutrality; and
 - iv. No Corrective Action Plans (CAP) for the demonstration.

3. Attachments

- 3.1. **Independent Evaluator.** This includes a discussion of the state’s process for obtaining an independent entity to conduct the evaluation, including a description of the qualifications that the selected entity must possess, and how the state will assure no conflict of interest. Explain how the state will assure that the Independent Evaluator will conduct a fair and impartial evaluation, prepare an objective Evaluation Report, and that there would be no conflict of interest. The Evaluation Design should include “No Conflict of Interest” signed by the independent evaluator.
- 3.2. **Evaluation Budget.** A budget for implementing the evaluation shall be provided with the draft Evaluation Design. It will include the total estimated cost, as well as a breakdown of estimated staff, administrative, and other costs for all aspects of the evaluation. Examples include, but are not limited to: the development of all survey and measurement instruments; quantitative and qualitative data collection; data cleaning and analyses; and reports generation. A justification of the costs may be required by CMS if the estimates provided do not appear to sufficiently cover the costs of the draft Evaluation Design or if CMS finds that the draft Evaluation Design is not sufficiently developed.
- 3.3. **Timeline and Major Milestones.** Describe the timeline for conducting the various evaluation activities, including dates for evaluation-related milestones, including those related to procurement of an outside contractor, if applicable, and deliverables. The Final Evaluation Design shall incorporate an Interim and Summative Evaluation. Pursuant to 42 CFR 431.424(c)(v), this timeline should also include the date by which the Final Summative Evaluation report is due.

ATTACHMENT D:

PREPARING THE INTERIM AND SUMMATIVE EVALUATION REPORTS

Introduction

For states that are testing new approaches and flexibilities in their Medicaid programs through section 1115 demonstrations, evaluations are crucial to understand and disseminate what is or is not working and why. The evaluations of new initiatives seek to produce new knowledge and direction for programs and inform Medicaid policy for the future. While a narrative about what happened during a demonstration provide important information, the principal focus of the evaluation of a section 1115 demonstration should be obtaining and analyzing data on the process (e.g., whether the demonstration is being implemented as intended), outcomes (e.g., whether the demonstration is having the intended effects on the target population), and impacts of the demonstration (e.g., whether the outcomes observed in the targeted population differ from outcomes in similar populations not affected by the demonstration). Both state and federal governments need rigorous quantitative and qualitative evidence to inform policy decisions.

Expectations for Evaluation Reports

Medicaid section 1115 demonstrations are required to conduct an evaluation that is valid (the extent to which the evaluation measures what it is intended to measure), and reliable (the extent to which the evaluation could produce the same results when used repeatedly). To this end, the already approved Evaluation Design is a map that begins with the demonstration goals, then transitions to the evaluation questions, and to the specific hypotheses, which will be used to investigate whether the demonstration has achieved its goals. States should have a well-structured analysis plan for their evaluation. With the following kind of information, states and CMS are best poised to inform and shape Medicaid policy in order to improve the health and welfare of Medicaid beneficiaries for decades to come. When conducting analyses and developing the evaluation reports, every effort should be made to follow the approved methodology. However, the state may request, and CMS may agree to, changes in the methodology in appropriate circumstances. When submitting an application for renewal, the Interim Evaluation Report should be posted on the state's website with the application for public comment. Additionally, the Interim Evaluation Report must be included in its entirety with the application submitted to CMS.

Intent of this Attachment

Title XIX of the Social Security Act (the Act) requires an evaluation of every section 1115 demonstration. In order to fulfill this requirement, the state's submission must provide a comprehensive written presentation of all key components of the demonstration, and include all required elements specified in the approved Evaluation Design. This Attachment is intended to assist states with organizing the required information in a standardized format and understanding the criteria that CMS will use in reviewing the submitted Interim and Summative Evaluation Reports.


The format for the Interim and Summative Evaluation reports are as follows:

- 13. Executive Summary;**
- 14. General Background Information;**

15. Evaluation Questions and Hypotheses;
16. Methodology;
17. Methodological Limitations;
18. Results;
19. Conclusions;
20. Interpretations, and Policy Implications and Interactions with Other State Initiatives;
21. Lessons Learned and Recommendations; and
22. Attachment(s).

Submission Timelines

There is a specified timeline for the state's submission of Evaluation Designs and Evaluation Reports. These dates are specified in the demonstration Special Terms and Conditions (STCs). (The graphic below depicts an example of this timeline for a 5-year demonstration). In addition, the state should be aware that section 1115 evaluation documents are public records. In order to assure the dissemination of the evaluation findings, lessons learned, and recommendations, the state is required to publish the Evaluation Design and reports to the state's website within thirty (30) calendar days of CMS approval, as per 42 CFR 431.424(d). CMS will also publish a copy to the Medicaid.gov website.



Required Core Components of Interim and Summative Evaluation Reports

The section 1115 Evaluation Report presents the research about the section 1115 Demonstration. It is important that the report incorporate a discussion about the structure of the Evaluation Design to explain the goals and objectives of the demonstration, the hypotheses related to the demonstration, and the methodology for the evaluation. A copy of the state's Driver Diagram (described in the Evaluation Design Attachment) must be included with an explanation of the depicted information. The Evaluation Report should present the relevant data and an interpretation of the findings; assess the outcomes (what worked and what did not work); explain the limitations of the design, data, and analyses; offer recommendations regarding what (in hindsight) the state would further advance, or do differently, and why; and discuss the implications on future Medicaid policy. Therefore, the state's submission must include:

- a. **Executive Summary** – A summary of the demonstration, the principal results, interpretations, and recommendations of the evaluation.

- b. **General Background Information about the Demonstration** – In this section, the state should include basic information about the demonstration, such as:
- i. The issues that the state is trying to address with its section 1115 demonstration and/or expenditure authorities, how the state became aware of the issue, the potential magnitude of the issue, and why the state selected this course of action to address the issues.
 - ii. The name of the demonstration, approval date of the demonstration, and period of time covered by the evaluation.
 - iii. A brief description of the demonstration and history of the implementation, and if the evaluation is for an amendment, extension, renewal, or expansion of, the demonstration.
 - iv. For renewals, amendments, and major operational changes: A description of any changes to the demonstration during the approval period; whether the motivation for change was due to political, economic, and fiscal factors at the state and/or federal level; whether the programmatic changes were implemented to improve beneficiary health, provider/health plan performance, or administrative efficiency; and how the Evaluation Design was altered or augmented to address these changes.
 - v. Describe the population groups impacted by the demonstration.
- c. **Evaluation Questions and Hypotheses** – In this section, the state should:
- i. Describe how the state’s demonstration goals were translated into quantifiable targets for improvement, so that the performance of the demonstration in achieving these targets could be measured. The inclusion of a Driver Diagram in the Evaluation Report is highly encouraged, as the visual can aid readers in understanding the rationale behind the demonstration features and intended outcomes.
 - ii. Identify the state’s hypotheses about the outcomes of the demonstration;
 - a. Discuss how the goals of the demonstration align with the evaluation questions and hypotheses;
 - b. Explain how this Evaluation Report builds upon and expands earlier demonstration evaluation findings (if applicable); and
 - c. Address how the research questions / hypotheses of this demonstration promote the objectives of Titles XIX and XXI.
- d. **Methodology** – In this section, the state is to provide an overview of the research that was conducted to evaluate the section 1115 demonstration consistent with the approved Evaluation Design. The Evaluation Design should also be included as an attachment to the report. The focus is on showing that the evaluation builds upon other published research (use references), and meets the prevailing standards of scientific and academic rigor, and the results are statistically valid and reliable.

- e. An Interim Evaluation Report should provide any available data to date, including both quantitative and qualitative assessments. The Evaluation Design should assure there is appropriate data development and collection in a timely manner to support developing an Interim Evaluation Report.

This section provides the evidence that the demonstration evaluation used the best available data and describes why potential alternative data sources were not used; reported on, controlled for, and made appropriate adjustments for the limitations of the data and their effects on results; and discusses the generalizability of results. This section should provide enough transparency to explain what was measured and how.

Specifically, this section establishes that the approved Evaluation Design was followed by describing:

- i. *Evaluation Design* – Will the evaluation be an assessment of: pre/post, post-only, with or without comparison groups, etc?
 - ii. *Target and Comparison Populations* – Describe the target and comparison populations; include inclusion and exclusion criteria.
 - iii. *Evaluation Period* – Describe the time periods for which data will be collected
 - iv. *Evaluation Measures* – What measures are used to evaluate the demonstration, and who are the measure stewards?
 - v. *Data Sources* – Explain where the data will be obtained, and efforts to validate and clean the data.
 - vi. *Analytic Methods* – Identify specific statistical testing which will be undertaken for each measure (t-tests, chi-square, odds ratio, ANOVA, regression, etc.).
 - vii. *Other Additions* – The state may provide any other information pertinent to the evaluation of the demonstration.
- f. **Methodological Limitations** – This section provides sufficient information for discerning the strengths and weaknesses of the study design, data sources/collection, and analyses.
- g. **Results** – In this section, the state presents and uses the quantitative and qualitative data to show to whether and to what degree the evaluation questions and hypotheses of the demonstration were achieved. The findings should visually depict the demonstration results (tables, charts, graphs). This section should include information on the statistical tests conducted.
- h. **Conclusions** – In this section, the state will present the conclusions about the evaluation results.
 - i. In general, did the results show that the demonstration was/was not effective in achieving the goals and objectives established at the beginning of the demonstration?

- ii. Based on the findings, discuss the outcomes and impacts of the demonstration and identify the opportunities for improvements. Specifically:
 - 1. If the state did not fully achieve its intended goals, why not? What could be done in the future that would better enable such an effort to more fully achieve those purposes, aims, objectives, and goals?
- i. **Interpretations, Policy Implications and Interactions with Other State Initiatives** – In this section, the state will discuss the section 1115 demonstration within an overall Medicaid context and long range planning. This should include interrelations of the demonstration with other aspects of the state’s Medicaid program, interactions with other Medicaid demonstrations, and other federal awards affecting service delivery, health outcomes and the cost of care under Medicaid. This section provides the state with an opportunity to provide interpretation of the data using evaluative reasoning to make judgments about the demonstration. This section should also include a discussion of the implications of the findings at both the state and national levels.
- j. **Lessons Learned and Recommendations** – This section of the Evaluation Report involves the transfer of knowledge. Specifically, the “opportunities” for future or revised demonstrations to inform Medicaid policymakers, advocates, and stakeholders is just as significant as identifying current successful strategies. Based on the evaluation results:
 - i. What lessons were learned as a result of the demonstration?
 - ii. What would you recommend to other states which may be interested in implementing a similar approach?

Attachment

Evaluation Design: Provide the CMS-approved Evaluation Design

ATTACHMENT E
EVALUATION DESIGN (Reserved)

ATTACHMENT F
MONITORING PROTOCOL (Reserved)

Attachment B: Independent Evaluator Assurance of No Conflict

INDEPENDENT EVALUATOR: ASSURANCE AND “NO CONFLICT” STATEMENT

The Wisconsin Department of Health Services assures that the independent evaluator, the University of Wisconsin Institute for Research on Poverty and its subcontracting investigators, will conduct a fair and impartial evaluation, prepare an objective and robust evaluation report, and there will be no conflict of interest.

The selected independent evaluator has a record of providing high-quality, independent evaluations for multiple organizations across Wisconsin. The independent evaluator also conducted the independent evaluation of the previous 1115 waiver approved in 2008, 2012, 2014, and 2019 as well as numerous other Medicaid initiatives in Wisconsin. Key research staff who participated in the prior waiver evaluations and who are familiar with the state’s Medicaid Eligibility Groups and data sources will be continuing their research efforts on this waiver evaluation.

The independent evaluator was screened to assure independence and freedom from conflict of interest. A series of interviews with the independent evaluator revealed that the entity has no conflicts of interest or preconceived notions about what they might find in terms of outcomes related to the new waiver provisions for CLAs. The state assures that the independent evaluator will be able to conduct the evaluation freely and without interference from the state or other outside parties connected to the state.

The state encourages the independent evaluator to address any potential conflict of interest in an open and honest manner at any stage of the evaluation process at which it may arise so that it does not diminish its capacity for impartiality and undermine the evaluation outcome. The state also encourages the independent evaluator to report on any pressures or interferences encountered during the evaluation process that did affect, or could have affected, the evaluator’s independence or objectivity. The state is committed to fostering transparency throughout the evaluation process by ensuring that necessary data is easily accessible to the independent evaluator.

Any conflicts of interest that may arise during the evaluation process will be required to be disclosed in the evaluation report. In reviewing draft evaluation reports, the state and independent evaluator will agree to follow procedures designed to improve the probability of organizational independence and protection from interference.

Confirmation Statement: The evaluator, the University of Wisconsin Institute for Research on Poverty submits this evaluation design report under its institutional letterhead and, in doing so, confirms no conflict of interest in serving as an independent evaluator on this project.

Attachment C: Timelines of Major Evaluation Milestones

	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027	Q1 2028	Q2 2028	Q3 2028	Q4 2028	Q1 2029	Q2 2029	Q3 2029	Q4 2029
EVALUATION PREPARATION																				
Wisconsin DHS contract set up																				
Attain needed BAA and DUAs																				
Secure IRB certification																				
Attain sub-agreements with collaborating investigators																				
MEDICAID BENEFICIARY SURVEYS																				
Draft Survey Instrument					Survey 1										Survey 2					
Identify and Select Medicaid sample																				
Attain mailing information from DHS																				
Survey Data Collection																				
Survey Data Analysis and Reporting																				
ADMINISTRATIVE DATA ANALYSIS																				
Attain Medicaid enrollment and claims files at 6-month intervals																				
Clean data and match enrollment file to claims and encounter data																				
Construct analytic files with treatment and comparison groups for each hypothesis and research question																				
Attain other administrative and survey data																				
Identify and construct relevant outcome measures																				
Conduct analyses for reports																				
REPORTS																				
Evaluation Design Report Finalized																				
Annual Progress Updates to DHS								*				*								*
CMS Interim Evaluation Report																*				

***Notes:** Annual evaluation progress updates to DHS will be in a format mutually agreed upon whether presentation or written reporting. The Final Summative Report is due June 30, 2031.

Attachment D: Budget and Budget Narrative

BadgerCare Waiver Evaluation Budget

NOTE: This budget is only for the BadgerCare Waiver Evaluation and is contingent on execution of the overall Medicaid Evaluation and Research (MER) contract for the period 07/01/2025 - 06/30/2030.

	Total Year 1	Total Year 2	Total Year 3	Total Year 4	Total Year 5	TOTAL
Personnel (salary and fringe)	\$457,292	\$472,679	\$487,292	\$497,690	\$511,535	\$2,426,488
Travel	\$1,500	\$1,500	\$1,500	\$1,500	\$1,500	\$7,500
Tuition Remission	\$21,456	\$22,100	\$22,763	\$23,446	\$24,149	\$113,913
Subcontracts	\$133,301	\$137,302	\$141,420	\$145,662	\$150,030	\$707,715
Survey, Data, Data Services & Data Storage Costs	\$133,132	\$119,118	\$616,191	\$123,633	\$720,985	\$1,713,059
Administrative support and infrastructure	\$267,404	\$267,404	\$267,404	\$267,404	\$267,404	\$1,337,022
Total Direct	\$1,014,085	\$1,020,103	\$1,536,570	\$1,059,335	\$1,675,603	\$6,305,697
Total F&A (15% of total direct costs)	\$152,113	\$153,015	\$230,486	\$158,900	\$251,340	\$945,855
Total	\$1,166,198	\$1,173,119	\$1,767,056	\$1,218,235	\$1,926,944	\$7,251,551

Budget Narrative – BadgerCare Waiver Evaluation FY26-30

The budget reflects a five-year evaluation period, from July 1st, 2025 to June 30th, 2030. Note that this budget narrative provides description information for the BadgerCare Waiver Evaluation only and is contingent on execution of the overall Medicaid Evaluation and Research (MER) contract for FY26-30.

UW Personnel

Co-Principal Investigator, Dr. Dan Sacks: 20% effort per year. Overall responsibility for the scientific elements of the project, in collaboration with Dr. Laura Dague. Primarily responsible for evaluation aims associated with waiver provisions 1 and 2. Will contribute to evaluation aims associated with waiver provision 3.

Co- Investigator, Dr. Marguerite Burns: 20% effort per year. Collaborate with Drs. Dague, Saks, and Tilhou on evaluation for waiver provision 3.

Post-doctoral Researcher, TBN: 100% effort per year. Econometric modeling, analysis, and other research support across all hypotheses on the project.

Data Scientist, TBN: 100% effort per year. Data steward, pulling, cleaning, de-identification, preparation of analytic files, matching, across data sets.

Project Assistants, 2 TBN: 100% effort per year per PA. Support analytic tasks and data preparation across all evaluation aims.

Travel

Travel for Co-PI of Co-I to attend one-two conferences or research meetings per year for the 5-year period.

Fringe Benefits

The fringe benefit rate for academic staff is 35.3%, 16.2% for post-doctoral researchers and 21.5% for project assistants in Year 1. The projected rate has been increased by 1% per year in all subsequent years of the budget.

Tuition Remission

University of Wisconsin – Madison has established a fee remission charge per regular academic semester per graduate student. This fee is not levied in the summer.

Subawards

- Texas A&M University, Dr. Laura Dague, Co-Principal Investigator: 3 months effort per year. Overall responsibility for the scientific elements of the project, in collaboration with Dr. Dan Sacks. Primarily responsible for evaluation aims associated with waiver provisions 2 and 3. Will contribute to evaluation aims associated with waiver provision 1.
- Boston University, Dr. Alyssa Tilhou: 2.4 calendar months per year. Dr. Tilhou will provide clinical insight into measure development for all provisions and will collaborate on evaluation of provision #3.

Survey, Data, Data Services & Data Storage Costs

Data Services

The Institute for Research on Poverty at the University of Wisconsin-Madison, working collaboratively with several State of Wisconsin agencies, has developed a data source, the Wisconsin Administrative Data Core (WADC, <https://www.irk.wisc.edu/wadc/>), to support the integrated analysis of the earnings, income, and multiple public program participation trajectories of individuals and families in Wisconsin. The Data Core matches each individual's records across multiple administrative data systems, identifies family and household relationships and connects each with historical program participation data files to allow researchers to analyze individuals' experiences by case and/or by various definitions or constellations of family. The WADC 2021 includes information for about 8.3 million individuals; this resource is re-built annually.

The Data Core is designed to support research that has the potential to inform the evaluation and administration of public policies. All research projects using this wealth of data must, therefore, have core policy issues and questions as a basis for the research, and the data may not be used for purely academic projects or without consultation with State partners. Further, all research projects using the data must contribute to both the fixed costs of developing and maintaining the data as well as the variable costs associated with their particular projects.

Specific project pricing is determined based on a formula that takes into account information provided by the researcher related to the number and quality of merging variables, number of variables of interest, number of underlying administrative data bases from which the variables of interest are drawn, sample size, and timeframe. An additional variable—the estimated amount of programming time for a specific data request—is developed internally. A discount is provided to affiliates who run their entire project grant through the Institute for Research on Poverty.

Data Purchase

Purchase of Vital Records from DHHS in Years 3 and 5 and All Claims Payer Database purchase (WHIO) yearly.

UW Survey Center

Costs associated with preparation, dissemination and data collection of the survey fielded in Years 2 and 4.

Administrative Support and Infrastructure

This budget line includes the proportion of administrative support and infrastructure allocated to the BadgerCare Waiver Evaluation, which is part of the overall Medicaid Evaluation and Research (MER) contract for the period 07/01/2025 – 06/30/2030. This cost includes the MER Principal Investigator, Katie Fitzpatrick's, effort in addition to effort allocated to the BadgerCare Waiver Evaluation by the Program Coordinator; Compliance Specialist; Systems Oversight Managers; IRP's Assistant Director; the Research Administrator; Data Engineer and Subject Matter Expert.

This budget line also includes allocable costs of travel for conferences for the PI and Program Coordinator, computers, the Social Science Computing Cooperative costs for data storage and computing support, IRP editing costs and membership fees for relevant publications and resources.

Indirect Costs: The UW rate of 15% for work with state government agencies within Wisconsin.